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Extracellular purines (adenosine, ATP and ADP) and pyrimidines (UTP, UDP) 
are important molecules which mediate several biological effects through the 
interaction with specific membrane receptors named purinergic receptors. 
Purinergic receptors are divided in P1 and P2 receptors (Figure 1); P1 receptors 
preferentially are able to bind adenosine while P2 receptors interact with ATP, 
ADP, UTP and UDP. P1 adenosine receptors are divided in four subtypes named 
A1, A2A, A2B and A3 that are coupled to G-protein. P2 receptors are divided into 
ionotropic P2X and metabotropic P2Y. Purines and pyrimidines through these 
receptors were involved in different processes like neurotransmission, exocrine 
and paracrine secretion, immunitary response, inflammation and pain. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: structure of purinergic receptors 
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Adenosine is a nucleoside composed of adenine attached to a ribose sugar 
molecule (ribofuranose) via a β-N9-glycosidic bond (Figure 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: chemical structure of adenosine 
 
Adenosine is an endogenous nucleoside-signalling molecule, which by acting on 
specific membrane receptors produces a number of physiological and 
pathophysiological effects in both central nervous system and peripheral organs. 
Adenosine is not a classical neurotransmitter because it is not principally 
produced and released vesicular in response to neuronal firing. Most tissues in the 
body and cells release adenosine to the extracellular medium, acting as an 
autacoid on the adenosine receptors (ARs). The basal levels of extracellular 
adenosine have been estimated as roughly 100 nM in the heart and 20 nM in the 
brain, which would only partially activate the ARs present (Fredholm et al., 
2005). In the case of severe ischemic stress, the levels can rapidly rise to the 
micromolar range, which would cause a more intense and generalized activation 
of the ARs. Extracellular adenosine may arise from intracellular break-down of 
the adenine nucleotides, such as ATP, outside the cell. Adenosine, which is 
present in higher concentration inside than outside the cell, does not freely diffuse 
across the cell membrane. There are nucleoside transporters, such as the 
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equilibrative nucleoside transporter 1 (ENT1) which bring it to the extracellular 
space. Extracellular nucleotides may also originate from cytosolic sources, 
including by vescicular release exocytosis, passage through channels and cell 
lysis. Ectonucleotidases break down the adenine nucleotides in stages to produce 
free extracellular adenosine at the terminal step (Zimmermann, 2000). For 
example, the extracellular enzyme ectonucleoside triphosphate 
diphosphohydrolase 1 (E-NTPDase1) converts ATP and ADP to AMP. The final 
critical step, with respect to AR activation, of conversion of AMP to adenosine is 
carried out by ecto-5’-nucleotidase, also known as CD37. The adenosine produced 
extracellulary is also subject to metabolic breakdown by adenosine deaminase to 
produce inosine or (re)phosphorylation by adenosine kinase to produce AMP. 
Therefore, when an organ is under stress there is a highly complex and time-
dependent interplay of the activation of many receptors in the same vicinity. In 
addition to the direct activation of ARs by selective agonists or their blockade by 
selective antagonists, inhibition of the metabolic or transport pathways 
surrounding adenosine is also being explored for therapeutic purposes 
(McGaraughty et al., 2005). 
 
P1 Purinergic Receptors 
 
Adenosine act on cell surface receptors that are coupled to intracellular signaling 
cascades. There are four subtypes of G-protein-coupled receptors (GPCRs) named 
A1, A2A, A2B and A3 ARs. The second messengers associated with the ARs are 
historically defined with respect to the adenylate cyclase system (Fredholm and 
Jacobson, 2009). The A1 and A3 ARs inhibit the production of cyclic AMP 
(cAMP) through coupling to Gi. The A2A and A2B subtypes are coupled to Gs or 
Go to stimulated adenylate cyclase. Furthermore, the A2B subtypes are coupled to 
Gq (Ryzhov et al., 2006) and it has the lowest affinity (Ki > 1 µM). Adenosine 
has the highest affinity at the A1 and A2A ARs (Ki values in binding of 10-30 nM 
at the high affinity sites) and the affinity of adenosine at the A3 AR is intermediate 
(ca. 1 µM) (Jacobson et al., 1995a). The ARs, as GPCRs, share the structural 
motif of a single polypeptide chain forming seven transmembrane helices (TMs), 
with the N-terminous being extracellular and the C-terminous being cytosolic 
(Costanzi et al., 2007). These helices, consisting of 25-30 amino acid residues 
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each, are connected by six loop, three intracellular (IL) and three extracellular 
(EL). The extracellular regions contains sites for posttranslational modifications, 
such as glycosylation. The A1 and A3 ARs also contains sites palmitoylation in the 
C-terminal. The A2A AR has a long C-terminal segment of more than 120 amino 
acid residues, which is not required for coupling to Gs, but can serve as a binding 
site for “accessory” proteins (Zezula and Freissmuth, 2008). The sequence 
identity between the human A1 and A3 ARs is 49%, and the human A2A and A2B 
ARs are 59% identical. Particular conserved residues point to specific functions. 
For example, there are two characteristic His residues in TMs 6 and 7 of the A1, 
A2A and A2B ARs. In the A3 AR, the His residue in TM6 is lacking but another His 
residue has appeared at a new location in TM3. All of these His residues have 
been indicated by mutagenesis to be important in the recognition and/or activation 
function of the receptors (Costanzi et al., 2007; Kim et al., 2003). Similar to the 
function and regulation of others GPCRs, both activation and desensitization of 
the ARs occur after agonist binding. Interaction of the activated ARs with the G 
proteins leads to second messenger generation and classical physiological 
responses. Interaction of the activated ARs with G protein-coupled receptor 
kinases (GRKs) leads to their phosphorylation. ARs responses desensitize rapidly, 
and this phenomenon is associated with receptor downregulation, internalization 
and degradation (Klaasse et al., 2008). The most rapid downregulation among the 
AR subtypes is generally seen with the A3 AR, due to phosphorylation by GRKs. 
The A2A AR is only slowly desensitized and internalized as a result of agonist 
binding. 
 
A1 adenosine receptors 
A1 ARs have been cloned from several species. The human A1 AR subtype gene 
(ADORA1) has been localized to chromosome 1q32.1 (Townsend-Nicholson et 
al., 1995). The variability in the primary sequence of the A1 AR between species 
is less than 10% for A1 from dog, rat and cow and less than 5% between bovine 
and human A1 AR (Tucker and Linden, 1993). The A1 ARs is widely express 
throughout the body, having its highest expression in the brain, spinal cord, atria 
and adipose tissue (Baraldi et al., 2000). Adenosine via A1 ARs reduces heart rate, 
glomerular filtration rate, and renin release in the kidney; it induces 
bronchocostriction and inhibits lipolysis (Elzein and Zablocki, 2008). The most 
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widely recognized signalling pathway of A1 ARs is inhibition of adenylate cyclase 
causing a decrease in the second messenger cAMP (Fredholm et al., 2001). This 
in turn modulates the activity of cAMP-dependent protein kinase, which 
phosphorilates diverse protein targets. Another signalling mechanism of A1 ARs is 
activation of phospholipase C (PLC) leading to membrane phosphoinositide 
metabolism and increased production of inositol 1,4,5-triphosphate (IP3) and Ca2+ 
mobilization. Elevation of cytosolic Ca2+ by IP3 can stimulate a variety of 
signalling pathways, including protein kinase C (PKC), phospholipase A2 (PLA2), 
Ca2+-dependent K+ channels and nitric oxide synthase (NOS). Depletion of Ca2+ 
from IP3-sensitive pools may promote Ca2+ influx from extracellular sources. A1 
AR display two different affinities for agonist, which have classically been 
attributed to a different coupling to heterotrimeric G proteins. According to this 
two independent site model, CGRP complex display high affinity for agonist and 
uncoupled receptors display low affinity. The reported cluster-arranged 
cooperative model predicts thet the high- and low-affinity sites are a consequence 
of the negative cooperativity of agonist binding and do not seem to be related to 
the content of G protein-coupled or –uncoupled receptors (Franco et al., 1996). In 
the early 1990s Bruns et co-workers reported on various allosteric modulators, 2-
amino-3-benzoylthiphene derivatives capable of enhancing the binding and 
activity of reference A1 receptor agonists, such as N6-cyclopentyladenosine (CPA) 
(Bruns et al., 1990a, Bruns et al., 1990b). It was demonstrated that 2-amino-4,5-
dimethylthien-3-yl)[3-(trifluoromethyl)phenyl]-methanone (PD 81,723) represents 
a specific and selective allosteric enhancer of agonist binding to the A1 ARs 
originally identified from a screening library of benzodiazepine-like compounds. 
PD 81,723 has been shown to enhance agonist binding and the functional 
activation of the A1 ARs in both brain and cardiovascular tissues (Amoah-Apraku 
et al., 1993, Bhattacharya et al., 1995, 1996; Janusz et al., 1991, 1993, Mudumbi 
et al., 1993). The available data indicate that PD 81,723 functions to stabilize a 
high affinity or agonist-preferring state of the A1 ARs (Bruns et al., 1990b, Bruns, 
1996, Linden et al., 1997). This hypothesis is supported by data demonstrating 
that the allosteric actions of PD 81,723 can be greatly enhanced in the presence of 
GTP (Bruns et al., 1990b) and that PD 81,723 can significantly slow the 
dissociation kinetics of agonist binding from rat brain membranes (Bruns et al., 
1990b) and from the recombinant human A1 ARs (Bhattacharya et al., 1995, 
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1996). Thus, the putative mechanism by which PD 81,723 enhances the activation 
of A1 ARs is thought to be via an allosterically mediated conformational shift of 
the receptor to a high affinity state thereby improving receptor/effector coupling 
(Bruns et al., 1990b). The binding site of PD 81,723 on the adenosine A1 ARs has 
yet to be elucidated. 
 
A2A adenosine receptors 
The A2A AR has been cloned from several species such as human, rat, mouse and 
canine. The gene for A2A AR has been mapped to human chromosome 22 with 
reported chromosomal localizations of 22q11.2 (Peterfreund et al., 1996). The A2A 
ARs is present in a wide variety of organs including major peripheral tissue (e.g. 
liver, heart, lung and the immune system) and the central nervous system (CNS) 
(Lee et al., 2003). The most commonly recognized signal transduction mechanism 
for A2A ARs is activation of adenylate cyclase. This implies primarly coupling 
with the Gs, although other G proteins may also be involved. In striatum the A2A 
ARs interacts with Golf proteins (Corvol et al., 2001). It is not known if there are 
significant differences in receptor affinity or in signalling closely dependent by 
the interaction with the specific G proteins. In addition other G protein pathways 
could be implicated, in the regulation of processes, for example via 
phosphorylation. There is no compelling reason to assume that this GPCR 
coupling to members of the Gs family would signal in anything but a canonical 
way. Thus, most effects are probably due to activation of adenylyl cyclase and 
generation of cAMP. The A2A ARs can recruit β-arrestin via a GRK-2 dependent 
mechanism (Khoa et al., 2006). This is influenced by activation of cytokine 
receptors, which cause reduced desensitization of the A2A ARs (Khoa et al., 
2006). One key target of PKA is the cAMP responsive element-binding protein 
(CREB) which is critical for many forms of neuronal plasticity as well as other 
neuronal functions (Josselyn and Nguyen, 2005). Phosphorilation of CREB by 
PKA activates CREB and turns on genes with cAMP responsive elements (CRE 
sites) in their promoters. One important feature of CREB is that it is a point of 
convergence for the cAMP/PKA and MAPK pathways. Stimulation of the A2A 
ARs counteracts the inhibition of neurite outgrowth due to MAPK blockade. 
Stimulation of the A2A ARs alone also activates the Ras/Raf-1/MEK/ERK 
signalling through PKA-dependent and PKA-independent pathways via Src- and 
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Sos- mediated mechanism, respectively (Schulte and Fredholm, 2003). 
Phosphorylated CREB was therefore proposed to mediate the anti-inflammatory 
effect of the A2A ARs and inhibition of NFκB by A2A ARs activation during acute 
inflammation in vivo was demonstrated (Fredholm et al., 2007). Activation of a 
multiple signalling pathways by the A2A ARs appears to contribute to its diverse 
and complex functions in various tissues. 
 
A2B adenosine receptors 
A2B AR mRNA was originally detected in a limited number of rat tissues by 
Northern blot analysis, with the highest levels found in cecum, bowel, and 
bladder, followed by brain, spinal cord, lung, epididymis, vas deferens, and 
pituitary. The use of more sensitive reverse transcriptase-polymerase chain 
reaction techniques revealed a ubiquitous distribution of A2B ARs (Spicuzza et al., 
2006). mRNA encoding A2B AR was detected at various levels in all rat tissues 
studied, with the highest levels in the proximal colon and lowest in the liver. In 
situ hybridization of A2B ARs showed widespread and uniform distribution of A2B 
AR mRNA throughout the brain (Dixon et al., 1996). The human A2B ARs gene 
(ADORA2B) has been localized to chromosome 1q32 (Jacobson et al., 1995b). 
Pharmacological identification of A2B ARs, based on their low affinity and 
characteristic order of potency for agonists, also indicates a widespread 
distribution of A2B ARs. Functional A2B ARs have been found in fibroblasts and 
various vascular beds, hematopoietic cells, mast cells, myocardial cells, intestinal 
epithelial and muscle cells, retinal pigment epithelium, endothelium, and 
neurosecretory (Gessi et al., 2005). Although activation of adenylyl cyclase is 
arguably an important signaling mechanism for A2A ARs, this is not necessarily 
the case for A2B ARs, as other intracellular signaling pathways have been found to 
be functionally coupled to these receptors in addition to adenylyl cyclase. In fact 
activation of A2B ARs can increase phospholipase C in human mast cells and in 
mouse bone marrow-derived mast cells. A2B ARs activation also elevates IP3 
levels, indicating this receptor can couple also to Gq-proteins. A2B ARs have been 
implicated in the regulation of mast cell secretion and, gene expression, intestinal 
function, neurosecretion, vascular tone and in particular asthma (Varani et al., 
2005). 
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A3 adenosine receptors 
A3 AR was identified relatively late in the history of ARs with the cloning, 
expression and functional characterization of a novel adenosine receptor from rat 
striatum (Zhou et al., 1992). The human A3 AR has been localized to chromosome 
1p13.3 (Monitto et al., 1995). The A3 ARs has widely distributed its mRNA being 
expressed in testis, lung, kidney, placenta, heart, brain, spleen, liver, uterus, 
bladder, proximal colon and eye of rat, sheep and humans. However, marked 
differences exist in expression levels within and among species. In particular rat 
testis and mast cells express high concentrations of A3 ARs mRNA, while low 
levels have been detected in most other rat tissues (Gessi et al., 2008). Lung and 
liver have been found as the organs expressing high levels of A3 ARs mRNA in 
human, while low levels have been found in aorta and brain. The classical 
pathways associated with A3 ARs activation are the inhibition of adenylyl cyclase 
activity, through the coupling with Gi proteins, and the stimulation of PLC, IP3 
and intracellular Ca2+, via Gq proteins (Fredholm et al., 2001). However, more 
recently additional intracellular pathways have been described as relevant for A3 
ARs signaling. For example, in the heart, A3 AR mediates cardioprotective effects 
through ATP-sensitive potassium (KATP) channel activation. Moreover, it is 
coupled to activation of RhoA and a subsequent stimulation of phospholipase D 
(PLD), which in turn mediates protection of cardiac myocytes from ischemia 
(Mozzicato et al., 2004). In addition, in different recombinant and native cell 
lines, A3 ARs is involved, like the other adenosine subtypes, in the modulation of 
mitogen-activated protein kinase (MAPK) activity (Schulte and Fredholm, 2003). 
A3 ARs signaling in Chinese Hamster Ovary cells transfected with human A3 ARs 
leads to stimulation of extracellular signal-regulated kinases (ERK1/2). In 
particular, A3 ARs signaling to ERK1/2 depends on βγ release from pertussis toxin 
(PTX)-sensitive G proteins, phosphoinositide 3-kinase (PI3K), Ras and mitogen-
activated protein kinase kinase (Schulte and Fredholm, 2003). It has been reported 
that A3 ARs activation is able to decrease the levels of PKA, a downstream 
effector of cAMP, and of the phosphorylated form of PKB/Akt in melanoma cells. 
This implies the deregulation of the Wnt signaling pathway, generally active 
during embryogenesis and tumorigenesis to increase cell cycle progression and 
cell proliferation (Fishman et al., 2002). Involvement of the PI3K/PKB pathway 
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has been linked with preconditioning effects induced by A3 ARs activation in 
cardiomyocytes from newborn rats (Germack and Dickenson, 2005). 
 
ADENOSINE TRIPHOSPHATE (ATP) 
 
Adenosine triphosphate or ATP is a ribonucleotide which is the main donor of 
energy in cellular reactions and is involved in the production of mechanical work 
in the active transport of ions and molecules and the synthesis of macromolecules. 
ATP consist af adenosine (composed of an adenine ring and a ribose sugar) and 
three phosphate groups connected with anhydride bonds (Figure 3). The energy 
content of an isolated molecule of ATP is a consequence of these anhydride bonds 
when they hydrolyzed, releases a large amount of energy. 
 
 
 
 
 
 
 
 
 
Figure 3: chemical structure of ATP 
 
The purine and pyrimidine nucleotides are compartimentalized in the cell 
cytoplasm, where there are involved in the synthesis of nucleic acid, or in the 
cellular metabolism, two key functions, from which depends the survival of any 
cell. Only recently ATP is recognized as an extracellular messenger (Burstock, 
2009). There are many studies in the literature indicating that ATP could function 
as a neurotransmitter. Infact it is released by the purinergic terminals and then 
recognized by membrane receptors (Ralevic and Burnstock, 1998; Boeynaems et 
al., 2005). Investigations conducted in the nervous system clarifies the role of 
extracellular nucleotides in different anatomical districts, as regulators of 
proliferation and cell differentiation, cytokine release, chemotaxis, the formation 
of reactive oxygen and nitrogen species, secretion of lysosomal factors, as well as 
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induction of apoptosis or cell necrosis (Burnstock, 2007). ATP and other 
nucleotides are taken up by and stored in secretory and synaptic vescicles. As 
revealed recently, accumulation of ATP into vescicular can be mediated by a Cl--
dependent vesicular nucleotide transporter (VNUT), which belongs to the SLC17 
anion transporter family, which includes also vesicular glutamate transporters 
(Sawada et al., 2008). VNUT preferentially recognizes ATP, GTP and ADP and is 
inhibited by diATP. ATP is probably present in every synaptic and/or secretory 
vesicle, although at different concentrations, and can be co-stored and co-released 
with other neurotransmitters (γ-aminobutyric acid, noradrenaline or glutamate). At 
present, it is unclear whether various physiological nucleotide-receptor agonists 
(ATP, ADP, UTP, UDP, UDP and NAD+) are released by common mechanisms. 
There is compelling evidence for exocytotic neuronal vesicular release of ATP 
(Pankratov et al., 2007) and recent studies also support a vescicular release of 
ATP from astrocytes, which perhaps involves lysosomes (Zhang et al., 2007). 
Evidence has been provided for additional mechanisms of nucleotide release, 
including ATP-binding cassette transporters, connexin or pannexin hemichannels, 
plasmalemmal voltage-dependent anion channels, in addition to P2X7 receptors 
(Pankratov et al., 2006; Dubyak, 2006; Scemes et al., 2007). After release, ATP 
and other nucleotides undergo rapid enzymatic degradation by ectonucleotidases, 
which is functionally important because ATP metabolites act as physiological 
ligands for various P2 purinergic receptors. 
 
P2 Purinergic Receptors 
Implicit in the concept of purinergic neurotransmission was the existence of 
postjunctional purinergic receptors, and the potent actions of extracellular ATP on 
many different cell types also implicated membrane receptors. The cytosolic 
concentration of ATP in mammalian cells is quite high (5-10 mM), but it increase 
within specialized structures for its accumulation, where ATP can reach values of 
over 100 mM. In extracellular fluids, however, the concentration of ATP is 
maintained at very low levels, in the order of 5-20 µM due to the presence of 
enzymes that hydrolyze (Burstock, 2007). Extracellular ATP interacts with the 
cell in two ways: at nanomolar and micromolar concentrations exerts its effects 
after the binding and activation of membrane receptors that mediate a fast 
response and a short distance. The action of these receptors occurs in a time 
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estimated to milliseconds. In 1994 Abbracchio and Burnstock (Abbracchio and 
Burnstock, 1994) on the basis of molecular structure and transduction 
mechanisms, proposed that purinoceptors should belong to two major families: a 
P2X family of ligand-gated ion channel receptors and a P2Y family of 
GPCRs.This nomenclature has been widely adopted and currently seven P2X 
subtypes and eight P2Y receptor subtypes are recognized, including receptors that 
are sensitive to pyrimidines as well as purines (Ralevic and Burnstock, 1998; 
North, 2002; Abbracchio et al., 2006). It is widely recognized that purinergic 
signalling is a primitive system involved in many non-neuronal as well as 
neuronal mechanisms, including exocrine and endocrine secretion, immune 
responses, inflammation, pain, platelet aggregation and endothelial-mediated 
vasodilatation (Burnstock and Knight, 2004; Burnstock 2006). Cell proliferation, 
differentiation and death that occur in development and regeneration are also 
mediated by purinergic receptors (Abbracchio and Burnstock, 1998; Burnstock 
2002). 
 
P2Y Purinergic Receptors 
Recent biochemical investigations have shown that receptors similar to the P2Y 
group, appeared very early during evolution, supporting the hypothesis that 
purinergic and pirimidinergic signaling pathways are among the most ancient 
mechanisms of intercellular communication. The P2Y receptors are metabotropic 
GPCRs, characterized by a typical seven-transmembrane helices: the N-terminal 
domain facing the extracellular side, while the C-terminal domain protudes into 
the cell cytoplasm interacting with G proteins to mediated the activation of 
intracellular pathways (Von Kügelgen, 2006). The first P2Y receptor was cloned 
in 1993, since then, numerous other family members were isolated and cloned. At 
the present, there are eight accept human P2Y receptors (P2Y1, 2, 4, 6, 11, 12, 13, 14) 
that have preferential affinity for ATP and related nucleotides. The missing 
numbers represent either non-mammalian orthologs, or receptors having some 
sequence homology to P2Y receptors, but for which there is no functional 
evidence of responsiveness to nucleotides. P2Y receptors differ from other 
families of GPCRs for their high heterogeneity in the amino acid sequence. 
Several studies have shown that these receptors are suitable for a neuromodulating 
function because they may perceive low levels of ATP (Abbracchio et al., 2006). 
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The binding to the receptors by extracellular nucleotides determines the activation 
of G proteins, phospholipase C (PLC) with subsequent formation of inositol 
phosphate 3 (IP3) which induces the release of Ca2+ from intracellular stores, and 
diacylglycerol (DAG), that activates the protein kinase C (PKC). Activation of 
adenylyl cyclase generates cAMP, which activates protein kinase A (PKA). The 
increasing cytosolic concentration of Ca2+ and the activation of PKA and PKC 
mediate the cellular responses due to activation of P2Y receptors. The complexity 
of the intracellular pathways of P2Y receptors translates into a wide-ranging 
effect on many cellular functions such as proliferation, apoptosis, metabolism, 
secretory activity and cell migration. It has been demonstrated that each P2Y 
receptor subtype is associated with one or more G proteins subfamily (Gs, Gi/o, 
Gq/11, G12/13). For example, P2Y2 subtype, is coupled to Gi, Go, Gq/11 or G12. It 
remains to clarify which mechanisms allow each P2Y subtype to associate to 
different G proteins and generate multiple pathways of signal transduction. A 
possible explanation might be that many of P2Y receptors have a binding 
specificity for more than one nucleotide, and it is possible that the binding of 
different nucleotides, on the same receptor, induces distinct conformational states 
that can interact with different G proteins (Abbracchio et al., 2006). For example, 
ADP is the preferential agonist of P2Y1, P2Y12 and P2Y13, ATP and UTP are 
equipotent in the activation of P2Y2, whereas UTP and UDP are preferential 
agonists of P2Y4 and P2Y6, respectively; P2Y11 is activated only by ATP. The last 
cloned P2Y receptor, P2Y14, has a pharmacological behaviour different from the 
other P2Y because it binds UDP-glucose as agonist (Chambers et al., 2000; 
Abbracchio et al., 2003). Mutagenesis study of P2Y receptors have demonstrated 
the importance of amino acid residues present in transmembrane regions 6 and 7 
to determining the power and specificity of the agonist (Erb et al., 1995). P2Y 
receptors have been identified in several cells tipes such as epithelial cells, 
endothelial cells, striated and smooth muscle cells, neurons, fibroblasts, 
monocytes, macrophages, neutrophils, eosinophils and activated T lymphocytes 
(Abbracchio et al., 2006). P2Y1 was identified in platelets, heart, connective 
tissue, immune system and nervous tissue. At the level of platelets plays an 
important role in the aggregation, where the absence of this receptor prolongs 
bleeding time and protects against thromboembolism ADP-dependent (Fabre et 
al., 1999). The expression of P2Y1 and P2Y2 in smooth muscle cells and vascular 
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endothelium induces vasodilatation (Di Virgilio et al., 2001). The P2Y4 receptor is 
expressed in the placenta, while it is slightly expressed in the vascular system. 
The P2Y6 receptor is expressed in the lung, heart, aorta, spleen, thymus, placenta 
and brain. The P2Y11 receptor is expressed in spleen, intestine, in the 
myocardium, in dendritic cells and macrophages (Abbracchio et al., 2006). It is 
also expressed in several cell lines such as HL-60, in which induces granulocyte 
differentiation (Communi et al., 2000a, van der Weyden et al., 2000). P2Y12 is 
expressed abundantly in platelets, lymphocytes and to a lesser degree in the brain, 
whereas P2Y13 is found predominantly in spleen and brain, but also in 
lymphnodes and bone. The P2Y14 receptor is mainly expressed in placenta, 
adipose tissue, stomach and intestine, and at low levels of it is detected in brain, 
spleen, lung and heart (Abbracchio et al., 2006). The activation of this receptor 
mediates chemotaxis in a population of hematopoietic cells of bone marrow (Lee 
et al., 2003). 
 
P2X Purinergic Receptors 
P2X receptors are ionotropic receptors, ie receptors whose activation causes the 
direct opening (or closure) of selective membrane channels for mono- and 
bivalent cations, capable of determining the leakage of K+ and the entry of Na+ 
and Ca2+ in the cell. The first cDNAs encoding P2X receptor subunits were 
isolated in 1994. Members of the family of ionotropic P2X1–7 receptors show a 
subunit topology of intracellular N- and C-termini possessing consensus binding 
motifs for protein kinases; two transmembrane spanning regions (TM1 and TM2), 
the first involved with channel gating and the second lining the ion pore; a large 
extracellular loop, with 10 conserved cysteine residues forming a series of 
disulfide bridges; a hydrophobic H5 region close to the pore vestibule, for 
possible receptor/channel modulation by cations and anATP-binding site, which 
may involve regions of the extracellular loop adjacent to TM1 and TM2. The 
P2X1–7 receptors show 30– 50% sequence identity at the peptide level (North 
2002; Stojilkovic et al., 2005; Egan et al., 2006; Roberts et al., 2006). The 
stoichiometry of P2X1–7 receptors is thought to involve three subunits, which form 
a stretched trimer or a hexamer of conjoined trimers (North 2002; Nicke et al., 
1998). The pharmacology of the recombinant P2X receptor subtypes expressed in 
oocytes or other cell types is often different from the pharmacology of P2X-
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mediated responses in naturally occurring sites (Gever et al., 2006). Several 
contributing factors may account for these differences. First, heteromultimers as 
well as homomultimers are involved in forming the trimer ion pore (Nicke et al., 
1998). For example, heteromultimers are clearly established for P2X2/3 receptors. 
P2X1/2, P2X1/5, P2X2/6, P2X4/6 and more recently P2X1/4 heteromultimers have 
also been identified. P2X7 does not form heteromultimers, and P2X6 will not form 
a functional homomultimer. Second, spliced variants of P2X receptor subtypes 
might play a part. For example, a splice variant of P2X4 receptor, while it is 
nonfunctional on its own, can potentiate the actions of ATP through the full-
length P2X4 receptors (Townsend-Nicholson et al., 1999). The P2X subunit 
proteins are 384 (P2X4) to 595 (P2X7) amino acids long (Roberts et al., 2006). 
Each has two hydrophobic regions. All the P2X receptor subunits have consensus 
sequences for N-linked glycosylation. There are seven genes for P2X receptor 
subunits. P2X4 and P2X7 subunit genes are located close to the tip of the long arm 
of chromosome 12 (North 2002). P2X4 and P2X7 subunits are among the most 
closely related pairs in amino acid sequences. P2X1 and P2X5 genes are also very 
close together on the short arm of chromosome 13. The remaining genes are on 
different chromosomes. Several full-length non-mammalian vertebrate sequences 
have been identified. There are no reports of homologous sequences from 
invertebrate species, although there is considerable functional evidence that 
extracellular ATP and other nucleotides can directly gate ion channels in 
invertebrates (Egan et al., 2006; Roberts et al., 2006). Following the binding with 
the ATP, the P2X receptor channel opens, generating a movement of cations 
across the cell membrane. This movement of ions produces changes in electrical 
potential of the cell, with membrane depolarization which, in turn, activates 
calcium-channel voltage-dependent. The accumulation of calcium ions in the 
cytoplasm is also responsible of the activation of numerous signal transduction 
pathways through the activation of MAPKs, PKC and calmodulin (Communi et 
al., 2000b; North, 2002). The extent of cellular responses induced by these 
receptors, in addition to being modulated by transmembrane potential difference, 
is also regulated by the duration of receptor stimulation. Continuous stimulation 
of the receptor leads to a state of desensitization, in which the receptor no longer 
responds to the endogenous agonist. The rate with which this process is 
established, and involves all the molecules of the receptor, is finely regulated by 
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the cell through specific phosphorylation induced by second messengers. For 
example, P2X1 and P2X3 receptors have a rapid desensitation when continuously 
stimulated with ATP and P2X2 receptor channel stays open until the ATP interacts 
with it. Receptor activity and intensity of the response is also strongly modulated 
by extracellular pH and the presence of heavy metals (zinc and cadmium) that act 
as allosteric modulators (Huidobro-Toro et al., 2008). For example, the sensitivity 
of P2X1, P2X3 and P2X4 receptors to ATP is attenuated when the extracellular pH 
is greater than seven, while the affinity of the P2X2 receptor in these conditions, 
significantly increases. Zinc, however, increases the ionic current through P2X2, 
P2X3 and P2X4 receptors while it inhibits the ionic current through P2X1 receptor 
(Gever et al., 2006). The ability of pH and metal allosteric modulators of these 
receptors appears to be attributed to the presence of histidine residues in the 
extracellular region (North, 2002). These receptors are generally expressed by 
excitable cells like neurons, smooth and striated muscle cells. P2X receptors are 
involved in fast synaptic interneuronal transmission in CNS or in muscle 
contraction. They are also present at the level of immune system cells such as 
monocytes, macrophages, dendritic cells, thymocytes and other lymphoid cells, in 
which seem to mediate multiple responses including apoptotic cell death (Pizzo et 
al., 1991; Chvatchko et al., 1996). P2X1 receptors are expressed predominantly in 
human smooth muscle cells of the deferens vessel and of the bladder as well as in 
brain, heart and platelets. While P2X2 receptors are present in sensory ganglia, 
brain, chromaffin cells, in the retina, cochlea and in smooth muscle. P2X3 
receptors are found in sensory fibers in the brain and heart. Experiments in vivo 
have been attributed to polymer P2X2/3 a role in signal transmission in chronic 
inflammatory pain and neuropathic pain (Barclay et al., 2002; Wirkner et al., 
2007). P2X4 receptors in addition to being expressed at high levels in the brain, 
are localized at the level of colon, heart, epithelia and smooth muscle. In the rat 
this receptors was detected in the hippocampus, the brain, in dorsal ganglion 
(DRG) and endocrine tissue. P2X5 receptors are localized in the brain, heart, 
spine, lymphocytes and thymus. In humans, P2X6 receptors are present in the 
brain, sensory and autonomous ganglia. The expression of P2X7 receptors are 
high in immune cells such as monocytes, macrophages, microglia, dendritic cells 
(North, 2002; Burnstock, 2007; Surprenant and North, 2008). In literature, 
numerous studies have attempted to define the pharmacological profile of agonists 
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and antagonists of P2X receptors (Burnstock, 2007). Indeed there are many works 
reporting the effect of agonists and/or antagonists of the purinergic system in 
different tissues and/or organs. These results show sometimes inconsistency on 
the results obtained, this is probably due to the low affinity and selectivity of the 
ligands used and to the ubiquitous presence of several purinergic subtypes. To 
date, there are numerous agonists and/or antagonists for the purinergic receptors 
even though most of them are not selective. 
 
P2X1 and P2X3 receptors 
P2X1 and P2X3 receptors are transmembrane channel permeable to cations (Na+, 
Ca2+ and K+) which represent respectively the first and the third member of the 
P2X family. Exposure to ATP or selective agonists activates these receptors 
transiently changing the channel conformation. Opening of these receptors 
generates a movement of cations across the cell membrane that produces changes 
in the electrical potential of the cell, with consequent membrane depolarization, 
which in turn, activates calcium-channel voltage-dependent (Surprenant and 
North, 2008). P2X1 purinergic receptors have been cloned and expressed in 
different animal species such as rat, mice and human. The human gene coding for 
the purinergic receptors P2X1 is mapped in 17p13.2 and shows characteristics 
very similar to that of rat (North, 2002). P2X1 receptors are proteins consisting of 
399 amino acids and has a molecular mass of 70 kD, almost double that provided 
by the amino acid sequence, probably because of glycosylation of the extracellular 
domain (Sun et al., 1998). P2X1 subunits have four potential glycosylation sites 
(Asn153, Asn184, Asn284, Asn300 in rat) (Nicke et al., 1998) whose deletion 
leads to inactivation of the ion channel (Newbolt et al., 1998, Torres et al., 1998). 
The human P2X1 receptor is expressed not only in certain brain areas, but mainly 
in peripheral vascular smooth muscle cells of the vas deferens, arteries, arterioles, 
bladder and bowel, and heart in platelets (Gever et al., 2006). At the level of 
smooth muscle, activation of this receptor by agonist leads to contraction. Studies 
in P2X1 knock-out mice have allowed to demonstrate that the absence of this 
receptor results in a reduced contraction of the vas deferens, male infertility, 
reduced vasoconstriction to nerve stimulation, reduced autoregolating blood flow 
in the kidney (Mulryan et al., 2000; Vial et al., 2000). P2X1 receptors are 
expressed at high concentration also in platelets, where their activation by ATP is 
partly involved in the regulation of various platelet function. The importance of 
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this receptor in promoting and maintaing the platelet activation was confirmed by 
knock-out mouse in which the lack of P2X1 receptor expression is associated with 
changes in aggregation, secretion and platelet adhesion and reduction of thrombus 
growth (Hechler et al., 2003). Even P2Y1 and P2Y12 receptors are abundantly 
expressed in platelets and involved in their regulation (Fabre et al., 1999). With 
immunohistochemical studies, it was shown that P2X1 receptors are expressed, 
even if in low concentrations, in lymphocytes (Wiley et al., 1996) and in heart 
muscle (Dhulipala et al., 1998). P2X3 purinergic receptors have been isolated 
from sensory neurons of dorsal root ganglia (DRG) of rat and human heart (Chen 
et al., 1995, Lewis et al., 1995, Garcia-Guzman et al., 1997). The human gene 
coding for them map 11q12 and the percentage of identity between the sequences 
of human and rat P2X3 is high. (North and Surprenant, 2000; North, 2002). P2X3 
receptors are composed of 397 amino acids and as P2X1 receptors have four 
potential glycosylation sites. Furthermore, both P2X1 that P2X3 subunits assemble 
as trimers (Nicke et al., 1998). P2X3 and P2X2/3 receptors are expressed 
predominantly in the major afferent neurons, ie in small diameter nociceptive 
sensory neurons of dorsal root and trigeminal ganglia and nodose (Thomas et al., 
1998; Virginio et al., 1998; Cockayne et al., 2005). The nociceptive afferents are 
widely distributed throughout the body and they include both Aδ myelinated 
fibers of medium diameter, both the C fibers of small diameter, non-myelinated 
slow conductance (Kirkup et al., 1999; Cockayne et al., 2000; Lee et al., 2000; 
Brouns et al., 2000; Wynn et al., 2004). At the central level P2X3 and P2X2/3 are 
present in the dorsal horn and in the nucleus of the solitary tract (NST) which 
appear to be involved in the modulation of presynaptic glutamate release (Gu et 
al., 1997; Hechler et al., 2003; Gever et al., 2006). Studies have shown that P2X3 
and P2X2/3 are expressed in the enteric nervous system (Poole et al., 2002) and in 
several epithelial tissues where responses appear to modulate some chemical or 
mechanical (Fu et al., 2004). In vivo experiments have allowed to attribute to 
P2X3 and P2X2/3 an important role in the signaling of chronic inflammatory and 
neuropathic pain (Barclay et al., 2002). Studies in mice P2X3 knock-out showed 
that the absence of this receptor results in reduced urinary and abnormal reflex 
response to pain stimuli (Cockayne et al., 2000; Gever et al., 2006). Antagonists 
for this receptor and its heteromeric form could therefore have a therapeutic role 
for the treatment of chronic pain (Wirkner et al., 2007). P2X3 receptors are 
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pharmacologically similar to P2X1 receptors, both rapidly desensitization when 
exposed to high concentrations of ATP. It was noted that the time of 
desensitization for the P2X1 receptor is approximately 300 milliseconds while for 
the P2X3 receptor is about 100 milliseconds. The ability for the P2X1 receptor to 
function again is achieved after 10-30 min and for P2X3 receptor is 15 min (North 
et al., 2000). It has been shown that both receptor subtypes are activated to ATP 
and to α,β-meATP (pEC50> 6) and inhibited not only by Suramin but also by 
TNP-ATP (pIC50> 8). In literature, studies have defined the pharmacological 
profile of agonists and antagonists specific for P2X1 and P2X3 receptors. Selective 
agonists for the P2X1 receptor were analog of ATP as γβ-MeATP (γ,β-methylene-
ATP) and diadenosine polyphosphates (Ap4A) while P2X3 receptor showed 
selectivity for diadenosine polyphosphates (Ap3A). Selective P2X1 antagonist 
were Suramin analogues NF449 and NF864 dipeptides and the compound RO-1 
while P2X3 receptor shown affinity to tricarboxylic acid A317491 and RO-3 
(composed of dipeptides) (Gever et al. , 2006). The activity and intensity of the 
response of these receptor subtypes is also strongly modulated by the presence of 
heavy metals such as zinc and extracellular pH that act as allosteric modulators. 
Recent studies have shown that the extracellular pH negatively regulates P2X1 
and P2X3 receptors while zinc inhibits P2X1 receptors and positively modulates 
P2X3 receptors. It is well known that calcium influences these receptors by the 
inhibition of P2X3 receptors even if no effect on P2X1 has been reported (Gever et 
al., 2006). 
 
ADENOSINE, ATP AND INFLAMMATION 
 
Adenosine receptors on immune cells 
Adenosine is an endogenous signalling molecule that engage cell surface ARs to 
regulate numerous physiological and pathological processes. Substantial evidence 
demonstrates that adenosine is an important signalling molecule and ARs are 
important molecular targets in the pathophysiology of inflammation. All 
inflammatory cells express ARs, and research into the consequences of ARs 
activation has identified numerous avenues for adenosine-based therapeutic 
intervention. Indeed , adenosine-based approaches are currently being developed 
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for the treatement of various disorders where inflammatory modulation is a key 
component. 
 
Neutrophils 
Neutrophils are the most abundant leukocyte and represent rhe body’s first line of 
defence in response to a pathogenic challenge; they are the predominant 
leukocytes involved in acute inflammation. All four adenosine receptors subtypes 
are expressed on neutrophils. At submicromolar concentrations, A1 ARs activation 
on human neutrophils produces proinflammatory response by promoting 
chemotaxis and adherence to the endothelium (Bours et al. 2006). Activation of 
A2A ARs and A2B ARs on neutrophils is anti-inflammatory. High concentration of 
adenosine inhibit neutrophils adhesion to endothelial cells by activating these 
receptors (Bours et al. 2006, Sullivan et al. 2004). In human neutrophils, A2A ARs 
activation inhibits the formation of reactive oxygen species (Salmon and 
Cronstein 1990). Activation of A2A ARs on neutrophils produced an anti-
inflammatory effect by decreasing the formation of the proinflammatory 
cytochine TNF-α (Harada et al. 2000), chemokines such as macrophage 
inflammatory protein (MIP)-1α/CCL3, MIP-1β/CCL4, MIP-2α/CXCL2 and MIP-
3α/CCL20 (McColl et al. 2006), and leukotriene LTB4 (Flamada et al. 2000, 
2002), and platelet activating factor (PAF) (Flamada et al. 2006). Other important 
immunoregulatory effects mediated by the A2A ARs include the inhibition of Fc 
gamma (Fcγ) receptor-mediated neutrophils phagocytosis and inhibition of 
degranulation (Bours et al. 2006, Sullivan et al. 1999). Activation of the A2B ARs 
inhibits neutrophils extravasation across human umbilical vein endothelial cell 
(HUVEC) monolayers and inhibits the release of vascular endothelial growth 
factor (VEGF) (Wakai et al. 2001). Conflicting reports suggest that activation of 
A3 ARs on neutrophils may produce proinflammatory or anti-inflammatory 
effects. Studies with A3 ARs knockout mice suggest that A3 ARs promotes 
recruitment of neutrophils to lungs during sepsis (Inoue et al. 2008). Moreover, A3 
ARs play an important role in the migration of neutrophils in response to 
chemoattractant molecules released by microbes (Chen et al. 2006). Selective A3 
ARs antagonists inhibit fMLP-mediated chemotaxis in neutrophils (Chen et al. 
2006). In other studies, activation of A3 ARs has been shown to counteract 
inflammation by inhibiting degranulation and oxidative burst (Gessi et al. 2002). 
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Monocytes and Macrophages 
Monocytes and macrophages are an heterogenous group of mononuclear cells that 
present an early line of innate immune defense. They represent a primary source 
of inflammatory modulators and are highly adaptable with a phenotype that can 
change rapidly in response to the local environment of the inflamed tissue. 
Macrophages also show an important role in terminating the inflammatory 
process, which is critical for preventing excessive tissue injury. All four ARs are 
expressed on monocytes and macrophages, although expression levels differ 
markedly throughout the maturation and differentiation process. (Thiele et al. 
2004). In human monocytes, A1 ARs activation produces a proinflammatory 
effect whereas A2A ARs activation produces an anti-inflattory effect. A key 
function of the A1 ARs is a rapid enhancement of the activity of the Fcγ receptor 
(Salmon et al. 1993). Activation of A2A ARs limits inflammatory reactions by 
inhibiting phagocytosis in monocytes (Salmon et al. 1993) and macrophages 
(Eppell et al. 1989), decreasing the production of reactive oxygen species (Thiele 
et al 2004) and altering cytokine release. In addition, A3 ARs activation inhibits 
fMLP-triggered respiratory burst in monocytes (Broussas et al. 1999). Monocytes 
and macrophages are primary sources of TNF-α, a proinflammatory cytokine 
involved in the pathophysiology of a number of chronic inflammatory diseases. 
Early studies suggested that activation of A2A ARs suppresses production of TNF-
α in monocytes activated by bacterial lipopolysaccharide (LPS) (Le Vraux et al. 
1993). In primary cultures of monocytes activated by LPS and LPS-stimulated 
mause macrophages, activation of the A2A ARs attenuate the release of TNF-α, 
wherease activation of the A1 ARs and A3 ARs had no effect on the formation of 
TNF-α (Zhang et al. 2005; Ezeamuzie and Khan 2007). Similar results were 
obtained in studies with primary cultures of mouse peritoneal macrophages 
(Kreckler et al. 2006). In other studies, activation of A3 ARs was shown to inhibit 
LPS-induced TNF-α release in vitro in the RAW 264.7 murine leukemia 
macrophage line (Martin et al. 2006), U937 human leukemic macrophage line 
(Sajjadi et al. 1996), murine J774.1 macrophages (McWhnney et al. 1996) and in 
vivo in endotoxemic mice (Hasko et al. 1996). In the RAW 264.7 macrophage 
line, the inhibitory effects of A3 ARs were mediated by a mechanism involving 
Ca2+-dependent activation of NF-κB (Martin et al. 2006). 
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Dendritic cells 
Dendritic cells (DCs) are highly specialized antigen-presenting cells that play an 
important role in the initiation and regulation of immune responses by migrating 
to sites of injury and infection, processing antigens, and activating naïve T cells. 
Immature DCs (imDCs) undergo a maturation process following exposure to 
proinflammatory signals, including pathogens, LPS, TNF-α, IL-1 and IL-6. the 
maturation process results in decreased phagocytic activity and increased 
expression of membrane major histocompatibility complex (MHC). Mature DCs 
release a number of cytokines, including TNF-α, IL-12 and IL-10. ARs are 
differentially expressed on human DCs (Fossetta et al. 2003). Immature, 
undifferentiated human DCs express mRNAs for the A1 AR, A2A AR and A3 AR 
but not for the A2B AR (Fossetta et al. 2003). Activation of the A1 ARs and A3 
ARs subtypes in undifferentiated DCs induces chemotaxis and mobilization of 
intracellular Ca2+, while activation of the A2A AR subtypes has no effect (Panther 
et al. 2001). Activation of A1 ARs in resting DCs suppresses vescicular MHC 
class I cross-presentation by a Gi-mediated pathways (Chen et al. 2008). 
Following treatment with LPS to induce differentiation and maturation, human 
DCs primarily express the A2A ARs (Panther et al. 2001; Fossetta et al. 2003). 
Activation of the A2A ARs increases adenylyl cyclase activity and inhibits 
production of the proinflammatory cytokine IL-12, thereby reducing the ability of 
the DC to promote the differentiation of T cells o the Th-1 phenotype, and 
stimulates the production of the anti-inflammatory cytokine IL-10 (Panther et al. 
2001, 2003). In mature DCs the A2A ARs is the predominant subtype and A2A 
ARs activation decreass the production of IL-6, IL-12 and TNF-α (Schnurr et al. 
2004). Moreover IL-3-induced maturation of human DCs results in a 
downregulation of A1 ARs and an upregulation of A2A ARs (Schnurr et al. 2004). 
The mouse DC line XS-106 expresses functional A2A ARs and A3 ARs 
(Dickenson et al. 2003). A2A ARs activation increases cAMP levels and p42/p44 
MAPK phosphorylation, whereas activation of  A3 ARs inhibits cAMP 
accumulation and increases in p42/p44 MAPK phosphorylation. Functionally, the 
activation of both subtypes produces a partial inhibition of LPS-induced release of 
TNF-α. 
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Lymphocytes 
Lymphocytes are critically involved in adaptive immunity. Adenosine regulates 
multiple physiologic processes and inflammatory actions on lymphocytes. In early 
studies, it was demonstrated in mixed human lymphocytes that R-PIA and low 
concentrations of adenosine (1-100 nM) inhibit cAMP accumulation via A1 ARs 
mechanism, while high concentrations of adenosine (100 nM- 100 µM) stimulated 
cAMP via an A2A ARs mechanism (Marone et al. 1986, 1992). CD4+ and CD8+ T 
lymphocytes express A2A ARs, A2B ARs and A3 ARs (Gessi et al. 2004, 2005; 
Hoskin et al. 2008). In activated human CD4+ and CD8+ T lymphocytes, A2B ARs 
expression is increased and its activation is linked to decreased IL-12 production. 
Activation of human CD4+ T lymphocytes with phytohemagglutinin results in 
increases in A3 ARs mRNA and protein levels that are accompanied by increased 
agonist potency (Gessi et al. 2004). A number of studies suggest that A2A ARs 
engagement on CD4+ T lymphocytes results in an anti-inflammatory effects. In 
mouse CD4+ T lymphocytes, A2A ARs engagements inhibits T-cell receptor 
(TCR)-mediated production of IFN-γ (Lappas et al. 2005). TCR activation results 
in A2A ARs mRNA upregulation, which functions as an anti-inflammatory 
mechanism for limiting T-cell activation and subsequent macrophage activation in 
inflamed tissues (Lappas et al. 2005). Activation of the A2A ARs on CD4+ T 
lymphocytes prevents myocardial ischemia-reperfusion injury by inhibiting the 
accumulation and activation of CD4+ T cells in the reperfused heart (Yang et al 
2006b). moreover, an anti-inflammatory role in chronic inflammation was 
demonstrated for the A2A ARs in an in vivo murine model of inflammatory bowel 
disease, where activation of the A2A ARs attenuated the production of IFN-γ, 
TNF-α and IL-4 in mesenteric T lymphocytes in a rabbit models of colitis 
(Odashima et al. 2005). The result of a study (Takahashi et al. 2007b) suggest that 
the anti-inflammatory effect of adenosine in lymphocytes is mediated by A2A ARs 
and a proinflammatory effect is closely associated with A1 ARs. As such, the net 
effect of adenosine on lymphocytes activated by IL-8 is a complex function due to 
the presence of ARs. In primary cultures of B lymphocytes, activation of B-cell 
antigen receptors results in the activation of NF-κB pathways (Minguet et al. 
2005). Adenosine inhibits the NF-κB pathways by a mechanism related to 
increased of cAMP levels and activation of PKA. This study suggest that 
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adenosine-mediated signals represent an important step in mediating the 
activation of B lymphocytes. In activated human and mouse natural killer (NK) 
cells, adenosine inhibited the production of cytokines and chemokines 
(Raskovalova et al. 2006). In in vitro studies with lymphocytes derived from 
mouse spleen, A1 ARs activation increased NK cells activity while A2A ARs 
activation decreased NK cells activity (Priebe et al. 1990). In mouse LAK cells, 
the adenosine agonist CADO inhibited the cytotoxic activity and attenuated the 
production of IFN-γ, granulocyte macrophage colony-stimulating factor, TNF-α 
and MIP-1 α (Lokshin et al. 2006). Taken together, these results suggest that 
elevated adenosine levels in tumors may inhibit the tumoricidal effect of activated 
NK cells. In addition, recent studies have shown that adenosine exhibits anti-
infllammatory activities by engagin A2A ARs on regulatory cells (Deaglio et al. 
2007). 
ATP receptors on immune cells 
Extracellular ATP is an important mediator of cell-to-cell interactions in the 
nervous, vascular and immune system. In pathologic conditions, as inflammation, 
ATP can highly increase, following its release by damage cells, elevated levels of 
ATP led to the activation of purinergic receptors (P2X and P2Y). The activation 
by ATP of inflammatory/immune cells leads to their release of some 
inflammatory mediators. The blockade of the purinergic-mediated activation of 
the inflammatory/immune cells might represent a useful tool to reduce the 
spreading of the inflammatory response. 
 
Neutrophils 
Neutrophils are the body's first line of defence against pathogens and are critical 
effectors in both innate and humoral immunity. ATP may contribute to the 
regulation of neutrophil function during inflammatory and immune responses 
Furthermore, neutrophils are capable of releasing both ATP and adenosine 
following inflammatory activation. The functions of neutrophils may thus be 
subject to autocrine and paracrine control by endogenous ATP and adenosine. 
Neutrophils have been shown to express P2Y1,2,4,6,11,14 and P2X1,4,5,7 receptor 
subtypes (Verghese et al., 1996; Jin et al., 1998; Mohanty et al., 2001; Moore et 
al., 2001b; Suh et al., 2001; Moore et al., 2003b; Chen et al., 2004; Meshki et al., 
2004). P2 receptor density in neutrophils may be subtype-specific. As a model of 
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promyelocytic neutrophil progenitors, human leukemic HL-60 cells have been 
shown to weakly express P2X1,5 moderately express P2X7 and P2Y1,11 and 
strongly express P2Y2,4,6 receptor subtypes. Granulocytic differentiation of HL-60 
cells was shown to induce upregulation of P2X5 and P2Y11 receptor subtypes, but 
downregulation of P2X7 receptors (Adrian et al., 2000; Communi et al., 2000, 
2001). ATP at high micromolar concentrations may contribute to the 
differentiation of HL-60 cells into neutrophil like cells via stimulation of P2Y11 
receptors (Communi et al., 2000, 2001). Although mRNA for the P2X7 receptor 
has been detected in human polymorphonuclear neutrophils (PMN) (Chen et al., 
2004), functional expression of this receptor subtype by neutrophils remains 
controversial. Using a mouse anti-human P2X7 receptor monoclonal antibody, Gu 
and co-workers detected little expression of P2X7 receptor protein on the surface 
of PMN. However, these authors reported the presence of large intracellular 
amounts of P2X7 protein in PMN, and suggested that these might constitute an 
intracellular receptor reserve from which P2X7 receptors may be recruited to the 
surface following cellular activation (Gu et al., 2000). Extracellular ATP has been 
shown to stimulate neutrophil adhesion to endothelial cells (Rounds et al., 1999). 
Up-regulation of endothelial adhesion molecules such as E-selectin near 
inflammatory sites allows circulating neutrophils to tether to the endothelium, 
which results in rolling of neutrophils. ATP at low millimolar concentrations has 
been shown to induce up-regulation of E-selectin through P2X7 receptor-mediated 
activation of NF-κB (Goepfert et al., 2000). During rolling along the endothelium, 
neutrophils are primed by various chemoattractants and chemokines secreted by 
endothelial cells. Micromolar concentrations of ATP have been shown to induce a 
rapid up-regulation of Mac-1 in neutrophils (Akbar et al., 1997). Following firm 
adhesion, neutrophils extravasate by transmigrating through the vascular 
endothelium. Extracellular ATP may facilitate transmigration by increasing 
endothelial permeability via activation of P2Y receptors (Tanaka et al., 2004). 
Once extravasated, neutrophils migrate to sites of inflammation or tissue damage; 
a process which is mediated by a variety of chemokines and chemoattractants. 
Effects of extracellular ATP on neutrophil migration are equivocal. At 
micromolar ATP concentrations, neutrophil motility (chemotaxis and 
chemokinesis) has been shown either to be: (a) unaffected (Aziz & Zuzel, 2001), 
(b) inhibited (Elferink et al., 1992), or (c) promoted via stimulation of P2Y2 
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receptors (Kaneider et al., 2004). ATP may also indirectly affect neutrophil 
migration by modulating formation of the potent neutrophil chemoattractant 
leukotriene (LT)-B4, which is formed from arachidonic acid (AA) through the 5-
lipoxygenase (5-LO) pathway. High micromolar ATP concentrations were shown 
to inhibit the release of AA, whereas low micromolar concentrations stimulated 
AA release by activating neutrophil P2Y2 receptors (Xing et al., 1992). These 
findings suggest that ATP may exert a dual modulatory role on neutrophil 
migration during inflammation. At low micromolar concentrations, ATP may 
promote neutrophil accumulation via P2Y2 receptor activation, either directly by 
acting as a chemoattractant or indirectly by facilitating LTB4 production. 
Moreover, since ATP has been shown to stimulate production of IL-8 by both 
eosinophils and astrocytes (John et al., 2001; Idzko et al., 2003), ATP-mediated 
stimulation of chemokine release by cells near sites of tissue damage may 
contribute to neutrophil recruitment towards these sites. Upon arriving at inflamed 
sites where ATP levels are the highest, neutrophil recruitment may be no longer 
affected, even inhibited by ATP, allowing the neutrophils to exert their 
bactericidal functions. The first step in the bactericidal function of neutrophils is 
phagocytosis of pathogens, which has been shown to be stimulated by low 
micromolar concentrations of both ATP and ADP via activation of Mac-1 
(Miyabe et al., 2004). Through activation of P2Y2 receptors (Meshki et al., 2004), 
micromolar concentrations of extracellular ATP stimulate the degranulation of 
both primary (Meshki et al., 2004) and secondary (specific) granules (Aziz & 
Zuzel, 2001). P2Y2 receptor-mediated LTB4 generation, which may subsequently 
enhance granule secretion in an autocrine manner, has been proposed as a 
mechanism for nucleotide-induced neutrophil degranulation during inflammation 
(Kannan, 2001, 2002, 2003). In addition to stimulating degranulation, 
extracellular ATP has been shown to contribute to the initiation of the oxidative 
burst. ATP appears to prime neutrophils for functional responses to various 
inflammatory mediators, as indicated by increased production of reactive oxygen 
species (ROS, O2− and H2O2) (Tuluc et al., 2005). Extracellular ATP at millimolar 
concentrations may induce ROS production even in quiescent neutrophils via 
stimulation of P2X7 receptors (Suh et al., 2001). Extracellular ATP at micromolar 
concentrations has been shown to delay neutrophil apoptosis in synergy with the 
neutrophil survival factor granulocyte macrophage colony-stimulating factor 
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(GM-CSF), thus extending the functional life span of neutrophils (Gasmi et al., 
1996). 
 
Monocytes and macrophages 
Monocytes and macrophages express multiple P2 receptor subtypes, i.e., 
monocytes express P2Y1,2,4,6,11,12,13 and P2X1,4,5,7 receptors (Gu et al., 2000; 
Chessel et al., 2001; Mehta et al., 2001; Moore et al., 2001b;Warny et al., 2001; 
Aga et al., 2002; Into et al., 2002a; Zhang et al., 2002; Derks and Beaman, 2004; 
Sluyter et al., 2004; Wang et al., 2004; Kaufmann et al., 2005), and macrophages 
express the same receptor subtypes except for P2Y13 (Bowler et al., 2003; Hanley 
et al., 2004; Coutinho-Silva et al., 2005). P2 receptor expression may depend on 
maturation stage, since up-regulated expression of P2X7 as well as P2Y receptors 
was noted upon differentiation of monocytes into macrophages (Falzoni et al., 
1995). P2 receptor expression may also depend on the nature of cellular 
activation, since P2X7 receptor expression and function appears to be up-regulated 
following classical activation of monocytes and macrophages by IFNγ, TNFα or 
LPS (Lemaire and Leduc, 2003). Classical activation of monocytes and 
macrophages with IFNγ and LPS has been shown to induce downregulation of 
P2Y2 receptor expression. (Martin et al., 1997). In contrast, activation of rat 
alveolar macrophages by the cytokines IL-4 and IL-10 was shown to induce 
down-regulation of functional P2X7 receptors (Lemaire and Leduc, 2003). 
Extracellular ATP and ADP have been shown to increase adhesiveness of human 
promonocytic U937 cells (Ventura and Thomopoulos, 1991, 1995), suggesting 
that endogenous nucleotides may contribute to the adhesion of inflammatory 
monocytes to the vascular endothelium. Interaction of selectins with their 
respective ligands slows down rapidly flowing monocytes (monocyte rolling), a 
process to which ATP may contribute by up-regulating E-selectin expression 
through P2X7-mediated activation of NFκB (von Albertini et al., 1998; Goepfert 
et al., 2000). Stimulation of monocyte P2X7 receptors has been shown to induce 
shedding of L-selectin from the surface of monocytes (Sluyter et al., 2004). This 
might indicate that ATP at high extracellular levels contributes to activation and 
transmigration of monocytes, as leukocytes shed L-selectin upon activation and 
during (trans-)migration. Indeed, ATP was shown to stimulate transmigration of 
murine monocytes through an endothelial cell monolayer (Goepfert et al., 2001). 
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Subsequent to transmigration, monocytes migrate to inflammatory foci in 
response to various chemoattractants. Both ATP and ADP at micromolar 
concentrations have been shown to stimulate chemotaxis of murine monocytes as 
well as rat microglial cells (McCloskey et al., 1999; Goepfert et al., 2001; Honda 
et al., 2001). Similar levels of extracellular ATP were also shown to stimulate 
chemokinesis (i.e. undirected cell motility) of human monocytes (Kaufmann et al., 
2005). Although the mechanism by which extracellular nucleotides mediate these 
chemotactic effects have not been clarified to date, stimulation of monocyte 
migration could be P2 receptor-mediated. Production of soluble immunomediators 
such as cytokines, chemokines and eicosanoids is essential in immunity and 
involves the activation of several transcription factors, including NFκB and 
activator protein AP-1. NFκB is activated in monocytes and macrophages by 
stimulation of P2X7 receptors Many studies have confirmed that ATP at 
millimolar concentrations stimulates production of IL-1α, IL-1β  IL-6, IL-18 
(Mehta et al., 2001; Muhl et al., 2003; Sluyter et al., 2004) and TNFα (Guerra et 
al., 2003). These stimulatory effects are likely mediated through P2X7 receptor 
activation. IL-1β is a potent pro-inflammatory cytokine mediating acute 
inflammatory responses. Mechanisms involved in ATP-mediated stimulation of 
IL-1β release have been extensively studied. Thus, extracellular ATP appears to 
be a crucial signal that triggers the synthesis and release of mature IL-1β 
following monocytes and macrophages priming by an inflammatory signal such as 
LPS. Binding of ATP to P2X7 receptors causes opening of the channel and 
depletion of intracellular potassium, resulting in activation of Ca2+-independent 
phospholipase A2 (iPLA2), which induces generation of active caspase-1 that 
catalyzes the formation of mature IL-1β from proIL-1β (Sluyter et al., 2004). An 
important function of inflammatory macrophages is phagocytosis and elimination 
of potentially harmful pathogens. For this purpose, macrophages are equipped 
with a diverse array of cytotoxic effector functions, including the secretion of 
proteolytic enzymes and the production of ROS and reactive nitrogen species 
(RNS) However, uncontrolled cytotoxicity and cell killing may result in 
considerable collateral damage to healthy tissues. ATP has been shown to 
modulate macrophage phagocytosis bi-directionally depending on its extracellular 
concentration. Phagocytosis was inhibited through P2X7 receptor activation at 
millimolar ATP concentrations, while it was stimulated through activation of 
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P2Y2 receptors at lower ATP levels (Sung and Silverstein, 1985; Ichinose, 1995). 
Proteolytic enzyme secretion is affected in a similar bidirectional fashion. 
Whereas ATP at millimolar levels has been shown to increase lysosomal enzyme 
secretion via stimulation of P2X7 receptors in macrophages (Labasi et al., 2002), 
ATP as well as ADP inhibited lysosomal enzyme secretion at micromolar 
concentrations in one study (Riches et al., 1985). 
 
 
Dendritic cells 
Dendritic cells (DCs) are antigen-presenting innate immune cells whose specific 
function is to activate naive T cells and to initiate primary immune responses. 
Human DCs have been shown to express P2X1,4,5,7 and P2Y1,2,4,6,11,13,14 receptor 
subtypes (Berchtold et al., 1999; Ferrari et al., 2000; Wilkin et al., 2001; Idzko et 
al., 2002; Zhang et al., 2002; Schnurr et al., 2003; Skelton et al., 2003; Georgiou 
et al., 2005). Purinergic receptor expression may depend on degree of DC 
maturity, since expression of P2Y11 and P2Y14 receptor subtypes was shown to be 
downregulated upon maturation of monocyte-derived DCs (MoDCs) (Skelton et 
al., 2003). ATP at low micromolar concentrations transiently enhanced 
endocytotic activity of human immature DCs (Schnurr et al., 2000). ATP also 
appears to affect migration of DCs, as originally reported by Liu and co-workers 
who demonstrated that DCs migrated towards a pipette containing ATP (Liu et al., 
1999). Subsequent studies showed that low micromolar concentrations of ATP as 
well as UDP and UTP stimulated migration of DCs by activating P2Y receptors 
(Idzko et al., 2002; la Sala et al., 2002; Schnurr et al., 2003; Idzko et al., 2004b). 
In contrast, a gradient of ATP and chemokines, which is likely to occur at sites of 
inflammation or tissue damage in vivo, resulted in inhibition of chemokine-
directed migration of human MoDCs through activation of P2Y11 receptors 
(Schnurr et al., 2003). The authors hypothesized that ATP, after initially 
stimulating DC migration towards sites of inflammation, may cause an arrest in 
movement of DCs arriving at these inflammatory sites by activating P2Y11 
receptors, thereby prolonging exposure of DCs to antigens and factors inducing 
DC maturation. Extracellular ATP may in fact be one of the factors involved in 
DC maturation, as micromolar ATP concentrations have been shown to induce 
up-regulation of maturation markers (CD80, CD83, CD86, CD54 and major 
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histocompatibility complex MHC-II) in human peripheral blood mononuclear cell 
(PBMC)-derived immature DCs (Schnurr et al., 2000; la Sala et al., 2001;Wilkin 
et al., 2001, 2002; Marteau et al., 2004), possibly by stimulation of the P2Y11 
receptor subtype. Purinergic signaling by extracellular nucleotides is thought to 
modulate cytokine production by DCs, resulting in a specific cytokine profile that 
appears to depend on which P2 receptor subtype is being activated. The first 
indication of such an effect came from an experiment showing that murine fetal 
skin-derived DCs (FSDCs) selected for low P2X7 receptor expression released 
less IL-1β upon co-incubation with Th lymphocytes than wild-type FSDCs, which 
express the P2X7 receptor subtype at a high level (Mutini et al., 1999). When 
coincubated with syngeneic Th cells, the ATP-resistant FSDCs also showed 
reduced T cell-stimulatory activity in comparison with wild-type cells, as judged 
by the ability to trigger IL-2 secretion by T cells (Mutini et al., 1999). Prolonged 
exposure (>15–30 min) to millimolar ATP concentrations causes morphological 
changes and eventually apoptosis of mouse and human DCs (Mizumoto et al., 
2002; Sluyter and Wiley, 2002). These cytotoxic effects of ATP, which were 
shown to be mediated by the P2X7 receptor and partly depended on activation of 
caspase-1 and caspase-3 (Coutinho-Silva et al., 1999; Falzoni et al., 2000), may 
contribute to the removal of DCs after antigen delivery to lymphocytes in 
lymphoid tissues. 
 
Lymphocytes 
Lymphocytes are central to humoral and cellular immune responses, two major 
lymphocyte subclasses are B and T cells expressing antigen-specific receptors, 
which are the hallmark of adaptive immunity. T lymphocyte function may be 
subject to autocrine or paracrine regulation by extracellular nucleotides as 
suggested by three lines of evidence. First, T lymphocytes are capable of releasing 
ATP upon activation (Filippini and Sitkovsky, 1990; Canaday et al., 2002; Into et 
al., 2002b; Loomis et al., 2003). Second, T lymphocytes express purinergic 
receptors for extracellular nucleotides. Several P2X receptor subtypes are 
expressed in peripheral T lymphocytes, such as, P2X1,4,5,7 (Chused et al., 1996; Gu 
et al., 2000; Smith et al., 2001; Di Virgilio et al., 2001; Li et al., 2001; Adinolfi et 
al., 2002; Budagian et al., 2003; Loomis et al., 2003; Wang et al., 2004). Although 
mRNA of P2Y1,2,4,6,11,12,13,14 receptor subtypes has been detected in resting 
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peripheral T lymphocytes (Jin et al., 1998; Somers et al., 1998; Moore et al., 
2001a; Duhant et al., 2002; Zhang et al., 2002; Moore et al., 2003a; Wang et al., 
2004), P2Y receptors are thought to be nonfunctional in these cells (Oshimi et al., 
1999; Duhant et al., 2002). However, T cell activation during immune responses 
may induce expression of functional P2Y receptor subtypes. The third line of 
evidence, which would suggest extracellular nucleotide-mediated regulation of T 
lymphocyte function, comprises the expression of several purine-metabolizing 
ecto-enzymes by T lymphocytes. Lymphocytes are thought to be characterized by 
an ATP regenerating/Adenosine-eliminating phenotype allowing them to maintain 
surrounding ATP at steady-state levels (Yegutkin et al., 2002). Extracellular ATP 
has been shown to induce shedding of L-selectin from T lymphocytes via 
activation of P2X7 receptors (Elliott and Higgins, 2004). Since L-selectin is 
primarily involved in lymphocyte homing to lymphoid tissues and is shed upon 
lymphocyte activation, ATP may be involved in migration of activated 
lymphocytes to sites of inflammation. Purine nucleotides may also indirectly 
facilitate transendothelial lymphocyte extravasation by impairing vascular barrier 
function. Henttinen and co-workers demonstrated that adhesion of lymphocytes to 
endothelial cells suppressed endothelial purine metabolism (Henttinen et al., 
2003). Extracellular ATP may be involved in lymphocyte proliferative responses. 
In murine peripheral T lymphocytes, ATP at concentrations of 0.5–2 mM was 
shown to inhibit proliferation of both resting and stimulated cells (Ikehara et al., 
2004; DosReis et al., 1986). These inhibitory effects might be due to breakdown 
of ATP to adenosine. Using human peripheral blood lymphocytes, ATP at 
micromolar levels (100–300 µM) was shown to be a co-stimulator of mitogen-
induced CD4+ and CD8+ T lymphocyte proliferation via activation of a P2X 
receptor channel, possibly the P2X7 receptor (Baricordi et al., 1996). The P2X7 
receptor is expressed on normal B lymphocytes (Collo et al., 1997; Markwardt et 
al., 1997; Smith et al., 2001), but also on CD5+ B lymphocytes from chronic 
lymphocytic leukemia (CLL) patients (Barden et al., 2003). NK cells are a subset 
of lymphocytes that appear to have a specific capacity for spontaneous cytolysis 
of tumor and virus-infected cells. Research on the effects of nucleotides on the 
activity of NK cells is very limited; existing knowledge derives mainly from 
studies done in the early 1990s. A study reported a dose-dependent inhibition of 
NK cell-mediated cytotoxic activity by exogenous ATP, probably by interacting 
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with P2 purinergic receptors. It was shown that ATP (micromolar) treatment of 
these NK cells neither induced a non-specific decrease in the number of viable 
cells, nor showed specific elimination of the NK cells (Krishnaraj, 1992). In 
human NK cells, incubation with extracellular purine nucleotides resulted in an 
inhibition of the IL-2 dependent NK proliferation, which was stronger for ATP 
than for adenosine. Koziak and co-workers showed in human NK cells a 
correlation between the levels of CD39 expression and ATP diphosphohydrolase 
(ATPDase) activity (Koziak et al., 1999) The presence of mRNAs specific for 
purinergic P2 receptors (P2Y1, P2X4, and P2X7) in these NK cells would suggest 
a regulation of the purinergic signaling by the CD39/ATPDase co-expression. 
 
 
ATP and adenosine as endogenous signaling molecules in immunity and 
inflammation 
 
The extensive available data on the immunologic effects of purinergic signaling 
by extracellular ATP and adenosine, as presented in the previous paragraphs, 
gives overwhelming evidence that these endogenous signaling molecules and their 
purinergic receptors play a major role in immunity and inflammation. However, 
the presented data also suggest that the role of ATP and adenosine in immunity 
and inflammation is extremely complex and interdependent. Existing knowledge 
derives mainly from in vitro studies, which are directed towards unravelling 
biochemical mechanisms at molecular receptor and post-receptor levels, rather 
than providing a general picture of physiological or pathological conditions in 
vivo. The immunological role of ATP and adenosine is best viewed within the 
scope of a model which provides a functional explanation for the initiation of 
inflammatory and immune responses as well as their resolution, in short, for the 
regulation of immunity. One theory, which has gained considerable empirical 
support over the past decade and that complements the classical infectious-nonself 
theory of immunity, is the so-called “Danger theory”, which proposes that the 
immune system is principally occupied with detecting “danger”, defined as 
anything causing tissue damage or cellular stress (Matzinger, 1994, 2001, 2002; 
Heath and Carbone, 2003; Jerome and Corey, 2004). According to this line of 
thought, substances causing damage or emerging during, after or because of 
damage constitute danger signals that alert and instruct the immune system 
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(Gallucci & Matzinger, 2001; Rock et al., 2004; Skoberne et al., 2004). A 
distinction is made between on the one hand exogenous danger signals, which are 
typically the pathogen-associated molecular patterns (PAMPs; e.g. LPS) 
triggering responses through ligation of pattern-recognition receptors (PRRs; e.g. 
TLRs), and on the other hand endogenous danger signals, which can be produced 
by activated immune cells (e.g. cytokines) or can derive from stressed or damaged 
tissue cells. These latter tissue-derived distress signals have recently also been 
called damage-associated molecular patterns (DAMPs) (Seong and Matzinger, 
2004). DAMPs initiate and regulate immune responses in co-operation with other 
danger signals, and should ideally be entities that: (1) are constitutively present at 
high intracellular concentrations, (2) are normally present at negligible 
extracellular concentrations, (3) are easily released in response to injury, infection 
or other inflammatory stimuli, (4) are able to activate selective and specific 
cellular receptors responsive over a wide range of concentrations, and (5) are 
quickly degraded following their release (Di Virgilio et al., 2003; Di Virgilio, 
2005). Both ATP and adenosine meet all five of the above prerequisites, and may 
therefore be considered as DAMP molecules. For the purpose of clarity, 
inflammatory and immune responses are divided into three stages, which partly 
overlap (Chaplin, 2003; Gilroy et al., 2004; Sherwood and Toliver-Kinsky, 2004). 
The first stage encompasses the onset of acute inflammation and the initiation of 
primary immune responses upon encounter with infectious or injurious agents. 
The second stage comprises the modulation and fine-tuning of ongoing 
inflammatory and immune responses by endogenous immunoregulatory 
substances. Finally, the third stage encompasses the down-regulation of immune 
responses, the induction of inflammatory resolution and the restoration of 
damaged tissues to preserve cellular homeostasis. These three stages will be used 
as a steppingstone to positioning purinergic signaling by extracellular ATP and 
adenosine in immunity and inflammation. In the first stage, extracellular ATP 
mainly functions as a proinflammatory and immunostimulatory mediator in the 
microenvironment of damaged cells. ATP may be part of a group of endogenous 
molecules that have recently been termed ‘alarmins’ (Oppenheim and Yang, 
2005). These multifunctional molecules appear to be an unique subgroup of 
endogenous danger signals since they exhibit both chemotactic and activating 
effects on leukocytes, particularly DCs, thereby displaying potent innate immuno-
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enhancing activity (Oppenheim and Yang, 2005). ATP is present in the cell 
cytosplasm at millimolar concentrations and is released from the intracellular 
compartment upon cellular stress or non-physiological necrotic cell death. 
Extracellular ATP concentrations in the local microenvironment of damaged cells 
can rise considerably, marking the damaged site and contributing to the promotion 
of inflammation and the initiation of primary immune responses. From this point 
of view, ATP at high extracellular concentrations appears to be a natural 
endogenous adjuvant released from injured and dying cells, which initiates 
inflammation and has an augmenting effect to amplify and sustain cell-mediated 
immunity through P2 receptor-mediated purinergic signaling. At an early phase 
following cell damage, when ATP levels are highest, the receptor subtype most 
likely involved in sensing the purinergic danger is the P2X7 receptor (Elliott and 
Higgins, 2004). Via activation of P2X7 receptors, ATP induces the production of 
cytokines such as IL-1β, IL-2, IL-12, IL-18 and TNFα by residing immune cells, 
triggering the inflammatory response and inducing type 1 lymphocyte 
polarization. Highlevel signaling through other P2 receptors probably also 
contributes to the pro-inflammatory and immunostimulatory role of ATP. 
Recruitment of leukocytes to damaged sites is promoted by ATP as well as other 
adenine and uridine nucleotides, which also induce inflammatory activation of 
neutrophils, classical activation of macrophages, maturation and Th1 cell-
stimulatory capacity of DCs, and proliferation and activation of lymphocytes. In 
the second stage, the immunological role of ATP appears to shift gradually from 
being mostly immunostimulatory to being more immunomodulatory. In addition, 
extracellular adenosine mainly appears to predominate as an anti-inflammatory 
mediator at this stage. Over-activation of the immune system may lead to 
uncontrolled or chronic inflammation resulting in collateral cell damage and 
destruction of healthy tissues. Therefore, inflammatory and immune responses 
must be tightly regulated to protect the host. For this purpose, the immune system 
disposes of several regulatory molecules that orchestrate host responses by 
controlling inflammatory and immune responses (Nathan, 2002). Extracellular 
ATP and adenosine could be endogenous regulatory molecules comprising a 
purinergic feedback system. Crucial components of such a purinergic feedback 
system are the purinergic receptors mediating the immunological effects of 
extracellular nucleotides and nucleosides, as well as the ectoenzymes mediating a 
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purinergic cascade that leads to a progressive decrease in nucleotide 
concentrations and an increase in nucleoside concentrations. The expression 
profile of purinergic receptors as well as of ecto-enzymes by immune cells 
changes under inflammatory conditions, allowing for the progressive acquisition 
of an immunomodulatory purinergic repertoire expressed by the cells involved in 
inflammatory and immune responses. The ecto-enzymes CD39 and CD73 control 
extracellular nucleotide concentrations and thereby regulate the extent of 
purinergic signaling, as evidenced by several studies using ecto-enzyme knock-
out models (Goepfert et al., 2000, 2001; Mizumoto et al., 2002; Eltzschig et al., 
2003, 2004; Koszalka et al., 2004). It appears that low-level purinergic signaling 
by P2 receptors, induced by nucleotides at decreased concentrations, modulates 
ongoing inflammatory and immune responses. Activation of P2 receptors, most 
probably P2Y receptor subtypes, attenuates pro-inflammatory cytokine production 
by monocytes and macrophages, diminishes Th1 cell-stimulatory capacity of DCs 
and inhibits lymphocyte effector functions. Thus, upon progression of the immune 
response, nucleotide-mediated purinergic signaling may switch from being 
predominantly pro-inflammatory to being mostly immunomodulatory, depending 
on the extracellular concentrations of the nucleotides as well as the P2 receptor 
subtype(s) ligated by these nucleotides. This switch could be part of a mechanism 
by which the effector class of an immune response is being fine-tuned and re-
directed by microenvironmental signals according to the tissue in which the 
response occurs (Di Virgilio et al., 2003; La Sala et al., 2003; Mazzoni and Segal, 
2004). However, evidence for such an immunomodulatory role of low-level ATP-
mediated purinergic signaling is very limited. ATP at low micromolar 
concentrations markedly inhibited the inflammatory reaction by inhibiting TNFα 
release and stimulating IL-10 release in immunostimulated whole blood, even 
under conditions of severe oxidative stress (Swennen et al., 2005, 2006). Since 
natural cell-to-cell interactions are preserved in this diluted whole blood system 
and blood components are present in in vivo ratios with non-cellular components, 
this ex vivo system is a good reflection of the natural environment. Furthermore, 
adenosine-mediated P1 receptor signaling during the second stage down-regulates 
neutrophil effector functions, contributes to alternative activation of macrophages, 
stimulates Th2 cell-stimulatory capacity of DCs and inhibits lymphocyte effector 
functions. At the final stage, extracellular adenosine appears to be an important 
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immunosuppressive and tissue-healing factor. Like ATP, adenosine can also be 
considered as a danger molecule because its extracellular levels rise markedly in 
response to tissue damage. However, unlike ATP, rising extracellular adenosine 
levels in response to damage inflicted by overactive host immune cells mediate an 
autoregulatory immunosuppressive loop to protect healthy tissues from these 
‘dangerous’ immune cells. Damage-associated increases in extracellular 
adenosine thus represent a ‘second’ danger signal that is sensed by P1 receptors 
(Frantz et al., 2005). Inflammatory mediators progressively up-regulate the 
expression of the P1 receptor subtypes through which adenosine mediates its 
immunosuppressive effects (Varani et al., 2003; Gessi et al., 2004b; Lappas et al., 
2005a; Murphree et al., 2005; Fortin et al., 2006). Using receptor knock-out 
models, the A2A AR subtype has been considered to play a non-redundant role in 
down-regulating cell-mediated immunity and in activating pro-resolution 
pathways (Thiel et al., 2005; McColl et al., 2006). A1, A2B and A3 ARs also 
contribute to the adenosine-mediated negative feedback signaling (Lee et al., 
2004a, 2004b; Tsutsui et al., 2004; Sun et al., 2005; Tilley and Boucher, 2005). 
Adenosine mediated signaling by these purinergic receptors induces an 
angiogenic switch in macrophages or deactivates macrophages, suppresses 
proliferation and effector functions of lymphocytes, and promotes angiogenesis 
and tissue regeneration. In conclusion, although it is still far from clear how 
extracellular ATP and adenosine exert their immunologic roles, they appear to be 
crucial endogenous signaling molecules in immunity and inflammation. Because 
ATP and adenosine are unstable molecules with a short half-life, they probably 
operate only transiently in the local microenvironment of cells in an autocrine or 
paracrine manner. Purinergic signaling constitutes one of the mechanisms by 
which the immune system tailors inflammatory and immune responses according 
to the host's need for protection against danger. Purinergic signaling molecules 
may be beneficial in the treatment of immune-related diseases, as signaling by 
extracellular adenosine may contribute to the anti-inflammatory effects of low-
dose methotrexate, which probably is one of the most prescribed anti-
inflammatory drug in the treatment of patients with RA (Cronstein, 2005). Thus in 
view of the pivotal role of the immune system in health and disease, current 
research on endogenous immunomodulatory molecules, ATP and adenosine 
included, may help devise novel strategies for the treatment of human diseases. 
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AIM OF THE THESIS 
 
The nucleotide ATP is normally present in every living cell of the human body 
and is well-known for its role in intracellular energy metabolism. In addition to 
this intracellular role, ATP in the extracellular compartment is thought to 
contribute to the regulation of a variety of other biological processes, including 
cardiac function, neurotransmission, muscle contraction, vasodilatation, bone 
metabolism, liver glycogen metabolism and inflammation. The human immune 
system comprises an interactive network of lymphoid organs and immune cells, 
and is essential to host defense. Interaction between the various components of the 
immune system during activation is realized by multiple signaling molecules. 
These molecules, which can be released in response to tissue injury or exogenous 
pathogens, signal danger to the host and are necessary for initiating primary 
immune responses as well as for controlling the course and resolution of the 
concomitant inflammatory processes. Extracellular nucleotides such as ATP may 
function as endogenous signaling molecules that control inflammation and 
immune responses. Modulation of inflammatory processes by extracellular ATP is 
complex and results from specific effects on a wide variety of both immune and 
non-immune cells. The role of ATP in immunity is closely related to one of its 
breakdown products, the nucleoside adenosine. Adenosine has an already 
established role in immunity, in which it may contribute to the engineering of 
inflammation and immune reponses by providing a suppressive tissue-protecting 
signal in a delayed, negative feedback manner. Animal models of asthma, 
ischaemia, arthritis, sepsis, inflammatory bowel disease and wound healing have 
helped to elucidate the regulatory roles of the various adenosine receptors in 
dictating the development and progression of disease. The notion of an 
interrelation between ATP and adenosine is firmly based on the presence of a 
large family of purinergic receptors. Several enzymes, which are also expressed 
by various immune and non-immune cells, are involved in a purinergic cascade by 
which extracellular purine levels and the ensuing purinergic signaling can be 
dynamically controlled during inflammatory. This recent heightened awareness of 
the role of ATP and adenosine in the control of immune and inflammatory 
systems has generated excitement regarding the potential use of purinergic-based 
therapies in the treatment of inflammatory diseases.  
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On this background, the aim of this study is to investigate the role of A1, A2A, A2B 
and A3 ARs, P2X1 and P2X3 in chondrocytes and fibroblast-like synoviocytes that 
are the cells mainly involved in inflammatory processes of joint diseases such as 
osteoarthritis and rheumatoid arthritis. The study in chapter 1 describes the 
presence and binding parameters of A1, A2A, A2B and A3 ARs in bovine 
chondrocytes and fibroblast-like synoviocytes. To this aim saturation, competition 
binding experiments and western blotting assays to adenosine receptors in bovine 
chondrocytes and fibroblast-like synoviocytes were performed. In the adenylyl 
cyclase and proliferation assays the potency of typical high-affinity agonists was 
evaluated to characterized the functional responses of ARs. In the chapter 2 the 
role of adenosine analogs stimulation on prostaglandin E2 (PGE2) release and 
cyclooxygenase-2 (COX-2) expression in bovine fibroblast-like synoviocytes was 
investigated. Saturation and competition binding experiments were performed by 
using adenosine agonists such as CHA, CGS 21680, NECA and Cl-IB-MECA. 
Bovine fibroblast-like synoviocytes were treated with TNF-α and 
lipopolysaccharide (LPS) to activate inflammatory response. Adenosine analogs 
were added to control and TNF-α- or LPS- treated cultures both in the absence 
and presence of adenosine deaminase (ADA) which is used to depleted 
endogenous adenosine. The modulation of PGE2 release was measured by 
immunoassay and COX-2 expression was evaluated by RT-PCR. Chapter 3 
reports the pharmacological and functional characterization of ARs in human 
fibroblast-like synoviocytes derived from patients with OA. To this aim mRNA, 
western blotting, saturation binding experiments and cAMP assays were 
performed. To better investigate the functional role of adenosine in human 
fibroblast-like synoviocytes, the activation of MAPK and NF-κB and the release 
of TNF-α and IL-8 were analized. In chapter 4 thermodynamic parameters such 
as standard free energy, enthalpy and entropy (∆G°, ∆H° and ∆S° respectively) of 
the binding equilibrium of well-known purinergic agonists and antagonists to 
human P2X1 and P2X3 receptors, expressed in HEK-293 cells, were determined. 
To this aim saturation binding experiments were performed by using 
[3H]αβmethyleneATP as radioligand, and the van’t Hoff analysis were conducted 
with the aim to investigate the driving forces associated with the drug-receptor 
interaction. The thermodynamic characterization of human purinergic P2X1 and 
P2X3 expressed in HEK-293 cells, represents an important point to better 
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investigate purinergic receptors in native tissues. As a consequence, in chapter 5 
a biochemical and functional characterization of P2X1 and P2X3 receptors were 
performed in bovine chondrocytes. In particular saturation, competition binding 
experiments, western blotting, thermodynamic analysis and 
immunohistochemistry assays in bovine chondrocytes were performed to better 
analized purinergic receptors. The pharmacological characterization of purine 
receptors was completed by functional assays to evaluated the effect of purinergic 
agonists and antagonists on NO and PGE2 release. The study in chapter 6 
describes, in fibroblast-like synoviocytes obtained from OA patients and in SW 
982 cells derived from human synovial sarcoma, a pharmacological 
characterization of P2X1 and P2X3 receptors. To this aim mRNA, western 
blotting, saturation and competition binding experiments were performed to 
characterize the purinergic receptors. In addition NF-κB activation, TNF-α, IL-6 
and PGE2 production were also evaluated by means of enzyme-linked 
immunosorbent assays. 
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CHAPTER 1: 
 
Characterization of adenosine receptors in bovine 
chondrocytes and fibroblast-like synoviocytes. 
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INTRODUCTION 
 
Chronic inflammation is a significant factor in the pathophysiology of many 
forms of joint disease. Adenosine has been reported to reduce inflammation in 
several in vivo models suggesting a potential value of this purine nucleoside as a 
therapeutic mediator of inflammatory joint disease able to limit articular cartilage 
degeneration (Tesh et al., 2002, 2004). In the peripheral system, adenosine has 
been shown to limit systemic inflammatory responses through receptor-mediated 
regulation of a wide variety of cell types (Varani et al., 1997; Gessi et al., 2004). 
Adenosine interacts with four cell surface receptor subtypes named as A1, A2A, 
A2B and A3, which are coupled to different G-proteins (Fredholm, 2001). A1 and 
A3 receptors mediate inhibition of the adenylate cyclase activity, in contrast both 
A2A and A2B subtypes stimulate cAMP (cyclic AMP) accumulation. A role of 
adenosine in modulating chondrocytes and fibroblast-like synoviocytes is 
documented by previous studies. In chondrocytes it has been reported that 
adenosine and its analogs were capable of altering cAMP and nitric oxide (NO) 
production (Tesh et al., 2002, 2004). In addition, it seems likely that for normal 
cartilage function, extracellular adenosine levels must be quite tightly regulated 
since depletion leads to increased glycosaminoglycan (GAG) release and the 
production of matrix metalloproteinases (MMPs) such as MMP-3 and MMP-13, 
prostaglandin E2 (PGE2) and NO, whilst its increase may trigger chondrocyte 
death (Tesh et al., 2004; Benton et al., 2002; Mistry et al., 2006). In fibroblast-like 
synoviocytes adenosine receptor stimulation is involved in the regulation of 
MMPs (Boyle et al., 1996, 1997). Recently, in human synoviocytes it has been 
reported the selective involvement of the A2A AR subtype in the 
immunomodulatory actions of methotrexate (Ralph et al., 2005) Further, in vivo 
adenosine A2A AR agonists inhibit cartilage damage when used in the treatment of 
septic arthritis by diminishing interleukin-8 expression and GAG loss and reduce 
rat adjuvant induced arthritis (Boyle et al., 2002; Cohen et al., 2004, 2005). 
Although A2A and A2B ARs transcripts have been described in articular 
chondrocytes (Koolpe et al., 1999), however, the binding parameters such as 
affinity and density of adenosine subtypes have not been investigated in 
chondrocytes and fibroblast-like synoviocytes. From this background, the aim of 
this study was to investigate the expression and binding parameters of the A1, A2A, 
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A2B and A3 ARs in bovine chondrocyte and fibroblast-like synoviocyte 
membranes. The ARs most involved in inflammatory process were the subtypes 
A2A and A3 thus we also performed competition experiments, cAMP levels and 
cell proliferation assays of A2A or A3 ARs agonists. 
 
MATERIALS AND METHODS 
 
Chondrocyte monolayer cultures 
Bovine articular cartilage derived from the metacarpophalangeal joints of 14-18-
month-old animals (Limousine breed). Chondrocytes were isolated from cartilage 
fragments obtained from the weight-bearing region of the articular surface 
(Pezzetti et al., 1999). Briefly, the cartilage was dissected out and cut into small 
pieces. Pieces were subjected to a sequential digestion in Dulbecco’s modified 
Eagle’s/Ham’s F12 (1:1) medium (DMEM/F12) with pronase from Streptomyces 
griseus  for 90 min and collagenase P from Clostridium histolyticum for about 12 
h. The resulting cell suspension was filtered to remove undigested cartilage. 
Chondrocytes were recovered by centrifugation, counted and plated at high 
density (150,000/cm2) in 75 cm2 flasks and in multiwells (6.6 x 6.6 cm, 1.6 cm the 
diameter of each well). Chondrocytes were cultured in DMEM/F12 supplemented 
with 10% fetal bovine serum (FBS) and antibiotics (penicillin 100 U/ml, 
streptomycin 0.1 mg/ml) (complete medium). Only chondrocytes without 
subculturing and maintained in culture for 1 week were used in the binding and 
functional experiments. 
 
Fibroblast-like synoviocyte cultures 
Fibroblast-like synoviocytes were obtained by culture of the bovine synovial 
fluid. Synovial fluid was aspirated from the metacarpophalangeal joints of 14-18-
month-old animals by a syringe. Then, fresh synovial fluid was diluted 1:4 with 
complete medium and plated in 25 cm2 culture flasks (Falcon, Becton Dikinson 
and Company, Franklin Lakes, NJ, USA). After 3 h, medium was removed and 
fresh complete medium was added to the flasks. Cells were maintained in culture 
and passaged when reaching confluence. Synovial cells at the third and fourth 
passages were used for the analysis of adenosine receptors. 
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Chondrocytes and fibroblast-like synoviocytes characterization 
The expression of aggrecan, type II and type I collagens in the same chondrocyte 
monolayer cultures used for binding experiments was evaluated by 
immunohistochemistry as previously described (De Mattei et al., 2004). 
Incubations with the primary mouse monoclonal antibody to aggrecan (1:50) and 
the rabbit polyclonal to collagen type II (1:200) (Abcam, Cambridge Science 
Park, Cambridge, UK) were performed for 1 h at 37°C. Fibroblast-like 
synoviocytes were characterized by immunofluorescence staining with vimentin, 
a specific cellular marker for mesenchymal cells (Upragarin et al., 2005). Cells 
were fixed with cold methanol, washed with phosphate buffer saline (PBS) and 
incubated with the primary mouse antibody specific for the human vimentin at 
1:200 dilution for 1 h at 37°C. Washed slides were then incubated with a 
secondary fluorescein isothiocyanate-conjugated goat anti-mouse antibody for 1 h 
at 37°C in the dark. Antibodies were from Sigma-Aldrich S.r.l. (Milan, Italy). 
Fluorescence was visualized using the Nikon Eclipse TE 2000-E microscope 
(Nikon Instruments Spa, Sesto Fiorentino, Firenze, Italy) equipped with a digital 
camera (DXM 1200F, Nikon Instruments Spa, Sesto Fiorentino, Firenze, Italy). 
To confirm that fibroblast-like synoviocyte cultures were not contaminated by 
macrophages, CD14 expression was evaluated by reverse transcription 
polymerase chain reaction (RT-PCR). Total RNA extraction was performed using 
a commercial kit. RNA conversion to cDNA was performed using the commercial 
kit Superscript First-strand Synthesis System for RT-PCR (Invitrogen Life 
Technologies, Carlsbad, CA, USA). Two microliters of cDNA were amplified by 
specific oligonucleotide primers for CD 14 (dp50-CTG GAA GCC GGC G-30; 
rp50-AGC TGA GCA GGA ACC TGT GC-30). Primer sequences were selected 
to amplify both human and bovine genome and were from separate exons to 
exclude a possibly genomic DNA contamination of the RNA samples. PCR 
reactions were performed in a total volume of 25 ml containing 1 U Taq DNA 
polymerase (Roche Molecular Biochemicals, Indiana, USA), 25 pmol of each 
primer, 200 mM deoxynucleotide triphosphates (dNTPs) in 1 x PCR buffer (10 
mM Tris, pH 8.3, 50 mM KCl, 1.5 mM MgCl2). Cycling parameters were as 
follows: 1 min at 94°C, 1 min at 55°C, 1 min at 72°C for CD14. The size of the 
amplified sequence was 403 bp. mRNA from human macrophages was used as a 
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positive control for CD14 expression. PCR products were analyzed on 1.5% 
agarose gel, stained with ethidium bromide. 
 
Preparation of bovine chondrocytes and fibroblast-like synoviocytes 
membranes 
For membrane preparation, the culture medium was removed the cells were 
washed with PBS and scraped off T75 flasks in ice-cold hypotonic buffer (5 mM 
Tris HCl, 2 mM EDTA pH 7.4). The cell suspension was homogenized by using a 
Polytron and was centrifuged for 30 min at 100,000g. The membrane pellet was 
resuspended in the same buffer solution used in the binding experiments, 
incubated with 2 IU/ml of adenosine deaminase for 30 min at 37°C and 
centrifuged for 30 min at 100,000g. Finally the suspension was used in saturation 
and competition binding experiments. The protein concentration was determined 
according to a Bio-Rad method with bovine albumin as reference standard. 
 
Western blotting of ARs  
Chondrocytes and fibroblast-like synoviocytes were harvested and washed with 
ice-cold PBS containing 1 mM sodium orthovanadate, 104 mM 4-(2-aminoethyl)-
benzenesulfonyl fluoride, 0.08 mM aprotinin, 2 mM leupeptin, 4 mM bestatin, 1.5 
mM pepstatin A, and 1.4 mM E-64. Then cells were lysed in Triton lysis buffer 
and the protein concentration was determined using bicinchoninic acid (BCA) 
protein assay kit (Pierce, Illinois, USA). Aliquots of total protein sample (50 mg) 
were analyzed using antibodies specific for human A1, A2A, A2B and A3 ARs (1 
mg/ml dilution) (Merighi et al., 2002). Filters were washed and incubated for 1 h 
at room temperature with peroxidase-conjugated secondary antibodies (1:2000 
dilution). Specific reactions were revealed with Enhanced Chemiluminescence 
Western blotting detection reagent (Amersham Biosciences, New York, USA). 
 
Saturation and competition binding experiments to ARs  
The chondrocyte and synoviocyte membranes were used for the A1, A2A, A2B and 
A3 binding experiments (Varani et al., 2002, 2003a). Saturation binding 
experiments to A1 ARs were performed according to the method described 
previously using [3H]-1,3-dipropyl-8-cyclopentyl-xanthine ([3H]-DPCPX, specific 
activity 120 Ci/mmol; NEN-Perkin Elmer Life and Analytical Sciences, USA) as 
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radioligand (Borea et al., 1994). The membranes derived from chondrocytes or 
fibroblast-like synoviocytes (100 mg of protein/assay) with 8-10 concentrations of 
the radioligand [3H]-DPCPX (0.01-20 nM) were incubated in Tris HCl 50 mM, 
pH 7.4, for 90 min at 4°C. Non specific binding was determined in the presence of 
DPCPX 1 µM. Saturation binding experiments to A2A ARs were performed 
according to the method described previously using [3H]-4-(2-[7-amino-2-(2-
furyl)[1,2,4] triazolo [2,3-a] [1,3,5] triazin-5-yl-amino]-ethyl ([3H]-ZM 241385, 
specific activity 27.4 Ci/mmol; American Radiolabeled Chemicals Inc, Saint 
Louis, MO, USA) as radioligand (Varani et al., 2003b). The membranes derived 
from chondrocytes or fibroblast-like synoviocytes (100 mg of protein/assay) were 
incubated for 60 min at 4°C with 8-10 concentrations of the radioligand [3H]-ZM 
241385 (0.01-20 nM) and Tris HCl 50 mM, MgCl2 10 mM, pH 7.4. Nonspecific 
binding was determined in the presence of ZM241385 1 µM. Saturation binding 
experiments to A2B ARs were performed using [3H]-N-benzo [1,3[dioxol-5-yl-2-
[5-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-1-methyl-1H-
pyrazol-3-yloxy]-acetamide ([3H]-MRE 2029F20, specific activity 123 Ci/mmol; 
Amersham International Chemical Laboratories, Buckinghamshire, UK) as 
radioligand (Gessi et al., 2005). The membranes obtained as previously described 
(100 mg of protein/assay) with 8-10 concentrations of [3H]-MRE 2029F20 in the 
range 0.01-20 nM were incubated in Tris HCl 50 mM, MgCl2 10 mM, EDTA 1 
mM, pH 7.4 at 4°C for 60 min. Nonspecific binding was determined in the 
presence of MRE 2029F20 1 µM. Saturation binding experiments to A3 ARs were 
performed using [3H]-5N-(4-methoxyphenylcarbamoyl) amino-8-propyl-2-(2-
furyl) pyrazolo [4,3-e]-1,2,4-triazolo [1,5-c]pyrimidine ([3H]-MRE 3008F20, 
specific activity 67 Ci/mmol; Amersham International Chemical Laboratories, 
Buckinghamshire, UK) as radioligand (Varani et al., 2000). The membranes 
treated as above mentioned (100 mg of protein/assay) with 8-10 concentrations in 
the range 0.01-50 nM of [3H]-MRE 3008F20 were incubated in Tris HCl 50 mM, 
MgCl2 10 mM, EDTA 1 mM, pH 7.4, at 4°C for 150 min. Nonspecific binding 
was determined in the presence of MRE 3008F20 1 µM. In competition 
experiments, carried out to determine the A2A or A3 affinity values, 1 nM of [3H]-
ZM241385 or 2 nM of [3H]-MRE3008F20, bovine chondrocyte or fibroblast-like 
synoviocyte membranes (100 mg of protein per assay) and at least 6-8 different 
concentrations of 2-[p-(2-carboxyethyl)-phenetyl-amino]-50-N-ethyl-
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carboxamido adenosine (CGS 21680, Sigma-RBI, St. Louis,MO,USA) or N6-(3-
iodobenzyl)2-chloroadenosine-50-N-methyluronamide (Cl-IB-MECA, Sigma-
RBI, St. Louis, MO, USA) as typical A2A or A3 adenosine agonists were incubated 
at 4°C for 60 or 150 min, respectively. In saturation or competition binding 
experiments, at the end of the incubation time, bound and free radioactivity was 
separated by filtering the assay mixture through Whatman GF/B glass fiber filters 
by using a Brandel cell harvester. The filter bound radioactivity was counted by 
Scintillation Counter Packard Tri Carb 2500 TR with an efficiency of 58%. 
 
Measurement of cAMP levels in bovine chondrocytes or fibroblast-like 
synoviocytes  
Bovine chondrocytes or fibroblast-like synoviocytes (106 cells/ml) were 
suspended in 0.5 ml incubation mixture Krebs Ringer phosphate buffer, 
containing 1.0 IU/ml adenosine deaminase and 0.5 mM 4-(3-butoxy-4-
methoxybenzyl)-2-imidazolidinone (Ro 20-1724) as phosphodiesterase inhibitor 
and preincubated for 10 min in a shaking bath at 37°C. Then the effect of a typical 
A2A adenosine agonist was studied by using CGS 21680 at different 
concentrations (1 nM-1 µM) that was added to the mixture for a further 5 min. In 
similar experimental conditions, the effect of N-ethylcarboxamidoadenosine 
(NECA) on adenosine nonselective agonist was studied. To evaluate the effect of 
a typical A3 adenosine agonist, forskolin 1 µM and Cl-IB-MECA at different 
concentrations (0.1 nM-100 nM) were added to the mixture and the incubation 
continued for a further 5 min. The effect of a selective A2A or A3 antagonists such 
as 7-(2-phenylethyl)-2-furyl)pyrazolo [4,3-e]-1,2,4-triazolo-[1,5-c] pyrimidine 
(SCH 58261) (1 mM) or MRE 3008F20 (1 mM) on CGS 21680(1 mM) or Cl-IB-
MECA (100 nM) was evaluated, respectively. The reaction was terminated by the 
addition of cold 6% trichloroacetic acid (TCA). The cells were also incubated 
with forskolin (1 mM) and/or Ro 20-1724 (0.5 mM) to evaluate the adenylyl 
cyclase activity. The TCA suspension was centrifuged at 2000g for 10 min at 4°C 
and the supernatant was extracted four times with water saturated diethyl ether. 
The final aqueous solution was tested for cAMP levels through a competition 
protein binding assay by using [3H]-cAMP as radioligand (specific activity 21 
Ci/mmol, NEN Research Products, Boston, MA, USA) (Varani et al., 2002). 
Samples of cAMP standards (0-10 pmol) were added to each test tube containing 
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trizma base 0.1 M, aminophylline 8.0 mM, mercaptoethanol 6.0 mM, pH 7.4 and 
[3H]-cAMP (at the final concentration of 1 nM). The binding protein, previously 
prepared from beef adrenals, was added to the samples and incubated at 4°C for 
150 min. At the end of the incubation time and after the addition of charcoal the 
samples were centrifuged at 2000g for 10 min. The clear supernatant was mixed 
with 4 ml of Atomlight and counted in a Scintillation Counter Packard Tri Carb 
2500 TR. 
 
[3H] Thymidine incorporation 
Chondrocytes or fibroblast-like synoviocytes were treated with CGS 21680 and 
Cl-IB-MECA (10 µM) in complete medium containing adenosine deaminase 
(ADA) and 1 mCi/ml [3H] thymidine. Cells cultured in the absence of adenosine 
agonists were used as controls. After 24 h of labeling cells were trypsinized, and 
[3H] thymidine was evaluated as previously described (Merighi et al., 2002). In all 
cultures, cell viability was evaluated by the Trypan blue exclusion test (Merighi et 
al., 2005). 
 
Statistical analysis 
A weighted nonlinear least-squares curve fitting program Ligand (Munson and 
Rodbard, 1980) was used for computer analysis of saturation and competition 
binding experiments. Functional experiments were calculated by nonlinear 
regression analysis using the equation for a sigmoid concentration-response curve 
(GraphPAD Prism, San Diego, CA, USA). Analysis of data was done with 
Student’s t test (unpaired analysis). Differences were considered significant at a 
value of p<0.01. All data are reported as mean ± S.E.M. of independent 
experiments (n=3-6). 
 
RESULTS 
 
Phenotype characterization of bovine chondrocytes and  
fibroblast-like synoviocytes 
Chondrocytes, cultured in monolayer, show phenotypic instability and can 
dedifferentiate toward the fibroblast phenotype shifting from the synthesis of type 
II to type I collagen (De Mattei et al., 2004). When analyzed by 
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immunohistochemistry, under the same experimental conditions of binding 
experiments, chondrocytes stained positive for aggrecan and type II collagen, 
specific markers of the chondrocytic phenotype, and resulted negative for type I 
collagen, which is expressed in dedifferentiated chondrocytes. Negative controls, 
obtained without primary antibodies, did not show any staining. Fibroblast-like 
synoviocytes used in our experiments showed the expression of vimentin, the 
main intermediate filament protein in mesenchymal cells and synovial fibroblast. 
Results obtained by RT-PCR showed the absence of CD14, thus indicating the 
absence of contaminating macrophages in our cultures (data not shown). 
 
Western blotting 
Figure 1.1A shows the immunoblot signals of A1, A2A and A2B ARs in bovine 
chondrocytes and fibroblast-like synoviocytes. The intensity of each band in 
immunoblot assay was quantified using molecular analyst/PC densitometry 
software (Bio-Rad). Mean densitometry data from three independent experiments 
were normalized to control that was set to 100% (figure1.1B-C). Unfortunately 
Western blot of A3 AR was undetectable probably due to the low degree of 
homology between bovines and humans. 
 
Saturation binding experiments in bovine chondrocytes and  
fibroblast-like synoviocytes 
A series of experiments were carried out to determine the binding parameters of 
A1, A2A, A2B and A3 ARs in bovine chondrocytes and fibroblast-like synoviocytes. 
Table 1.1 reports the affinity (KD, nM) and density (Bmax, fmol/mg protein) of 
A1, A2A, A2B and A3 ARs in bovine chondrocyte and in fibroblast-like synoviocyte 
membranes. The affinity values were in the low nanomolar range for both the 
substrates. Bmax values confirm the presence of all the ARs. For chondrocytes 
membrane the Bmax values were 41, 53, 51,and 79 fmol/mg protein for A1, A2A, 
A2B and A3 ARs respectively. For the fibroblast-like synoviocytes the Bmax 
values were 30, 76, 84 and 83 fmol/mg protein for A1, A2A, A2B and A3 ARs 
respectively (figure 1.2-1.3). 
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Competition binding experiments in bovine chondrocytes and  
fibroblast-like synoviocytes 
Figure 1.4 and figure 1.5 shows the competition curves of CGS 21680 and Cl-IB-
MECA in bovine chondrocyte or in fibroblast-like synoviocyte membranes, 
respectively. The affinity (Ki) of CGS 21680 or Cl-IBMECA in bovine 
chondrocyte membranes was 28 ± 3 or 2.6 ± 0.3 nM, respectively (n = 4). In 
fibroblast-like synoviocyte membranes CGS 21680 or Cl-IBMECA showed a Ki 
value of 30 ± 3 or 3.3 ± 0.3 nM, respectively (n = 4). The competition curves of 
both the agonists examined, exhibited Hill coefficients near the unity and were 
best described by the existence of one high-affinity binding site. 
 
cAMP assay in bovine chondrocytes and fibroblast-like synoviocytes 
The A2A ARs are coupled to stimulation of adenylate cyclase via Gs stimulatory 
proteins, which leads to an increase of cAMP formation. Bovine chondrocyte or 
fibroblast-like synovial cells did not reveal change of basal enzyme activity and of 
the response of adenylate cyclase activator forskolin. No change in cAMP 
production was also observed in the absence or in the presence of the cAMP-
dependent phosphodiesterase inhibitor, Ro 20-1724 (Table 1.2). We have also 
evaluated the effect of a typical A2A adenosine agonist such as CGS 21680 on the 
adenylate cyclase activity. When CGS 21680 was incubated with examined cells 
an amplification of adenylate cyclase response was detected revealing a 
significant increase of cAMP production in a concentration-dependent manner. In 
particular CGS 21680 elicited a stimulation of cAMP levels in bovine 
chondrocytes with an EC50 of 82 ± 7 nM (Figure 1.6A). Moreover, CGS 21680 
elicited a stimulation of cAMP levels in fibroblastlike synoviocytes with an EC50 
of 91 ± 8 nM (Figure 1.7A). The selective A2A antagonist SCH 58261 (1 µM) 
totally inhibited the rise in cAMP levels induced by CGS 21680 (1 µM) 
suggesting that the stimulatory effect was essentially A2A mediated (Table 1.2). 
On the contrary, the A3 ARs are coupled to inhibition of adenylyl cyclase via Gi 
proteins, which leads to decreases of cAMP formation. We have also evaluated 
the inhibitory effect of a typical A3 adenosine agonist like Cl-IBMECA on the 
adenylyl cyclase activity. Cl-IB-MECA determined a decrease of cAMP levels in 
bovine chondrocytes with an IC50 values of 6.33 ± 0.64 nM (Figure 1.6B). 
Moreover Cl-IB-MECA induced a decrease of cAMP levels in fibroblast-like 
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synoviocytes with an IC50 values of 7.90 ± 0.71 nM (Figure 1.7B). The selective 
A3 antagonist MRE 3008F20 (1 µM) antagonized Cl-IB-MECA (100 nM) 
mediated cAMP inhibition suggesting that the inhibitory effect was essentially A3 
mediated (Table 1.2). NECA, a typical adenosine receptor agonist, determines a 
stimulation of cAMP levels in bovine chondrocytes with an EC50 value of 40 ± 3 
nM. Analogous results were obtained in fibroblast-like synoviocytes with an EC50 
value of 37 ± 3 nM. This stimulatory effect due to the interaction of NECA with 
A2A and A2B ARs predominates on the inhibitory effect mediated by A1 and A3 
ARs. 
 
Cell proliferation and viability 
Chondrocytes or fibroblast-like synoviocytes treated with CGS 21680 or Cl-IB-
MECA (10 µM) showed no statistically significant modulation of cell 
proliferation (Figure 1.8). However, in fibroblast- like synoviocytes, Cl-IB-
MECA induced a slight reduction of cell proliferation. In all tested conditions cell 
viability was not changed with respect to control conditions (99% viable cells). 
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Table 1.1: Saturation binding experiments on ARs in bovine chondrocyte and 
in fibroblast-like synoviocyte membranes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Chondrocyte membranes Fibroblast-like synoviocyte 
membranes 
 
 
 
KD (nM) 
Bmax 
(fmol/mg 
protein) 
 
KD (nM) 
Bmax 
(fmol/mg 
protein) 
A1 AR 2.18±0.22 41±2 0.67±0.01 30±2 
 
    
A2A AR 1.71±0.32 53±5 2.05±0.17 76±6 
 
    
A2B AR 2.19±0.24 51±3 1.21±0.13 84±5 
 
    
A3 AR 4.61±0.35 79±5 1.86±0.22 83±4 
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Table 1.2: Basal and stimulated cAMP production in bovine chondrocytes 
and in fibroblast-like synoviocytes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*, p<0.01 vs basal levels + Ro 20-1724 for CGS 21680 and vs Forskolin + Ro 20-
1724 for Cl-IB-MECA 
 
 
 
 
 
 
 
 Chondrocytes 
(pmol cAMP x 106 cells) 
Fibroblast-like synoviocytes 
 (pmol cAMP x 106 cells) 
 
   
Basal levels 
 
10±1 11±1 
 
+ Ro 20-1724 (0.5 mM) 
 
25±2 23±2 
+ CGS 21680 (1 µM) 
A2A stimulation 
 
51±4* 50±4* 
+ CGS 21680 (1 µM) 
+ SCH 58261 (1 µM) 
 
27±2 25±2 
Forskolin  
(1 µM) 
 
98±10 96±9 
Forskolin  (1 µM) 
Ro 20-1724 (0.5 mM) 
 
120±12 112±11 
+ Cl-IBMECA (100 nM) 
A3 inhibition 
82±6* 
 
 
84±6* 
 
+ Cl-IBMECA (100 nM) 
+ MRE 3008F20 (1 µM) 
 
116±11 
 
108±11 
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Figure 1.1: Western blotting analysis of bovine chondrocytes and fibroblast-
like synoviocytes for A1, A2A and A2B ARs (A) and densitometric analysis for 
chondrocytes (B) and fibroblast-like synoviocytes (C). 
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Figure 1.2: Saturation curves and Scatchard plots of A1, A2A, A2B and A3 ARs 
(A, B, C, D respectively) in chondrocyte membranes. 
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Figure 1.3: Saturation curves and Scatchard plots of A1, A2A, A2B and A3 ARs 
(A, B, C, D respectively) in fibroblast-like synoviocyte membranes. 
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Figure 1.4: Competition curves of CGS 21680 (A) and Cl-IB-MECA (B) in 
bovine chondrocyte membranes. 
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Figure 1.5: Competition curves of CGS 21680 (A) and Cl-IB-MECA (B) in 
bovine fibroblast-like synoviocyte membranes. 
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Figure 1.6: cAMP experiments by using CGS21680 (A) and Cl-IB-MECA (B) 
in bovine chondrocytes. 
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Figure 1.7: cAMP experiments by using CGS 21680 (A) and Cl-IB-MECA 
(B) in bovine fibroblast-like synoviocytes. 
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Figure 1.8: Proliferation activity measured by [3H] thymidine incorporation 
assay in bovine chondrocytes (A) or fibroblast-like synoviocytes (B). 
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DISCUSSION 
 
The purpose of the current investigation was to document the presence and the 
binding parameters of adenosine receptor subtypes in bovine chondrocytes or in 
fibroblast-like synoviocytes. Preliminary characterization of cells used in our 
experiments showed the expression of chondrocyte and synoviocyte phenotypic 
markers, as well as the absence of contaminating cells in fibroblast-like 
synoviocyte cultures (De Mattei et al., 2004). Our pharmacological data in these 
cells report that A1, A2A, A2B and A3 ARs are expressed and similarly distributed 
in both cell types showing high-affinity values in the nanomolar range and a 
receptor density from 30 to 83 fmol/mg of protein. The results obtained in 
competition binding experiments show that the affinity of CGS 21680 or Cl-IB-
MECA in bovine chondrocytes were 28 ± 3 and 2.6 ± 0.3 nM respectively. In 
fibroblast-like synoviocytes the affinity of CGS 21680 was 30 ± 3 nM and for Cl-
IB-MECA was 3.3 ± 0.3 nM. The effect of A2A and A3 agonists on adenylyl 
cyclase activity and cell proliferation was investigated. Our results did not show 
any change of basal enzyme activity and of the response of adenylyl cyclase to the 
direct activator forskolin used in the absence or in the presence of cAMP-
dependent phosphodiesterase inhibitor (Ro 20-1724). Forskolin, which directly 
activated adenylate cyclase was utilized in this study as a positive control for 
cAMP production. Ro 20-1724, a type IV phosphodiesterase inhibitor prevented 
the rapid degradation of cAMP allowing the accurate detection of the cAMP 
levels produced. Moreover, the capability of typical A2A or A3 adenosine agonists 
such as CGS 21680 or Cl-IB-MECA to modulate cAMP levels was evaluated. 
These compounds showed potency values in the nanomolar range, in agreement 
with their affinity in binding experiments. To further confirm that the effects 
induced by the agonists on cAMP formation were due to the modulation of 
adenosine receptors investigated, we performed experiments in the presence of 
typical selective A2A or A3 adenosine antagonists such as SCH 58261 or MRE 
3008F20. These antagonists were able to prevent the effect of cAMP induced by 
CGS21680 or Cl-IB-MECA through a selective modulation of the adenylyl 
cyclase via the A2A or A3 ARs, respectively. In addition, the levels of cAMP 
increased in response to NECA, a nonselective agonist, suggesting that in 
physiological condition (presence of endogenous adenosine) the activation of A2A 
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ARs may prevail over the A3 ARs inhibitory action. This is not surprising because 
a similar behavior has already been reported in other substrates (Gessi et al., 2002, 
2004). In line with cAMP data, cell proliferation in the absence of adenosine 
agonists and in the presence of ADA was not modify even if Cl-IB-MECA 
inhibited slightly cell proliferation in fibroblast-like synoviocytes. In conclusion, 
this study shown for the first time the presence and the binding parameters of the 
A1, A2A, A2B and A3 ARs, in bovine chondrocytes and fibroblast-like 
synoviocytes. Functional assays performed on A2A and A3 ARs showed the 
involvement of these subtypes in bovine chondrocytes and fibroblast-like 
synoviocytes. These results open interesting perspectives on the modulation of 
adenosine pathways for the treatment of joint inflammatory diseases. 
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CHAPTER 2: 
 
Adenosine analogs inhibit prostaglandin E2 (PGE2)  
release in bovine fibroblast-like synoviocytes. 
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INTRODUCTION 
 
OA and RA are the most common degenerative diseases of the joints, 
characterized by the progressive and permanent degradation of the articular 
cartilage, synovial hyperthrophy and change in underlying bone. Although the 
pathophysiologic events of OA and RA are quite different, inflammation and 
altered fibroblasts-like synoviocytes activities are observed in affected joints 
(Pelletier and Martel-Pelletier, 2007; Goldring, 2007; Muller-Landner et al., 2005; 
Moulton, 1996; Christodoulou and Choy, 2006; Abeles and Pillinger, 2006). In 
RA, fibroblasts-like synoviocytes play a central role to the pathogenesis of joint 
destruction by an increased proliferation and the secretion of a wide range of 
proinflammatory mediators, including cytokines, growth factors, and lipid 
mediators of inflammation (Muller-Landner et al., 2005; Abeles and Pillinger, 
2006). Pro-inflammatory mediators produced by fibroblasts-like synoviocytes are 
detrimental to articular cartilage also in OA, although fibroblasts-like 
synoviocytes play a less central role than in RA (Pelletier and Martel-Pelletier, 
2007; Goldring, 2007). Inflammatory mediators released by SFs can impact 
several cell types including lymphocytes, neutrophils, endothelial cells, 
osteoclasts and chondrocytes and a range of processes including maintenance of 
inflammation, angiogenesis, chemoattraction. Furthermore, fibroblasts-like 
synoviocytes are involved in cartilage destruction via the synthesis and secretion 
of matrix degrading enzymes such as matrix metalloproteinases (MMPs) and 
aggrecanases (Asano et al., 2006; Westra et al., 2004; Davidson et al., 2006). 
Prostaglandins, in particular PGE2, are important lipid inflammatory mediators 
produced by fibroblasts-like synoviocytes and their levels are increased in the 
synovial fluid and synovial membrane of patients with inflammatory joint 
diseases (Park et al., 2006; Burger et al., 2003; Fahmi et al., 2001; Goetzl et al., 
1995). PGE2 is synthesized from arachidonic acid via the actions of 
cyclooxygenase (COX) enzymes, either constitutively or in response to cell 
specific trauma, stimuli, or signalling molecules such as IL-1β or TNF-α and it 
accounts for many of the proinflammatory actions induced by these peptides 
(Berenbaum, 2000; Funk, 2001; Crofford, 1999). PGE2 contributes to 
vasodilatation, vascular permeability, pain, cytokine and proteinase production in 
inflamed tissues (Hill et al., 2001; Cha et al., 2004; Agro et al., 1996). 
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Accordingly, the use of non-steroidal anti-inflammatory drugs (NSAIDs) and/or 
selective COX-2 inhibitors which control inflammation and inhibit PGE2 
production represent the standard recommended treatment of OA and RA 
(Schnitzer, 2001; Hochberg et al., 1995). Adenosine, interacting with four types of 
cell surface receptor (AR) proteins, termed A1, A2A, A2B and A3 acts as a potent 
endogenous inhibitor of inflammatory processes in several tissues (Fredholm et 
al., 2001; Varani et al., 2003a; Gessi et al., 2002, 2004). In fibroblasts-like 
synoviocytes and chondrocytes adenosine has been involved in the production of 
matrix metalloproteinases (MMPs) and inflammatory mediators (Tesch et al., 
2002, 2004). Moreover, in human fibroblasts-like synoviocytes the selective 
involvement of the A2A AR subtype in the immunomodulatory actions of 
methotrexate has been reported (Ralph et al., 2005). Further, in vivo adenosine 
analogs inhibit joint destruction when used in the treatment of adjuvant induced 
arthritis and septic arthrosis (Boyle et al., 2002). On the bases of the above 
observations and of the role of fibroblasts-like synoviocytes to elicit and to 
maintain joint inflammation, we investigated if adenosine receptor agonists, might 
limit PGE2 release in fibroblasts-like synoviocytes treated with known 
inflammatory stimuli: TNF-α and the bacterial lipopolysaccharide (LPS) (Westra 
et al., 2004; Park et al., 2004). COX-2 expression was also evaluated by RT-PCR 
as it appears to be the primary enzyme controlling PGE2 synthesis in response to 
inflammatory stimuli (Park et al., 2006; Crofford, 1999). Further, adenosine 
analogs were used to characterise the presence of adenosine receptors and their 
affinity in bovine fibroblasts-like synoviocytes. 
 
MATERIALS AND METHODS 
 
Fibroblasts-like synoviocytes cultures 
Fibroblasts-like synoviocytes were obtained by culture of the bovine synovial 
fluid, aspirated from the metacarpophalangeal joints of 14-18 month-old animals, 
as previously described (Varani et al., 2007). Fibroblasts-like synoviocytes at the 
third-fourth passage were used in the experiments. Cells were characterized by 
immunofluorescence staining with vimentin, a marker for fibroblasts (Upragarin 
et al., 2005). To confirm that SF cultures were not contaminated by macrophages, 
CD14 expression was evaluated by RT-PCR. 
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Immunofluorescence staining 
Fibroblasts-like synoviocytes were fixed with cold methanol, washed with 
phosphate-buffered saline (PBS) and incubated with the primary monoclonal 
antibody (mAb) for the human vimentin (SigmaeAldrich, Italy) at 1:200 dilution 
for 1 h at 37°C. Washed slides were then incubated with a secondary fluorescein 
isothiocyanate-conjugated goat anti-mouse antibody for 1 h at 37°C. Nuclei were 
stained with the DNA dye, 4’,6-diamidino-2-phenylindole (DAPI) (0.1 mg/ml in 
PBS ethylene glycol tetraacetic acid (EGTA)) for 10 min. Fluorescence was 
visualized using the Nikon Eclipse TE 2000-E microscope (Nikon Instruments, 
Italy) equipped with a digital camera (DXM 1200F). 
 
RT-PCR experiments 
CD14 and COX-2 expression in fibroblasts-like synoviocytes cultures was 
assayed by RT-PCR. Total RNA extraction was performed by a commercial kit 
(RNeasy Kit, Qiagen, Deutschland). RNA conversion to cDNA was performed by 
the kit SuperscriptTM First-Strand Synthesis System (Invitrogen, USA). 
Oligonucleotide primers for CD14 were dp50’-CTGGAAGCCGGCG-3’; rp5’-
AGCTGAGCAGGAACCTGTGC-3’ and oligonucleotides for glyceraldehydes 3-
phosphate dehydrogenase (GAPDH) were dp5’-TGGCAT 
CGTGGAGGGACTTAT-3’; rp5’-GACTTCAACAGCGACACTCAC-3’. 
Sequences were selected to amplify both human and bovine genome. 
Oligonucleotides for COX-2 were dp5’-TCCAGATCACATTTGATTGACA-3’; 
rp5’-TCTTTGACTGTGGGAGGATACA-3’. Oligonucleotides sequences were 
from separate exons to exclude genomic DNA contaminations. Two microliters of 
cDNA were amplified by the specific oligonucleotide sets and PCR reactions 
were performed as previously described (Varani et al., 2007). Cycling parameters 
were as follows: 1 min at 94°C; 1 min at the specific annealing temperature (55°C 
for CD14, 61°C for GAPDH, 60°C for COX-2); and 1 min at 72°C. PCR product 
sizes were 403 bp for CD14, 370 bp for GAPDH and 450 bp for COX-2. mRNA 
from human macrophages was used as a positive control for CD14 expression. 
PCR products were analyzed on 1.5% agarose gel, stained with ethidium bromide 
and visualized under UV. 
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Saturation and competition binding experiments to ARs 
Fibroblasts-like synoviocytes, used for cellular membrane preparations, were 
washed with PBS and scraped off T75 flasks in ice-cold hypotonic buffer (5 
mMTris HCl, 2 mM EDTA, pH 7.4). The cell suspension was homogenized by a 
Polytron, centrifuged for 30 min at 100,000g and used in saturation and 
competition binding experiments (Varani et al., 2007, 2002, 2003a,b). Saturation 
experiments to A1 ARs were performed using [3H]-N6-cyclohexyladenosine 
([3H]-CHA, 34.4 Ci/mmol; NEN - Perkin Elmer, USA) as radioligand for an 
incubation time of 90 min. Non-specific binding was determined in the presence 
of CHA 1 µM. Saturation experiments to A2A ARs were performed using [3H]-
CGS 21680 (39.6 Ci/mmol; NEN - Perkin Elmer, USA) as radioligand with an 
incubation time of 120 min. Non-specific binding was determined with CGS 
21680 1 µM. Saturation experiments to A2B ARs were performed using [3H]-MRE 
2029F20, (123 Ci/mmol; Amersham Laboratories, UK) as radioligand for 60 min. 
Non-specific binding was determined with MRE 2029F20 1 µM. Saturation 
experiments to A3 ARs were performed using [125I]-4-aminobenzyl-50-N-
methylcarboxamidoadenosine ([125I]-AB-MECA, 2000 Ci/mmol; Amersham 
Laboratories, UK) as radioligand, for 60 min (Varani et al., 1998). Non-specific 
binding was determined with AB-MECA 1 µM. In competition experiments, 
carried out to determine A1, A2A, A2B and A3 affinity values, 1 nM radioligands 
were used on fibroblasts-like synoviocytes membranes (100 mg protein per assay) 
and 6-8 different concentrations of the examined agonists. At the end of 
incubation time, in binding experiments performed in fibroblasts-like 
synoviocytes membranes, bound and free radioactivities were separated by 
filtering the assay mixture through Whatman GF/B filters (Brandel Harvester) and 
radioactivity was counted (Scintillation Counter Packard Tri Carb 2500TR). 
 
Fibroblasts-like synoviocytes treatments with adenosine agonists  
For the analysis of PGE2 release, fibroblasts-like synoviocytes at third-fourth 
passage were plated at 10,000/cm2 in complete medium DMEM/F12 containing 
10% FBS and antibiotics in multiwells (Nunc, Denmark, 1.6 cm the diameter of 
each well) and used after 5 days plating. In preliminary experiments increasing 
doses of the recombinant human TNF-α (Preprotech, USA) and the bacterial LPS 
(Sigma, USA) selected in the range of those used in previous studies, were tested. 
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In the following experiments TNF-α and LPS were used, respectively, at 10 ng/ml 
and 1 mg/ml, which elicited maximal PGE2 increase in preliminary experiments. 
Control cells were incubated in complete medium alone. In a first series of 
experiments adenosine analogs were added to both control and TNF-α- or LPS-
treated cultures in the presence of endogenous adenosine. The adenosine agonists 
CHA (A1 AR), CGS 21680 (A2A AR), NECA (non-selective), and Cl-IB-MECA 
(A3 AR) were used at 1 µM (Sigma, USA). In a second series of experiments, 
treatments with adenosine agonists in the presence of TNF-α or LPS were 
performed in complete medium containing 2 IU/ml adenosine deaminase (ADA, 
FlukaeSigmae Aldrich, Switzerland) to deplete endogenously released adenosine. 
Different ADA concentrations (0.5-4 IU/ml) were analyzed on PGE2 release and 
cell viability to evaluate the effect of endogenous adenosine. In some 
experiments, 1 µM forskolin (Sigma, USA), a direct activator of adenylate 
cyclase, was added to both control and TNF-α-treated cultures. At each condition 
tested, after 24 h treatment, medium was removed from the well, stored at -80°C 
for subsequent determination of PGE2 and the monolayer protein content was 
evaluated (Lowry et al., 1951). 
 
PGE2 Assay 
The concentration of PGE2 was measured using a commercially available 
competitive enzyme immunoassay according to the manufacturer’s instructions 
(PGE2 ASSAY, R&D Systems, Inc. Minneapolis, USA). Samples and standards 
were assayed in duplicate. PGE2 production was normalized to the total protein 
content and expressed as pg PGE2/µg protein. 
 
MTT assay 
Effects of ADA on cell proliferation and viability of fibroblasts-like synoviocytes 
were evaluated by the MTT assay (Ahmed et al., 2006). Briefly, 100 µl of MTT 
solution (5 mg/ml in PBS) (Sigma-Aldrich, Irvine UK) were added to each well 
and incubated at 37°C for 3 h. The medium was then discarded and 500 µl of 
isopropanol/HCl 0.04 N were added to each well for the formazan solubilization. 
The solution absorbance was measured at 540 nm (Cary-50, UV-Visible 
Spectrophotometer, Varian). 
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Statistical Analysis 
Data were obtained from at least five independent experiments. Each experiment 
was performed in triplicate. All values are expressed as mean ± SEM of four 
independent experiments. Analysis of data was done with Student’s t test. 
Differences were considered significant at a value of p<0.05. 
 
RESULTS 
 
Phenotype characterization of fibroblasts-like synoviocytes  
Fibroblasts-like synoviocytes used in our experiments are shown in Figure 2.1. 
Cells showed a fibroblast-like morphology and the expression of vimentin, the 
main intermediate filament protein in mesenchymal cells and fibroblasts-like 
synoviocytes. Results obtained by RT-PCR showed the absence of CD14 
expression, indicating the absence of contaminating macrophages. 
 
Evaluation of ARs affinity and density by saturation and competition binding 
experiments 
Table 2.1 reports the affinity (KD, nM) and density (Bmax, fmol/mg protein) of 
A1, A2A, A2B and A3 receptors in fibroblasts-like synoviocytes membranes. The 
affinity values of AR subtypes were in the low nanomolar range and the Bmax 
values were from 24 to 65 fmol/mg of protein. Table 2.2 reports the affinity 
values (Ki, nM) of CHA, NECA, CGS 21680 and Cl-IB-MECA in bovine 
fibroblasts-like synoviocytes. The major affinity of CHA (Ki = 3.5 ± 0.4 nM) was 
reported in [3H]-CHA binding suggesting a high affinity vs A1 AR. NECA and 
CGS 21680 showed similar affinity for A2A AR even if NECA had a good affinity 
also for the other subtypes. Cl-IB-MECA showed a high affinity vs A3 AR with a 
Ki value of 2.3 ± 0.2 nM. Saturation and competition binding experiments 
allowed to select, on the basis of the Ki values, the adenosine agonist 
concentrations to be used in subsequent experiments. 
 
TNF-α and LPS induce a dose response increase on PGE2 release in 
fibroblast-like synoviocytes 
In preliminary experiments we investigated the effects of increasing doses of 
TNF-α and LPS, which are known to stimulate PGE2 production in human 
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fibroblast-like synoviocytes, on PGE2 release in bovine fibroblast-like 
synoviocytes cultures (Figure 2.2). PGE2 production by control fibroblast-like 
synoviocytes was at very low levels. TNF-α and LPS significantly increased PGE2 
production in a dose-dependent manner. The most efficient doses were 10 ng/ml 
for TNF-α and 1 mg/ml for LPS yielding a maximal 7.9- and 9.8-fold increase, 
respectively. On these results, these TNF-α and LPS doses were used to stimulate 
PGE2 production in subsequent experiments. 
 
Adenosine agonist inhibit PGE2 release in TNF-α- or LPS-treated fibroblast-
like synoviocytes in the presence of endogenous adenosine  
The effects of adenosine agonists on PGE2 release in TNF-α or LPS unstimulated 
and stimulated fibroblast-like synoviocytes, in the presence of endogenous 
adenosine, are shown in figure 2.3. Treatment of cells with the A1 agonist CHA, 
the A2A agonist CGS 21680, the non-selective agonist NECA and the A3 agonist 
Cl-IB-MECA did not modify basal PGE2 production in the absence of TNF-α or 
LPS. In TNF-α stimulated fibroblast-like synoviocytes, all agonists, except for Cl-
IBMECA, significantly inhibited PGE2 production. PGE2 inhibition ranged from 
38.6% in the presence of CHA to 54.9% in the presence of NECA (Figure 2.3B). 
Similar data were obtained in LPS stimulated fibroblast-like synoviocytes (Figure 
2.3C). The effects of adenosine agonists reduced PGE2 levels to those of 
unstimulated control cells. Adenosine agonists were used at 1 µM, the 
concentration that assured a complete saturation of adenosine receptors as 
suggested from the affinity values (Ki, nM) of Table 2.2. 
 
Depletion of endogenous adenosine with ADA increases basal PGE2 release in 
fibroblast-like synoviocytes  
Fibroblast-like synoviocytes were exposed to increasing doses of ADA (0.5-2 
IU/ml) to determine the effects of depleting endogenous adenosine. PGE2 release 
slightly but significantly increased in a dose-dependent manner with maximal 
effect at 2 IU/ml (Figure 2.4A). In parallel experiments, MTT assay was 
performed to verify that in our experimental conditions ADA did not modify 
fibroblast-like synoviocytes proliferation or viability. At all the doses, ADA had 
no effect on cell proliferation and viability (Figure 2.4B). 
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Depletion of endogenous adenosine with ADA potentiates adenosine agonist’s 
effects on PGE2 release in TNF-α- or LPS- treated fibroblast-like 
synoviocytes  
As 2 IU/ml ADA induced the maximal increase in PGE2 production, this dose was 
used to deplete endogenous adenosine (Figure 2.5). Both TNF-α and LPS 
significantly stimulated PGE2 synthesis similarly to what observed in the absence 
of ADA. Also, Cl-IB-MECA did not modify PGE2 levels in TNF-α or LPS 
stimulated cells. In TNF-α or LPS stimulated fibroblast-like synoviocytes, CHA, 
CGS 21680 and NECA induced a stronger inhibition on PGE2 production than in 
the absence of ADA. In fact, CHA, CGS 21680 and NECA reduced PGE2 levels 
to those of unstimulated control cells. 
 
Forskolin stimulates PGE2 release in activated fibroblast-like synoviocytes  
As shown in figure 2.3 and 2.5, CHA and CGS 21680, which inhibit and stimulate 
adenylate cyclase, respectively, decreased PGE2 release in TNF-α or LPS 
stimulated fibroblast-like synoviocytes. To clarify the potential involvement of 
adenylate cyclase activity in the modulation of PGE2 production, we investigated 
the effects of forskolin, a potent stimulator of adenylate cyclase, on PGE2 release. 
Forskolin did not modify basal PGE2 levels. However, in fibroblast-like 
synoviocytes activated by the inflammatory stimuli, forskolin induced a further 
24.3% increase in PGE2 release. 
 
Changes in COX-2 expression are associated to the changes in PGE2 release 
induced by adenosine agonists in TNF-α- or LPS- treated fibroblast-like 
synoviocytes 
Since PGE2 levels were regulated by adenosine agonists we investigated whether 
changes in PGE2 release were associated to a regulation of COX-2 transcripts. 
COX-2 expression, evaluated by RT-PCR, at 24 h treatment, is shown in figure 
2.6. As reported in literature, in our experiments the stimulation of PGE2 synthesis 
induced by TNFα and LPS was associated to an increase of COX-2 expression 
with respect to control cells. All adenosine agonists, except for Cl-IB-MECA, 
inhibited COX-2 expression in TNF-α or LPS stimulated cells. 
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Table 2.1 Affinity and density of adenosine receptors in bovine fibroblast-like 
synoviocytes. 
 
 
 
 
 
   
 
 
 
 
 
 
Table 2.2 Affinity (Ki) of typical adenosine agonists versus A1, A2A, A2B and 
A3 ARs,  in bovine fibroblast-like synoviocytes. 
 
 
 
 
 
 
 
 
 
[3H]CHA 
binding to  
A1 ARs 
 
[3H]CGS 21680 
binding to  
A2A ARs 
[3H]MRE 2029F20 
binding to  
A2B ARs 
[3H]AB-MECA 
binding to  
A3 ARs 
KD= 1.82 ± 0.16 nM 
 
Bmax= 24 ± 3 
fmol/mg protein 
 
KD= 4.6 ± 0.5 nM 
 
Bmax= 62 ± 6 
fmol/mg protein 
KD= 1.32 ± 0.12 nM 
 
Bmax= 78 ± 8 
fmol/mg protein 
KD= 1.65 ± 0.15 nM 
 
Bmax= 65 ± 6 
fmol/mg protein 
 [3H]CHA 
binding to  
A1 ARs 
Ki (nM) 
[3H]CGS 
 21680 binding 
to A2A ARs 
Ki (nM) 
[3H]MRE 
2029F20 binding 
to A2B ARs 
Ki (nM) 
[3H]AB-MECA 
binding to  
A3 ARs 
Ki (nM) 
CHA 
 
3.5 ± 0.4 812 ± 75 > 1000 83 ± 7 
NECA 
 
22 ± 2 8.4 ± 0.8 156 ± 17 36 ± 4 
CGS21680 
 
740 ± 70 7.2 ± 0.7 > 1000 985 ± 90 
Cl-IB-MECA 
 
185 ± 22 643 ± 60 > 1000 2.3 ± 0.2 
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Figure 2.1: Bovine fibroblast-like synoviocytes in culture. Phase contrast (A) 
and vimentin expression by immunofluorescence (B) nuclei were 
counterstained in blue with DAPI. 
 
 
A 
 
 
 
 
 
B 
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Figure 2.2: Effect of increasing doses of TNF-α and LPS on PGE2 production 
in bovine fibroblast-like synoviocytes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Indicates statistical significance (p<0.05) vs control. 
 ** Indicates statistical significance (p<0.05) vs the previous dose.  
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Figure 2.3: Effect of AR agonists, in the presence of endogenous adenosine, 
on basal (A), TNF-α (B) or LPS (C) induced PGE2 production in bovine 
fibroblast-like synoviocytes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Indicates statistical significance (p<0.05) vs control. 
 ° Indicates statistical significance (p<0.05) vs inflammatory stimuli  
(TNF-α 10 ng/ml, LPS 1 µg/ml).  
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Figure 2.4: Effect of increasing doses of ADA on PGE2 production (A) and 
cell proliferation/viability evaluated by MTT test (B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Indicates statistical significance (p<0.05) vs control. 
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Figure 2.5: Effect of adenosine agonists, in the presence of ADA (2 IU/ml), on 
TNF-α (A) or LPS (B) induced PGE2 production in bovine fibroblast-like 
synoviocytes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Indicates statistical significance (p<0.05) vs control. 
 ° Indicates statistical significance (p<0.05) vs inflammatory stimuli  
(TNF-α 10 ng/ml, LPS 1 µg/ml).  
Co
ntr
ol α
TN
F-
 
+ 
CH
A
α
TN
F-  
+ 
NE
CA
α
TN
F-
 
+ 
CG
S
α
TN
F-
 
+ 
Cl-
IB-
ME
CA
α
TN
F-
0
20
40
60
80
100
120
140
160
180
*
*
° ° °
A
pg
 
PG
E 2
/ µµ µµ
g 
Pr
o
te
in
Co
ntr
ol
LP
S
LP
S +
 
CH
A
LP
S +
 
NE
CA
LP
S +
 
CG
S
LP
S +
 
Cl-
IB-
ME
CA
0
20
40
60
80
100
120
140
160
180
*
°
*
°
°
B
pg
 
PG
E 2
/ µµ µµ
g 
Pr
o
te
in
 113 
Figure 2.6: Effect of adenosine agonists on control and TNF-α (upper panel) 
or LPS (lower panel) induced COX-2 expression. 
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DISCUSSION 
 
In this study we investigated how AR agonists, might modify PGE2 release in 
bovine fibroblast-like synoviocytes treated with pro-inflammatory stimuli. 
Saturation binding experiments confirmed the presence of A1, A2A, A2B and A3 
ARs in fibroblast-like synoviocytes (Varani et al., 2007, 2002). In agreement with 
previous studies, TNF-α and LPS induced an approximately 8-10-fold increase in 
PGE2 levels in fibroblast-like synoviocytes. In a first series of experiments we 
analyzed the effects of adenosine agonists in the presence of endogenous 
adenosine. All the agonists had no effect on basal PGE2 release, however, CHA, 
NECA and CGS 21680 caused a significant inhibition on PGE2 increase induced 
by TNF-α and LPS. These data indicate for the first time the involvement of A1 
and A2 ARs in the negative modulation of PGE2 synthesis in fibroblast-like 
synoviocytes. Cl-IB-MECA did not modify PGE2 production suggesting that the 
activation of the A3 AR is not involved in the modulation of PGE2 synthesis. As 
endogenous adenosine potentially could mask the selective involvement of a 
specific AR, we investigated the agonist effects also in the presence of ADA, an 
enzyme capable to deplete adenosine levels by its ability to convert adenosine to 
inosine (Tesh et al., 2004). The presence of ADA increased basal PGE2 levels, 
confirming the involvement of adenosine in modulating PGE2 production, a 
finding consistent with the first series of experiments and with previous studies in 
cartilage cells (Petrov et al., 2005). Further, in cells treated with TNF-α and LPS, 
CHA, NECA and CGS 21680 induced a stronger PGE2 inhibition than in the 
absence of ADA; this can be explained by the increased potency of adenosine 
agonists in comparison to adenosine. Collectively, our results show that A1 and 
A2A ARs are involved in the inhibition of PGE2 production in fibroblast-like 
synoviocytes. The similar effects on PGE2 release obtained by using NECA (non-
selective agonist) and CGS 21680 (A2A AR agonist) suggest that A2B AR are not 
involved in this functional response. In addition, the lack of an effect of Cl-IB-
MECA excludes a role for the A3 AR in modulating PGE2 production. The 
canonical transduction pathway coupled to A1 and A2A ARs include, respectively, 
the inhibition and the stimulation of adenylate cyclase with consequent reduction 
and increase in cAMP levels. As both A1 and A2A agonists inhibited PGE2 release 
to a similar degree, this suggested that cAMP changes were not involved in the 
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PGE2 inhibition. Therefore, as a positive control for the adenylate cyclase 
activation, we investigated the effects of forskolin, a direct activator of this 
enzyme, on PGE2 release. Forskolin increased PGE2 release in stimulated 
fibroblast-like synoviocytes confirming that the PGE2 release inhibition observed 
in our experiments was not linked to cAMP production; these findings are 
consistent with the results described by Kojima and co-workers (Kojima et al., 
2003) in human fibroblast-like synoviocytes. Other signal transduction pathways, 
activated by ARs, might be involved in the negative regulation of PGE2 
production (Schulte and Fredholm, 2003; Ciccarelli et al., 2007). Finally, our 
results show that the ability of adenosine agonists to inhibit PGE2 release is 
mediated by a down-regulation of TNF-α - and LPS-induced COX-2 mRNA 
expression. Worth of note, a similar effect is also induced in human fibroblast-like 
synoviocytes by known anti-inflammatory drugs (Fahmi et al., 2001). The 
pharmacologic PGE2 blockade by aspirin, NSAIDs and COX-2 inhibitors has 
been a useful anti-inflammatory strategy for more than a century, however, it is 
known that the appearance of side-effects may limit the chronic use of these 
drugs. The findings of the present study open new perspectives to the control of 
inflammation associated to joint diseases. It is to note that adenosine modulate 
chondrocyte activities too. In cartilage cells, adenosine and the A2A AR have been 
involved in the inhibition of inflammatory and matrix degradative events (Tesh et 
al., 2002, 2004) promote anabolic activities and prevent cartilage degradation (De 
Mattei et al., 2003, 2004, 2007). Thus, previous observations and the results of 
this study suggest that adenosine analogs, may reduce inflammation and cartilage 
degradation in articular joints, by targeting both fibroblast-like synoviocytes and 
chondrocytes. Indeed, in vivo, the separate ability of adenosine analogs to limit 
joint destruction has been previously proven in animal models (Ciombor et al., 
2003). In conclusion, our results add new relevant data in the analysis of 
adenosine anti-inflammatory activities by showing the involvement of A1 and A2A 
ARs in the inhibition of fibroblast-like synoviocytes responses to inflammatory 
stimuli. From a clinical point of view, the pharmacological modulation of 
adenosine pathways might have relevant therapeutic potential for the treatment of 
joint inflammatory diseases. 
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CHAPTER 3: 
 
Expression and functional role of adenosine 
receptors in regulating inflammatory responses 
in human fibroblast-like synoviocytes. 
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INTRODUCTION 
Human fibroblast-like synoviocytes play a central role in the pathogenesis of joint 
destruction primarily by the secretion of a wide range of pro-inflammatory 
mediators including cytokines, growth factors and lipid mediators of 
inflammation. Pro-inflammatory agents produced by synoviocytes are detrimental 
to articular cartilage in different joint diseases such as OA and RA (Abeles and 
Pillinger, 2006; De Mattei et al., 2009). OA is the most common form of arthritis, 
and is the single most important cause of disability in older adults (Benito et al., 
2005; Goldring et al., 2007). At the present the current recommended treatment of 
OA involves weight loss, physical therapy and the use of pain relievers (Altman 
and Barkin, 2009). However these drugs do not reverse the degenerative process 
in OA and show some adverse effect on cartilage metabolism (Zhang et al., 2008). 
Adenosine is a modulator which interact with four cell surface receptor subtypes 
named as A1, A2A, A2B and A3  ARs which are coupled to different G-proteins 
(Burnstock, 2008). A1 and A3 ARs, through Gi proteins, mediate inhibition of the 
adenylate cyclase activity, whilst A2A and A2B ARs via Gs proteins stimulate 
cAMP production (Haskò et al., 2008). ARs modulation has an important role in 
the regulation of the inflammatory processes (Palmer and Trevethic, 2008; Ham 
and Rees, 2008; Gessi et al., 2008). Understanding how cytokine release is 
regulated endogenously can give important insight in various disease pathologies. 
It is well known that MAPKs like p38 are involved in controlling cellular 
responses as the release of pro-inflammatory cytokines (Fotheringham et al., 
2004). The cell signaling pathways initiated by pro-inflammatory events converge 
on activation of the NF-kB which drive cytokines transcription and production 
(Wen et al., 2006). Notably, p38 MAPK is one of the kinases implicated in the 
phosphorylation of NF-kB inhibitors (IkBs) (Westra and Limburg, 2006). Once 
phosphorylated, IkBs undergo polyubiquitination and ultimately proteosomic 
degradation, allowing NF-kB to enter the nucleus and promote the transcription of 
inflammatory genes, such as TNF-α and IL-8 (Barnes and Karin, 1997). A role of 
adenosine in modulating bovine chondrocytes and fibroblast-like synoviocytes 
activity has been documented by previous studies of our group. In bovine 
fibroblast-like synoviocytes ARs have been characterized from saturation, 
competition binding experiments and western blotting analysis (Varani et al., 
2008). Functional studies suggested an anti-inflammatory effect relative to A1 and 
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A2A ARs activation in LPS-induced PGE2 production mediated by a down-
regulation of TNF-α and COX-2 mRNA expression (De Mattei et al., 2009). It has 
been recently reported that in fibroblast-like synoviocytes from RA patients, A3 
ARs are over-expressed and an A3 stimulation mediated a reduction in 
inflammation as a decrease in NF-kB and TNF-α release (Ochaion et al., 2008). 
Furthermore it has been demonstrated that in different cells or tissues adenosine is 
a regulator of NF-kB and MAPK signalling through the interaction with their 
receptor subtypes (Majumdar et al., 2003; Schulte and Fredholm, 2003; Jijon et 
al., 2005). From this background, the aim of this study was to investigate the 
presence of ARs in primary cultures of human fibroblast-like synoviocytes cells 
from OA patients by using mRNA and western blotting assays. Saturation binding 
experiments were performed to evaluate affinity (KD) and density (Bmax) of A1, 
A2A, A2B and A3 ARs. Affinity values (Ki) of adenosine agonists and antagonists 
were determined by using competition binding experiments. In order to complete 
the pharmacological characterization, ARs were evaluated from a functional point 
of view. The effect of adenosine agonists and antagonists was investigated on 
cAMP production. Moreover, we focused the involvement of ARs on the signal 
transduction pathways including p38 MAPK and NF-kB. Consequently, the effect 
of adenosine agonists on TNF-α and IL-8 secretion were analyzed. The capability 
of adenosine antagonists to block the effect of the adenosine agonists was also 
carried out to better verify the involvement of ARs. Finally Gi, Gs and 
phosphatidylinositide-3-OH kinase (PI3K) pathways were investigated to study 
ARs signalling. 
 
MATERIALS AND METHODS 
Subjects  
Synovial tissues were obtained from patients with end-stage OA undergoing total 
joint replacement surgery. The diagnosis was based on clinical and radiological 
criteria. Human samples were collected with approved informed consent in 
accordance with the principles of the Declaration of Helsinki. The study protocol 
was approved by the local Ethics Committee of the University of Ferrara and the 
subjects provided written consent after receiving detailed verbal and written 
explanations of the study. All patients (n=35, F/M: 23/12; age: 63.7 ± 3.4 yrs) 
enrolled in this study were recruited from the Department of Biomedical Sciences 
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and Advanced Therapies, Orthopaedic Clinic of the University Hospital of 
Ferrara, Italy. Each patient underwent medical history, physical examination, 
electrocardiogram and routine blood tests. Mean disease duration expressed as 
years ± SEM was 6 ± 1. Regarding pharmacological therapy of OA, 80% of the 
enrolled patients were receiving non steroidal anti-inflammatory drugs (NSAIDs) 
and 20% had no medications. 
 
Cell culture  
Primary lines of surface adherent fibroblast-like synoviocytes were isolated by 
enzymatic digestion of synovial tissues for 2-3 hours at 37°C in DMEM 
containing 1.5 mg/ml of collagenase type I-A and 1 mg/ml of hyaluronidase 
(Sigma-Aldrich, Milan, Italy). After digestion the cells have been recovered by 
centrifugation and plated in T25 culture flasks (Miyashita et al., 2004). Human 
fibroblast-like synoviocytes were maintained in culture in DMEM, 10% FBS, 
penicillin (100 U/ml), streptomycin (100 µg/ml), L-glutamine (2 mmol/L), 
passaged when reaching confluence and used at the 3rd-4th passages for binding 
and functional experiments. CHO or HEK 293 cells transfected with human A1, 
A2A, A2B and A3 ARs were prepared as previously described. Membrane 
preparation was performed prior of the competition binding experiments as 
previously described (Varani et al., 2000; 2005). 
 
Human fibroblast-like synoviocyte characterization 
Immunofluorescence with the primary monoclonal antibody specific for the 
human vimentin (Sigma Aldrich, St Louis, MO) was used to evaluate the 
expression of vimentin, a fibroblasts marker, in primary cultures of human 
fibroblast-like synoviocytes cells, as previously described. Nuclei were stained 
with the selective DNA dye, DAPI (0.1 mg/ml in PBS-EGTA) for 10 minutes. 
Fluorescence was visualized using the Nikon Eclipse TE 2000-E microscope 
equipped with a digital camera DXM 1200F (Nikon Instruments, Firenze, Italy). 
To exclude the presence of contaminating macrophages or endothelial cells, 
fibroblast-like synoviocyte cultures have been analyzed for CD14 and von-
Willebrand factor (vWF) expression by reverse transcription polymerase chain 
reaction (RT-PCR). Briefly, 2 µl cDNA have been amplified by specific 
oligonucleotide primers for CD14 (for-5’-CTG GAA GCC GGC G-3’; rev5’-
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AGC TGA GCA GGA ACC TGT GC-3’) and for vWF (for-5’-TGG CCA GAC 
CTT GCT GAA GA-3’; rev-5’-CCA TTA TGG AGA ATC ACC TCC A-3’). 
Cycling parameters have been as follows: 1 min at 94°C; 1 min at the specific 
annealing temperature (62°C for CD14 and 55°C for vWF); and 1 min at 72°C. 
PCR product sizes are 405 bp for CD14 and 252 bp for vWF. mRNA from human 
macrophages and endothelial cells have been used as a positive control for CD14 
and vWF expression respectively (Miyashita et al., 2004). 
 
RT-PCR experiments  
Total cytoplasmic RNA was extracted by the acid guanidinium thiocyanate phenol 
method. Quantitative real-time RT-PCR assay (Gessi et al., 2004) of A1, A2A, A2B 
and A3 mRNAs was carried out using gene-specific fluorescently labelled 
TaqMan MGB probe (minor groove binder) in a ABI Prism 7700 Sequence 
Detection System (Applied Biosystems, Warrington Cheshire, UK). For the real-
time RT-PCR of A1, A2A, A2B and A3 adenosine receptors the assays-on-demandTM 
Gene expression Products NM 000674, NM 000675, NM 000676 and NM 000677 
were used respectively. For the real-time RT-PCR of the reference gene the 
endogenous control human GAPDH kits was used, and the probe was fluorescent-
labeled with VICTM (Applied Biosystems, Warrington Cheshire, UK). Genomic 
contamination was ruled out by including an RT-negative sample in each PCR set 
as a control.  
 
Western blotting analysis  
Human fibroblast-like synoviocytes were washed with ice-cold phosphate buffer 
saline containing sodium orthovanadate 1 mM,  4-(2-aminoethyl)-benzenesulfonyl 
fluoride 104 mM, aprotinin 0.08 mM, leupeptin 2 mM, bestatin 4 mM, pepstatin 
A 1.5 mM, E-64 1.4 mM (Sigma Aldrich, St Louis, MO). Cells were then lysed in 
Triton lysis buffer and the protein concentration was determined using BCA 
protein assay kit (Pierce, Rockford, IL). Aliquots of total protein sample (50 µg) 
were analyzed using antibodies specific for human A1, A2A, A2B and A3 ARs (1 
µg/ml dilution, Alpha Diagnostic, San Antonio, TX) and P-p38 (1 µg/ml dilution, 
Cell Signaling Technology, Danvers, MA)  (Merighi et al., 2002). Filters were 
washed and incubated for 1 hour at room temperature with peroxidase-conjugated 
secondary antibodies (1:2000 dilution). Specific reactions were revealed with 
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Enhanced Chemiluminescence Western blotting detection reagent (GE 
Healthcare, UK). Western blotting assays were also normalized against the 
housekeeping protein β-actin. 
 
Saturation and competition binding experiments to ARs 
To obtain membrane preparation the culture medium was removed and the cells 
were washed with PBS and scraped off T75 flasks in ice-cold hypotonic. The cell 
suspension was homogenized by using a Polytron, centrifuged for 30 min at 
100000 g and used in the saturation and competition binding experiments. 
Saturation binding experiments on human fibroblast-like synoviocyte membranes 
were performed by using [3H]-DPCPX, [3H]-ZM241385, [3H]-MRE 2029F20 and 
[3H]-MRE 3008F20 as radioligands to study the presence of A1, A2A, A2B and A3 
ARs, respectively. Briefly, these radioligands at different concentrations (0.01-20 
nM or 0.01-30 nM) were incubated with 100 µg of protein per assay of membrane 
suspension for 90 min at 25°C (A1 AR) or 60 min at 4°C (A2A and A2B ARs) or 
150 min at 4°C (A3 AR). Competition binding experiments of 1 nM [3H]-DPCPX, 
[3H]-ZM 241385, [3H]-MRE 2029F20 and [3H]-MRE 3008F20 were carried out 
to determine the A1, A2A, A2B and A3 ARs affinity values of the selected adenosine 
agonists and antagonists, respectively. In these assays human fibroblast-like 
synoviocyte membranes (100 µg protein per assay) were incubated with different 
concentrations of the examined agonists CHA, CGS 21680, NECA, Cl-IB-MECA 
and antagonists DPCPX, SCH 58261, MRE 2029F20 and MRE 3008F20. Non 
specific binding was determined in the presence of DPCPX, ZM 241385, MRE 
2029F20 or MRE 3008F20 at the 1 µM concentration, respectively and was 
always < 25% of the total binding. Similar experiments were also performed by 
using A1, A2A, A2B and A3 adenosine agonists such as CHA, CGS 21680, NECA 
and Cl-IB-MECA at the 1 µM concentration, respectively and was always < 30% 
of the total binding. At the end of incubation time, bound and free radioactivity 
were separated by filtering, in a Brandel cell harvester, the assay mixture through 
Whatman GF/B glass-fiber filters. The filter bound radioactivity was counted in a 
liquid Scintillation Counter Tri Carb Packard 2500 TR (Perkin-Elmer Life and 
Analytical Sciences, Boston, USA). Similar competition binding experiments 
were performed in CHO cells transfected with human A1, A2A or A3 ARs and 
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A2BHEK 293 cells with the aim to evaluate affinity and selectivity of adenosine 
agonists and antagonists used in functional assays. 
 
Measurement of cAMP levels 
Human fibroblast-like synoviocytes (106 cells per sample) were suspended in 0.5 
ml incubation mixture Krebs Ringer phosphate buffer, containing adenosine 
deaminase 1.0 IU/ml (Sigma, St Louis, MO) and preincubated for 10 min in a 
shaking bath at 37°C. Then the effect of  selected adenosine agonists was studied 
by using CHA, CGS 21680, NECA and Cl-IB-MECA at 1 µM concentration. To 
better investigate the inhibitory effect of CHA and Cl-IB-MECA the cells were 
also incubated with forskolin (1 µM) and/or Ro 20-1724 (0.5 mM) as 
phosphodiesterase inhibitor. A1, A2A, A2B and A3 selected adenosine antagonists 
as DPCPX, SCH 58261 MRE 2029F20 and MRE 3008F20 at the 1 µM 
concentration were also used to verify the specific involvement of these subtypes 
in cAMP production. The final aqueous solution was tested to evaluate cAMP 
levels by using a competition protein binding assay with [3H]-cAMP. At the end 
of the incubation time (150 min at 4°C) and after the addition of charchoal the 
samples were centrifuged at 2000 x g for 10 min and the clear supernatant was 
counted in a liquid Scintillation Counter Tri Carb Packard 2500 TR (Perkin-Elmer 
Life and Analytical Sciences, Boston, USA). 
 
NF-kB activation  
Nuclear extracts from human fibroblast-like synoviocytes were obtained by using 
a nuclear extract kit (Active Motif, Carlsbad, USA) following the manufacturer’s 
instructions. The NF-kB activation was evaluated by detecting phosphorylated 
p50 and p65 proteins in nuclear extracts by using the TransAM NF-kB kit (Active 
Motif, Carlsbad, USA). Phosphorylated NF-kB subunits specifically bind to the 
immobilized oligonucleotides containing the NF-kB consensus site (5’-
GGGACTTTCC-3’). The primary antibody used to detect NF-kB recognized an 
epitope on each subunit that is accessible only when activated and bound to its 
DNA target. A horseradish peroxidase (HRP)-conjugated secondary antibody 
provided a sensitive colorimetric readout that was quantified by 
spectrophotometry at 450 nm. 
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TNF-α and Il-8 release  
TNF-α and Il-8 levels were measured in human fibroblast-like synoviocytes by 
using a highly sensitive enzyme linked immunosorbent assay (R and D Systems, 
Minneapolis, USA) in accordance with the manufacturer’s instructions. 
 
Data and statistical analysis 
The protein concentration was determined according to a Bio-Rad method with 
bovine albumin as reference standard (Bradford MA, 1976). A weighted non 
linear least-squares curve fitting program Ligand was used for computer analysis 
of saturation and competition binding experiments (Munson and Rodbard, 1980). 
Functional experiments were calculated by non linear regression analysis using 
the equation for a sigmoid concentration-response curve (GraphPAD Prism, San 
Diego, CA, USA). Analysis of data was performed by repeated measures analysis 
of variance (ANOVA) followed by Bonferroni test that was used for multiple 
comparisons of data sets and was considered significant at a value of p<0.02. All 
data are reported as mean ± SEM of independent experiments. Each experiment 
was performed by using the fibroblast-like synoviocytes derived from one single 
donors, and was done in duplicate (for binding experiments) or in triplicate (for 
functional experiments). The experiments were repeated at least 3 or 4 times as 
indicated from n values that showed the number of patients used.  
 
RESULTS 
 
Phenotype characterization of human fibroblast-like synoviocytes  
Cells isolated from synovial of OA patients showed to be a homogenous 
population as demonstrated by their fibroblast-like morphology (Figure 3.1A). 
Primary cultures of human fibroblast-like synoviocytes cells also showed the 
expression of vimentin, a specific cellular marker for mesenchymal cells and 
fibroblast-like synoviocytes (Figure 3.1B). RT-PCR data showed that, under our 
experimental conditions, mRNA for CD14 and vWF were not amplified, 
suggesting the absence of macrophage and endothelial cell contamination in 
fibroblast-like synoviocytes cell cultures (Figure 3.1C).  
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Evaluation of ARs mRNA expression and protein level  
Figure 3.2A shows adenosine mRNA in human fibroblast-like synoviocytes by 
using real-time quantitative RT-PCR. The present analysis performed with 
primers specifically designed for the various cloned human ARs revealed the 
expression of A1, A2A, A2B and A3 mRNA. In particular, high levels of A2A and A3 
mRNA were found in human fibroblast-like synoviocytes. The presence of ARs 
was also confirmed by western blot analysis (Figure 3.2B). In human fibroblast-
like synoviocytes A2A and A3 ARs were present with a higher expression than A1 
and A2B ARs as demonstrated by densitometric analysis reported in figure 3.2C.  
 
Saturation and competition binding experiments 
Saturation binding experiments in primary cultures of human fibroblast-like 
synoviocytes membranes were performed to evaluate affinity (KD) and receptor 
density (Bmax) of ARs. Figure 3.3A illustrate saturation binding curves relative to 
A1, A2A, A2B and A3 ARs showing affinity in the nanomolar range and different 
receptor density. Scatchard plot analysis revealed the presence of an high affinity 
binding site as suggested by the linearity of the lines (Figure 3.3B). Computer 
analysis of the data failed to show a significantly better fit to a two site than to a 
one site binding model, indicating that in our experimental conditions is primarily 
present one class of high affinity binding site. Competition binding experiments to 
A1, A2A, A2B and A3 ARs by using selected adenosine agonists and antagonists in 
human fibroblast-like synoviocytes membranes were performed (Figure 3.4). As 
expected, CHA and Cl-IB-MECA showed biphasic competition binding curves 
versus A1 and A3 ARs, respectively as suggested by a significantly better fit to a 
two site binding model and by an Hill coefficient less than unity (0.54 and 0.63, 
respectively). Their competition binding curves were best described by the 
existence of one high affinity (KH) and low affinity (KL) agonist-receptor binding 
state (Figure 3.4A,D). Moreover, CGS 21680 and NECA agonists revealed good 
affinity values versus A2A and A2B ARs confirming a tight coupling between the 
receptors and G protein. For CGS 21680 and NECA, Hill coefficients were close 
to unity excluding the involvement of multiple coupling affinity states (Table 3.1). 
In addition, competition binding experiments were also carried out studying 
selected adenosine antagonists as DPCPX, SCH 58261, MRE 2029F20 and MRE 
3008F20 revealing Ki values in the nanomolar range (Table 3.1). The affinity of 
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the adenosine agonists and antagonists versus human A1, A2A, A2B and A3 ARs 
expressed in CHO or HEK 293 cells was reported and compared with human 
fibroblast-like synoviocytes in Table 3.1. CHA showed an high affinity versus A1 
AR similarly to those obtained in human fibroblast-like synoviocytes. Our 
experimental data revealed a good affinity of CGS 21680 and NECA versus A2A 
AR. Cl-IB-MECA presented a very high affinity versus human A3 AR. DPCPX, 
SCH 58261, MRE 2029F20 and MRE3008F20 showed an high affinity versus A1, 
A2A, A2B and A3 ARs, respectively (Table 3.1). The high affinity in human 
fibroblast-like synoviocytes of these adenosine antagonists confirmed the binding 
with A1, A2A, A2B and A3 ARs, respectively (Table 3.1). 
 
cAMP assays 
The A2A and A2B ARs are coupled to stimulation of adenylate cyclase via Gs 
proteins which mediates an increase of cAMP production. CGS 21680 and NECA 
at the 1 µM concentration were able to mediate a significant increase in cAMP 
formation reaching 65-90 pmoles per 106 cells, respectively. The presence of a 
selective A2A antagonist as SCH 58261 demonstrates a complete reduction in 
cAMP production (Figure 3.5A). MRE 2029F290 an A2B adenosine antagonist, 
was only able partially to inhibit NECA-stimulated cAMP levels because of the 
dual effect of NECA as stimulatory agent for A2A and A2BARs (Figure 3.5A). The 
effect of A1 and A3 agonists as CHA and Cl-IB-MECA (1 µM) was evaluated in 
the presence of 1 µM forskolin and Ro 20-1724 (0.5 mM). This experimental 
condition was chosen for the low basal levels (15-20 pmol cAMP per assay) 
which hamper the evaluation of a direct inhibitory effect. In our experimental 
conditions CHA and Cl-IB-MECA were able to decrease cAMP levels by 70%. 
DPCPX was not able to abrogate completely the inhibitory effect of CHA 
probably for A3 AR activation. On the other hand, MRE 3008F20 blocked the 
inhibitory effect induced by the selective A3 agonist.  
 
p38 MAPK activation 
Western blotting analysis showed that LPS (10 µg/ml) was able to increase 
phospho-p38 levels of 72% in comparison to basal levels. All adenosine agonists 
investigated at the 100 nM  concentration were not able to significantly modify 
phospho-p38 levels (data not shown). Interestingly, at the 1 µM concentration 
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adenosine agonists such as CGS 21680 and NECA were able to inhibit 
significantly in a similar way the LPS-stimulated P-p38 levels (Figure 3.6A,B). 
Moreover, Cl-IB-MECA (1 µM) was also able to inhibit the LPS-stimulated P-
p38 levels although in a minor extent (Figure 3.6A,B). SCH 58261 and MRE 
3008F20 blocked the inhibitory effect of CGS 21680 and Cl-IB-MECA, 
respectively. On the contrary, MRE 2029F20 was not able to abrogate NECA 
effect probably due to the persistent A2A and A3 NECA modulation. CHA (1 µM) 
in the absence and in the presence of DPCPX (1 µM) had no effect in the 
modulation of P-p38 levels suggesting that A1 AR were not implicated. 
 
NF-kB activation in human fibroblast-like synoviocytes  
NF-kB levels were evaluated studying p50 (Figure 3.7A) and p65 (Figure 3.7B) 
subunits activation. In primary cultures of human fibroblast-like synoviocytes, 
adenosine agonists examined were not able to decrease the LPS-stimulated NF-kB 
levels at a concentration of 100 nM with the exception of Cl-IB-MECA that 
mediated a reduction in p50 and p65 levels by 33 ± 3% and 24 ± 3%, respectively 
(p<0.05). All adenosine agonists investigated at the 1 µM concentration were able 
to inhibit the LPS-stimulated NF-kB levels. The inhibitory effect of CHA was 
reverted only by the A3 antagonist MRE 3008F20. In addition, SCH 58261, but 
not MRE 3008F20, was able to block the reduction of NF-kB levels mediated by 
CGS 21680 because of the high or low affinity of this agonist for A2A AR or A3 
AR, respectively (Table 3.1). The inhibitory effect of the adenosine agonist 
NECA was partially blocked (p<0.05) only by SCH 58261 and MRE 3008F20 
suggesting the involvement of A2A and A3 ARs. Interestingly, the effect of NECA 
was completely abrogated by the simultaneous incubation with SCH 58261 and 
MRE 3008F20. The reduction in p50 and p65 activation mediated by Cl-IB-
MECA was reverted only by MRE 3008F20 and not by SCH 58261. This effect 
was most likely due to the low affinity of the A3 agonist, Cl-IB-MECA for A2A 
AR (Table 3.1, Figure 3.7 A,B). 
 
TNF-α and  IL-8 production 
In human fibroblast-like synoviocytes the effect of adenosine agonists and 
antagonists on TNF-α (Figure 3.8A) and IL-8 (Figure 3.8B) release was evaluated 
in the presence of LPS 10 µg/ml. Of the agonists examined at 100 nM 
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concentration only Cl-IB-MECA was able to decrease significantly TNF-α and 
IL-8 production by 35 ± 3% and 28 ± 2%, respectively (p<0.05). All adenosine 
agonists investigated at 1 µM concentration were able to significantly inhibit LPS-
stimulated release of TNF-α and IL-8. The inhibitory effect of CHA was 
counteracted by MRE 3008F20 and not by DPCPX or SCH 58261 suggesting the 
involvement of A3 ARs (Table 3.1). The effect of CGS 21680 was only blocked 
by SCH 58261 and not by MRE 3008F20 probably because of the low affinity of 
CGS 21680 for A3 AR. NECA was able to significantly decrease the LPS-
stimulated release of TNF-α and  IL-8, an effect blocked by SCH 58261 or MRE 
3008F20 (p<0.05), but not by DPCPX or MRE 2029F20. The simultaneous use of 
SCH 58261 and MRE 3008F20 completely reverted the inhibitory effect of 
NECA (p<0.01). Finally, only MRE 3008F20 was able to abrogate the effect of 
Cl-IB-MECA on TNF-α and IL-8 release.  
 
Modulation of Gi, Gs and PI3K proteins 
To determine whether the Gi pathway or phosphatidylinositide-3-OH kinase 
(PI3K) was involved in A3 AR responses, human fibroblast-like synoviocytes 
were preincubated with the Gi inactivator pertussis toxin (100 ng/ml) for 2 h or 
with the PI3K inhibitor LY294002 (25 µM) for 20 min and then stimulated with 
Cl-IB-MECA (1 µM). The preincubation with pertussis toxin did not modify the 
Cl-IB-MECA-mediated inhibition of P-p38, NF-kB p50 or p65, TNF-α and IL-8 
levels. In contrast, LY294002 incubation completely abolished the inhibition of P-
p38, NF-kB p50 or p65, TNF-α and IL-8 levels by Cl-IB-MECA. These data 
suggest that the A3 ARs signals through a PI3K pathway (Table 3.2). In order to 
verify whether the Gs pathway was involved in A2A functional responses, human 
fibroblast-like synoviocytes were incubated with a direct activator of adenylyl 
cyclase activity, forskolin (1 µM). This compound was able to reduce P-p38, NF-
kB p50 or p65, TNF-α and IL-8 levels suggesting the involvement of cAMP in 
A2A-mediated responses (Table 3.2). 
 
 
 
 
 
 134 
Table 3.1: Affinities expressed as pKi values of well-known adenosine 
agonists and antagonists in CHO or HEK 293 cells expressing human A1, 
A2A, A2B or A3ARs and in human fibroblast-like synoviocytes. 
 
 
Compounds 
 
[3H] DPCPX 
binding to  
hA1CHO cells 
pKH, pKL or pKi 
[3H] ZM 241385 
binding to  
hA2ACHO  cells 
pKi 
 
[3H] MRE 2029F20  
binding to  
hA2BHEK 293 cells 
pKi  
[3H] MRE 3008F20 
binding to  
hA3CHO cells   
pKH, pKL or pKi  
Human synoviocytes 
 
pKi                  nH 
CHA 
 
8.96 ± 0.04 
6.76 ± 0.03 
6.09 ± 0.03 4.38 ± 0.02 7.19 ± 0.05 
5.57 ± 0.04 
9.08 ± 0.03a 
6.94 ± 0.04 
 
0.54±0.05 
CGS 21680 
 
> 5.3 7.92 ± 0.03 > 5.3 5.91 ± 0.04 7.55 ± 0.05b 
 
1.04±0.09 
NECA 
 
7.70 ± 0.04 8.08 ± 0.04 6.74 ± 0.03 7.44 ± 0.05 7.02 ± 0.04c 
 
0.91±0.08 
Cl-IBMECA > 5.3 6.19 ± 0.04 > 5.3 8.89 ± 0.05 
6.80 ± 0.04 
9.04 ± 0.04d 
7.06 ± 0.03 
 
0.63±0.05 
DPCPX 
 
8.80 ± 0.03 6.58 ± 0.04 7.40 ± 0.04 5.94 ± 0.06 8.65 ± 0.06a 
 
1.14±0.10 
SCH 58261 
 
6.26 ± 0.04 8.60 ± 0.05 > 5.3 > 5.3 8.56 ± 0.03b 
 
1.06±0.09 
MRE 
2029F20 
6.55 ± 0.03 > 5.3 8.46 ± 0.05 > 5.3 8.57 ± 0.06c 
 
1.11±0.11 
MRE 
3008F20 
5.93 ± 0.04 6.72 ± 0.03 5.83 ± 0.03 9.05 ± 0.05 8.55 ± 0.04d 
 
0.99±0.08 
 
Affinity values are represented as pKH, pKL and pKi values;  nH = Hill coefficient. 
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Table 3.2: Modulation of Gi, PI3K and  Gs pathways in different 
inflammatory responses on human fibroblast-like synoviocytes. 
 
 
 
 
 
LPS  
(10 µg/m1) 
 
 
Cl-IB-MECA 
(1 µg/m1) 
pertussis toxin 
(100 ng/m1) 
 Cl-IB-MECA 
(1 µg/ml)  
LY294002  
(25 µg/ml) 
Cl-IB-MECA 
(1 µg/ml)  
 
Forskolin 
(1 µg/ml) 
P-p38 
 
172 ± 10 
 
135 ± 6 a 133 ± 7 175 ± 8 c 
 
128 ± 8 b 
 
NF-kB (p50) 
 
169 ± 14 
 
110 ± 12 b 104 ± 10 173 ± 13 d 109 ± 9 b 
NF-kB (p65) 
 
353 ± 14 234 ± 12 b 242 ± 13 338 ± 14 d 226 ± 11 b 
TNF-α 358 ± 21 128 ± 13 b 134 ± 12 344 ± 19 d 
 
136 ± 14 b 
 
IL-8 
 
455 ± 20 262 ± 11 b 278 ± 15 437 ± 22 d 287 ± 14 b 
 
The data are expressed as % of control ± SEM. a p<0.02 versus LPS; b p<0.01 
versus LPS; c p<0.02 versus Cl-IB-MECA; d p<0.01 versus Cl-IB-MECA.  
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Figure 3.1: Culture of human fibroblast-like synoviocytes. In A, phase 
contrast and in B vimentin expression by immunofluorescence. Nuclei were 
counterstained in blue with DAPI. Original magnification, ×200. In C CD14 
and vWF mRNA expression in macrophages (MC), endothelial cells (EC) and 
in fibroblast-like synoviocytes (S).  
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Figure 3.2: mRNA expression of ARs (A) and representative western blotting 
analysis (B) in human fibroblast-like synoviocytes. Densitometric analysis for 
ARs were also shown (C). 
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Figure 3.3: Saturation curves (A) and Scatchard plot (B) of [3H]DPCPX,  
[3H]ZM 241385,  [3H]MRE 2029F20,  [3H]MRE 3008F20 binding to A1, A2A, 
A2B and A3 ARs in human fibroblast-like synoviocytes, respectively.  
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Figure 3.4: Affinity values of selected A1, A2A, A2B and A3 adenosine agonists 
and antagonists obtained by using competition binding experiments versus 
A1 (A), A2A (B), A2B (C) and  A3 (D) ARs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 140 
0
20
40
60
80
100
A
*
*
*
CGS 21680
SCH 58261
NECA
MRE 3008F20
_
+
_ _
_ _ _
+
_
_ _
_ _
_ _
+ +
+
cA
M
P 
pr
od
uc
tio
n
(pm
ol
 
pe
r 
10
6  
ce
lls
)
+
_
0
20
40
60
80
100
120
B
*
*
*
Ro 20-1724
CHA
DPCPX
ClIB-MECA
_
+
_
_
_ _
Forskolin _ +
MRE 3008F20 _
cA
M
P 
pr
od
u
ct
io
n
(pm
ol
 
pe
r 
10
6  
ce
lls
)
+
+
+
+
+
+
+
+
+
_
_ _
_
+
+
_ _
_ _
+
_
_
__
+
+
_
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* p<0.01 versus control conditions. 
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Figure 3.6: Western blotting analysis of P-p38 in the absence and in the 
presence of LPS. The effect of examined adenosine agonists and antagonists 
was also evaluated (A). Densitometric analysis of the bands obtained were 
also shown (B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*, p< 0.01 versus control conditions; **, p< 0.01 versus LPS conditions; #, p< 
0.02 versus LPS conditions; $, p< 0.01 versus CGS 21680; §, p< 0.02 versus Cl-
IB-MECA. 
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Figure 3.7: Effect of adenosine agonists and antagonists in human fibroblast-
like synoviocytes on NF-kB activation which was evaluated by detecting 
phosphorylated p50 (A) and p65 (B) proteins in nuclear extracts.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*, p<0.01 versus control conditions. **, p<0.01 versus LPS conditions; #, p< 0.01 
versus CHA; $, p< 0.01 versus CGS 21680; †, p< 0.05 versus NECA; ‡, p< 0.01 
versus NECA; §, p< 0.01 versus Cl-IB-MECA. 
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Figure 3.8: TNF-α (A) and IL-8 (B) levels in human synoviocytes in control conditions 
and stimulated by LPS (10 µg/ml). TNF-α and IL-8 levels were also calculated in the 
presence of adenosine agonists and antagonists.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*, p<0.01 versus control conditions. **, p<0.01 versus LPS conditions; #, p< 0.01 
versus CHA; $, p< 0.01 versus CGS 21680; †, p< 0.05 versus NECA; ‡, p< 0.01 
versus NECA; §, p< 0.01 versus Cl-IB-MECA. 
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DISCUSSION 
 
Chronic inflammatory processes are based on a sustained and tightly regulated 
communication network among different cells types. It is generally accepted that 
fibroblast-like synoviocytes have a key function in the development of sustained 
inflammation in joint diseases such as OA. The aetiology of OA is multifactorial 
and includes the release of both systemic and local biochemical factors (Peat et 
al., 2001). Recently, growing evidence suggest that synovial inflammation have 
an important role in the pathophysiology of OA contributing to signs and 
symptoms of the disease (Liu et al., 2009; Sutton et al., 2009). The activation by 
inflammatory stimuli of fibroblast-like synoviocytes mediate the production of 
different chemokines, cytokines and matrix metalloproteinases (Georganas et al., 
2000; Nanki et al., 2001). There is growing evidence that pro-inflammatory 
mediators could play critical roles in the development of inflammation and 
damage in joint tissues (Wen et al., 2006; Inoue et al., 2005). Several studies have 
indicated that adenosine, via stimulation of its receptors, is involved in the 
modulation of inflammatory processes (Palmer and Trevethic, 2008; Ham and 
Rees, 2008; Gessi et al., 2008). In particular, A2A AR agonists inhibit cartilage 
damage when used in the treatment of septic arthritis by diminishing IL-8 
expression and reduce rat adjiuvant induced arthritis (Cohen et al., 2005). In 
fibroblast-like synoviocytes the selective involvement of A2A and A3 ARs in the 
immunomodulatory actions of methotrexate has been studied (Montesinos et al., 
2003; Cronstein, 2005). Recently, A3 AR stimulation inhibits human fibroblast-
like synoviocytes growth and the inflammatory manifestations of arthritis 
(Ochaion et al., 2008). The purpose of the present paper was to document the 
expression and the binding parameters of A1, A2A, A2B and A3 ARs in human 
fibroblast-like synoviocytes derived from OA patients. ARs are coexpressed in 
these cells and were investigated through mRNA, western blotting analysis and 
saturation binding experiments. To exactly quantify the affinity and density of 
ARs, saturation binding studies were performed. In human synoviocytes ARs 
affinities (KD, nM) were in the nanomolar range and the receptor densities (Bmax, 
fmol/mg protein) were from 125 to 287 fmol/mg protein. No data are present in 
literature on the ARs binding parameters in human fibroblast-like synoviocytes. 
Moreover, binding and functional characterization was previously performed in 
 145 
bovine fibroblast-like synoviocytes. In these cells, ARs affinity was similar in 
nanomolar range to those observed in human fibroblast-like synoviocytes. ARs 
density was higher in human than bovine fibroblast-like synoviocytes (Varani et 
al., 2008). The competition binding experiments in human fibroblast-like 
synoviocytes were performed with the aim to calculate the affinity of adenosine 
agonists and antagonists which have been also studied in functional assays. As 
expected, competition of [3H] DPCPX and [3H] MRE 3008F20 by increasing 
concentrations of CHA and Cl-IB-MECA, respectively revealed two binding sites 
for these agonists probably due to the presence of two different high and low 
receptor affinity states. On the contrary, competition binding curves with 
antagonists were monophasic (Varani et al., 2000; Merighi et al., 2001). In 
addition, competition of [3H] ZM 241385 and [3H] MRE 2029F20 by increasing 
concentrations of CGS 21680 and NECA, respectively showed simple inhibition 
curves excluding the involvement of multiple affinity states because of the tight 
coupling between A2 ARs and Gs proteins (Varani et al., 1998; Gessi et al., 2005). 
Affinity values of adenosine agonists and antagonists versus human ARs 
expressed in CHO or HEK 293 cells were closely similar to those obtained in 
human fibroblast-like synoviocytes. CGS 21680 and Cl-IB-MECA were selective 
versus A2A and A3 ARs, CHA was able to interact with A1 and A3 ARs whilst 
NECA bound all ARs. The adenosine antagonists, DPCPX, SCH 58261, MRE 
2029F20 and MRE 3008F20 chosen in this study are selective versus A1, A2A, A2B 
and A3 ARs, respectively. Another purpose of the present study was to investigate 
the ARs functional activities in human fibroblast-like synoviocytes where 
adenosine agonists and antagonists were able to modulate cAMP production. As 
expected CGS 21680 and NECA stimulated adenylyl cyclase activity whereas 
CHA and Cl-IB-MECA decreased cAMP production. These adenosine agonist 
effects have been blocked by selected antagonists with the aim to discriminate 
selectively the involvement of specific ARs. These data are in agreement with 
those reported in human or bovine fibroblast-like synoviocytes where A2A and A2B 
ARs are coupled positively to adenylyl cyclase whereas A1 and A3 ARs are linked 
to Gi proteins and inhibit cAMP production (Boyle et al., 1996; Varani et al., 
2008). There is a large body of evidence suggesting that p38 MAPK represents 
one key signal transduction pathway crucial for the induction and maintenance of 
chronic inflammation (Westra and Limburg, 2006). This network comprises the 
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extracellular mediators such as cytokines, chemokines and matrix-degrading 
proteases which orchestrate the participation of the cells in chronic inflammatory 
process (Karin, 2005). The mirrors of this outside communication world are 
intracellular transcription factor pathways such as NF-kB, which shuttle 
information about inflammatory stimuli to the cell nucleus (Pomerantz and 
Baltimore, 2002). To address this issue, p38 MAPK activation was studied 
following ARs modulation in human fibroblast-like synoviocytes. We found that 
the stimulation of A2A and A3 ARs by using CGS 21680 and Cl-IB-MECA, 
respectively mediated a significant decrease of the phosphorylated, hence 
activated form of p38 MAPK. In literature are present few papers on human 
fibroblast-like synoviocytes and functional response of ARs (Boyle et al., 1996; 
Ochaion et al., 2008). On the other hand these data are in agreement with those 
previously reported in human pro-monocytic U937 cells where CGS 21680 
decreased phospho-p38 protein levels (Fotheringham et al., 2004). It is well 
known that phospho-p38 acts as a kinase implicated in the phosphorylation of the 
NF-kB inhibitors IkB, allowing the p50 and p65 subunits to enter the nucleus and 
promoting the transcription of inflammatory genes. Therefore, we have 
investigated the effects of adenosine agonists and antagonists on p50 and p65 
subunit levels in the nuclear extract of human fibroblast-like synoviocytes. Our 
data demonstrated that adenosine agonists were able to reduce p50 and p65 levels 
primarily through the involvement of A2A and A3 ARs as revealed by the use of 
adenosine antagonists. In particular, the effect of CHA, that bind A1 and A3 ARs 
with high affinity and A2A ARs with low affinity (Table 3.1), was reverted only by 
the A3 antagonist MRE3008F20 and not by the A1 antagonist DPCPX excluding 
the involvement of A1 ARs. The effect of the A2A agonist CGS 21680 was 
reverted by the selective A2A antagonist SCH 58261, confirming the involvement 
of A2A AR in the reduction in p50 and p65 levels. The inhibitory effect of the 
adenosine agonist NECA was only abrogated by SCH 58261 and MRE 3008F20, 
but not by the A1 antagonist DPCPX or the A2B antagonist MRE 2029F20, 
demonstrating the involvement of A2A and A3 ARs but not of A1 or A2B ARs. The 
direct role of A3 AR in the down-regulation of nuclear NF-kB levels was further 
confirmed by the inhibitory effect of the A3 agonist Cl-IB-MECA that was 
completely abrogated by the A3 antagonist MRE 3008F20. 
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The present data strongly support several pieces of evidence performed in 
different cellular models such as murine microglial cells, mouse macrophages and 
leukemic cell line indicating that adenosine and in particular A2A and A3 
stimulation mediated the inhibition of NF-kB (Lee et al., 2006; Martin et al., 
2006; Majumdar and Aggarwal, 2003). The transcription factor NF-kB represents 
a major component of the TNF-α gene activation machinery and its activation is 
necessary for TNF-α production. In our study we found that the suppression of 
TNF-α release was mediated by A2A and A3 ARs. Our data are in agreement with 
those previously reported by several authors showing that A2A and A3 ARs 
mediated a reduction of TNF-α production (Haskò et al., 1996; Szabò et al., 1998; 
Haskò et al., 2000; Mabley et al., 2003). This reduction of TNF-α levels could be 
explained as a direct inhibition of NF-kB, thus at a transcriptional level (Lee et al., 
2006). Alternatively, it is also possible that A2A and A3 ARs-mediated inhibition 
of TNF-α production is closely associated with p38 MAPK that has been 
proposed to be a key regulator of TNF-α mRNA stability and protein translation 
(Fotheringham et al., 2004). The cell signalling pathways initiated by pro-
inflammatory events converge on the activation of p38 and NF-kB which are also 
implicated in the regulation of  IL-8 expression, a critical mediator of tissue 
inflammation. As a result of p38 and NF-kB inhibition, A2A and A3 ARs 
stimulation resulted in a decrease of IL-8 production. Previous contrasting studies 
obtained in different cells have reported that adenosine acts as a positive or 
negative regulator of IL-8 suggesting that this disparity of the effect could be in 
part explained by the presence of different target cells or tissues (Jijon et al., 2005; 
Murakami et al., 2001). To better investigate the role of G proteins in A2A or A3 
ARs functionality, selective experiments were performed with the aim to evaluate  
the effect of Cl-IB-MECA in the presence of Gi protein or PI3K inhibitors. We 
found that the A3-mediated reduction in NF-kB activation and cytokines release 
was not affected by the block of Gi proteins but only by the inhibition of PI3K 
suggesting that, for these responses, A3 AR signals through a PI3K pathway. In 
contrast, the A2A AR-mediated reduction of inflammatory responses was most 
likely due to the activation of Gs protein and to the increase in cAMP levels, as 
demonstrated by the use of adenylyl cyclase direct activator forskolin that leads to 
similar responses to those of A2A ARs. Clearly, further studies will be needed 
regarding the differential roles of other MAPKs and transcription factors on 
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various inflammatory mediators to delineate the mechanisms underlying cytokine 
production by adenosine signalling. In conclusion, the novel findings of this study 
in human fibroblast-like synoviocytes from OA patients are represented by the 
presence of ARs that are also quantified by high levels of density. The functional 
results revealed the direct involvement of A2A and A3 ARs in the inhibition of 
inflammatory cascade in human fibroblast-like synoviocytes. Taken together these 
results suggest that ARs could represent potential therapeutic pharmacological 
target in the complex pathways regulating inflammatory processes in joint 
diseases.  
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CHAPTER 4: 
 
Binding thermodynamic characterization of  
human P2X1 and P2X3 purinergic receptors. 
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INTRODUCTION 
 
P2 purinergic receptors are divided in two subfamilies: G-protein coupled (P2Y) 
and ligand-gated ion channels (P2X). In mammalian cells eight P2Y 
(P2Y1,2,4,6,11,12,13,14), 7 homomeric P2X (P2X1-7) and four heteromeric (P2X2/3, 
P2X1/5, P2X2/6, P2X4/6) receptors have been cloned and characterized 
pharmacologically (North, 2002). Both of these receptor families are activated by 
the presence of extracellular ATP, an important local regulatory factor under 
physiological, inflammatory and neuropathic pain conditions (North et al., 2000; 
Burnstock, 2006; Sawynok, 2007). Briefly, P2X receptors are abundantly 
distributed, and functional responses have been reported in neurons, glia, 
epithelia, endothelia, bone, muscle and hemopoietic tissues (Khakh and North, 
2006). The widespread expression of P2X1 receptors suggests that ATP may 
contribute in various pathophysiological conditions (Burnstock and Knight, 2004). 
P2X3 receptors have been found primarily localised to specific subsets of sensory 
nociceptor neurones, and there is now much evidence that P2X3 homomeric and 
P2X2/3 heteromeric receptors in sensory pathways are involved in neuropathic and 
chronic pain (Kennedy, 2005; Jarvis, 2003). Pharmacological methods and 
manipulations, that can differentiate between P2X1 and P2X3 receptors, could be 
very useful in the development of P2X1 or P2X3 receptor-specific ligands 
(Abbracchio and Williams, 2001; King and Notrh, 2000). This is especially 
important because the rapidly desensitising kinetics and the agonist and antagonist 
pharmacology of these two P2X receptors are remarkably similar to each other 
(North, 2000; North, 2002; Burnstock, 2006). ATP, and the ATP analogues, 
BzATP, 2meSATP and αβmeATP show equipotent agonist profiles at P2X1 and 
P2X3 receptors (Jacobson et al., 2002). Considerable changes in binding affinity 
of purinergic antagonists are also reported probably due to the little information 
available with respect to the regions of the receptor involved in antagonist binding 
(North, 2000, 2002). More recently, a submicromolar affinity, non-nucleotide 
antagonist, A 317491, has been described which is more than 100-fold selective 
for P2X3/P2X2/3 receptors over P2X1 receptors in electrophysiological and calcium 
flux functional assays (Jarvis et al., 2004; Burgard et al., 2000). Radioligand 
binding techniques have had limited success in differentiating between 
endogenous or recombinant P2X receptors, probably due to the lack of highly 
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selective and potent ligands (Jacobson et al., 2002). The ATP bioisosteres, 
[3H]αβmeATP, [35S]ADPβS and [35S]ATPγS have been used in ligand-binding 
studies of purinergic receptors in various tissues and recombinant expression 
systems (Jarvis et al., 2004; Bo and Burnstock, 1990; Michel et al., 1995, 1996; 
Schafer and Reiser, 1997). In spite of the problems associated with the use of 
these radioligands, information obtained from specific binding assays has long 
proved invaluable for screening potential drug candidates, for basic 
pharmacological characterization of receptor subtypes and for identification of 
signal transduction pathways.  It can be of interest to obtain determinations of 
drug-receptor binding association (KA) and dissociation (1/KA or KD) constants 
over a range of temperatures, in contrast to the single-point temperature assays, 
which add significant information on the molecular mechanisms involved in the 
drug-receptor interaction (Borea et al., 2000). Determination of KA or KD values 
makes it possible to calculate the standard free energy ∆G° = -RtlnKA = RTlnKD 
(T=298.15 K), but not its two components, the equilibrium standard enthalpy 
(∆H° ) and entropy (∆S°) as defined by the Gibbs equation ∆G° = ∆H° -T∆S°. As 
a consequence, van’t Hoff plot analysis was performed to obtain KD values over a 
range of temperatures and to obtain the thermodynamic terms of this equation. 
From such analysis, it is generally proposed that standard enthalpy is a 
quantitative indicator of the changes in intermolecular bond energies, such as 
hydrogen bonding and van der Waals interactions, occurring during the binding. 
In addition standard entropy can be considered an indicator of the rearrangements 
undergone by the solvent, normally water molecules, during the same process 
(Borea et al., 2000). In the last few years it has been shown that the ∆H° and ∆S° 
values of drug interaction with a defined receptor can often give a simple in vitro 
way to discriminate agonists from antagonists suggesting the manner in which the 
drug interferes with the signal transduction pathways. Such “thermodynamic 
discrimination” reveals that the binding of agonists may be entropy-driven and 
that the antagonists are enthalpy-driven, or vice versa. At the present fourteen 
receptor systems have been extensively studied so far from thermodynamic point 
of view: eleven of these show the agonist-antagonist discrimination and three are 
not discriminated (Borea et al., 1996, 1998, 2000; Merighi et al., 2002; Gilli et al., 
2005). In particular, all the ligand-gated ion channel receptors, i.e. glycine, 
GABA, 5HT3 and neuronal nicotinic receptors have been reported to discriminate 
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in vitro the effect of their agonists and antagonists (Maksai, 2001; Gessi et al., 
1999; Borea et al., 2004). Analysis of thermodynamic data of drug-receptor 
interactions appears to be an effective tool in the study of the role, at the 
molecular level, played during the binding of the ligands (Stoop et al., 1997; 
Froldi et al., 1997; Borea et al., 1995). From this background, the aim of this 
study was to determine the thermodynamic parameters of typical agonists and 
antagonists in HEK 293 cells transfected with human P2X1 and P2X3 receptors by 
using [3H]αβmeATP radioligand binding assays and van’t Hoff analysis in order 
to gain further insight into possible differences in pharmacological properties 
between these two therapeutically important P2X receptor subtypes. This research 
could provide information in the development of novel and potent P2X1 and  
P2X3 purinergic ligands 
 
MATERIALS AND METHODS 
 
Materials 
[3H]αβmeATP ([3H]αβmethyleneATP specific activity 15.0 Ci mmol-1) was 
obtained from NEN-Perkin Elmer Life and Analytical Sciences (USA). ATP, 
ADP, αβmeATP, BzATP (benzoilATP), TNP-ATP (2’-3’-O-(2,4,6-
trinitrophenyl)adenosine 5’-triphosphate), suramin, NF023 (8,8'-[carbonylbis 
(imino-3,1-phenylene carbonylimino)]bis(1,3,5-naphthalene-trisulfonic acid), 
PPADS (pyridoxal 5-phosphate 6-azophenyl-2’,4’-disulphonic acid), A317491 (5-
({[3-phenoxybenzyl][(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]amino}carbonyl)-
1,2,4-benzenetri-carboxylic acid) and apyrase were obtained from Sigma-Aldrich 
Advanced Sciences (Milan, Italy). NF279 (8,8'-[carbonylbis(imino-4,1-
phenylenecarbonyl-imino-4,1-phenylene carbonyl- imino)] bis-1,3,5-naphthalene-
trisulphonic acid)and 2meSATP (2methylSATP) were obtained from Tocris 
Cookson Ltd (Bristol, UK). All other reagents were of analytical grade and 
obtained from commercial sources. 
 
Cell culture and membrane preparation 
HEK293-hP2X1 and HEK293-hP2X3 cells were kindly provided by Prof. A. 
Surprenant (Institute of Molecular Physiology, University of Sheffield, Sheffield, 
England, UK). Methods of maintenance of HEK293 cells and their stable 
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transfection with hP2X1 and hP2X3 receptors cDNA have been described 
previously (Stoop et al., 1997). Briefly, the cells were  grown adherently and 
maintained in DMEM/F12, containing 10% FBS, penicillin (100 U/ml), 
streptomycin (100 µg/ml) and Geneticin (G418, 0.2 mg/ml) at 37°C in 5% 
CO2/95% air. Cells were split 2 or 3 times weekly at a ratio of 1:5. For membrane 
preparation, the culture medium was removed and the cell suspension was washed 
with PBS and scraped in ice-cold hypotonic buffer. The cell suspension was 
homogenized with Polytron (Kinematica, Switzerland) at a setting of 6 for 40 sec 
and the homogenate was spun for 30 min at 100,000 g and frozen at -80°C until 
binding experiments. 
 
Effect of various factors on purinergic receptor binding assays 
The effect of pH at the different values (6.0, 7.0, 7.4, 8.0, 9.0) on the 
[3H]αβmeATP binding at the 3 nM concentration was evaluated and obtained 
incubating in Tris HCl 50 mM the HEK-293 membranes containing hP2X1 or 
hP2X3 purinergic receptors. The effect of different concentrations of Ca2+ (from 0 
to 10 mM) and Mg2+ (from 0 to 10 mM) was also investigated by using 3 nM of 
[3H]αβmeATP as radioligand in Tris HCl 50 mM pH 7.4 and HEK-293 
membranes containing hP2X1 or hP2X3 purinergic receptors. The effect of  
Apyrase (1 U/ml for 30 min at 37°C) was evaluated incubating the hP2X1 or 
hP2X3  membranes in Tris HCl 50 mM pH 7.4 CaCl2 , 4 mM and 3 nM of 
[3H]αβmeATP as radioligand. Non specific binding was determined in the 
presence of 10 µM αβmeATP (Froldi et al., 1997). After the incubation time (40 
min at 5°C) bound and free radioactivity were separated by rapid filtration 
through Whatman GF/B glass-fiber filters using a Brandel instrument. The filter 
bound radioactivity was counted on a Scintillation Counter Tri Carb Packard 2500 
TR (efficiency 57%). 
 
Kinetics of  [3H]αβmeATP binding  
Kinetic studies of  3 nM [3H]αβmeATP were performed by incubating 
membranes in Tris HCl 50 mM, CaCl2 4 mM pH 7.4  obtained as described above 
in a thermostatic bath at 5°C. For the measurement of the association rate of 
human P2X1 receptors, the reaction was terminated at different times (from 1 to 
80 min) by rapid filtration under vacuum, followed by washing four times with ice 
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cold buffer. Similarly, for human P2X3 receptors the reaction was terminated from 
10 sec to 30 min by rapid filtration. For the measurement of the dissociation rate, 
the samples were incubated at 5°C for 40 min and then 10 µM αβmeATP  was 
added to the mixture. The reaction was terminated for P2X1 receptors from 1 to 40 
min and for P2X3 receptors from 30 sec to 40 min. 
 
Saturation and competition binding experiments  
Saturation and competition binding assays were performed on HEK293-hP2X1 
and  HEK293-hP2X3 membranes at 5, 10, 15, 20, 25 and 30°C, in a thermostatic 
bath assuring a temperature of ± 0.1°C. Analogous experiments in HEK293 wild 
type and in HEK293 transfected with the vector alone were executed. Saturation 
binding experiments of [3H]αβmeATP (0.1 to 50 nM) to the membranes 
previously obtained were performed in Tris-HCl 50 mM, CaCl2 4 mM pH 7.4 for 
an incubation time ranged from 40 min at 5°C to 90 min at 30°C according to the 
results of previous time-course experiments. Competition experiments of 3 nM 
[3H]αβmeATP were performed in the same buffer described above and at least 8-
10 different concentrations of P2X1 and P2X3 agonists or antagonists studied. Non 
specific binding was determined in the presence of 10 µM αβmeATP (Froldi et 
al., 1997). Bound and free radioactivity were separated by rapid filtration through 
Whatman GF/B glass-fiber filters using a Brandel instrument. The filter bound 
radioactivity was counted on a Scintillation Counter Tri Carb Packard 2500 TR 
(efficiency 57%). The affinity values expressed as KD or Ki were used in the 
thermodynamic parameter determination.  
 
Thermodynamic data determination 
For a generic binding equilibrium L+R = LR (L = ligand, R = receptor) the 
affinity association constant KA = 1/KD is directly related to the standard free 
energy ∆G° (∆G° = -RTlnKA) which can be separated in its enthalpic and entropic 
contributions according to the Gibbs equation: ∆G° = ∆H° -T∆S°. The standard 
free energy was calculated as ∆G° = -RTlnKA at 298.15 K, the standard enthalpy, 
∆H°, from the van’t Hoff plot lnKA versus (1/T) (the slope of which is -∆H°/R) 
and the standard entropy as ∆S° = (∆H°- ∆G°)/T with T = 298.15 K and R = 8.314 
J/K/mol (Borea et al., 1995, 2000, 2004). 
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Data analysis 
Kinetic, saturation and competition binding experiments were analysed with the 
program Ligand (Bradford, 1976) which performs weighted non linear least-
squares curve fitting program. The protein concentration was determined 
according to a Bio-Rad method with bovine albumin as reference standard 
(Munson and Rodbard, 1980). All experimental data are reported as mean ± SEM 
of three or four independent experiments performed in duplicate. 
 
RESULTS 
 
Effect of various factors on purinergic receptor binding assays 
Preliminary assays were performed to determine the experimental conditions for 
the evaluation of specific [3H]αβmeATP binding. The incubation of the HEK293-
hP2X1 and HEK293-hP2X3 membranes with apyrase (1U/ml) with the aim to 
eliminate extracellular ATP and minimize receptor desensitization during binding 
experiments produced no differences in the percentage of specific binding 
(HEK293-hP2X1 = 85±8% and 88±9% or HEK293-hP2X3 = 89±9% and 92±10%, 
respectively). The effect of pH values (from 6 to 9) on the [3H]αβmeATP binding 
reveals that the optimal pH value for the binding experiments was around 7.4 in 
both cell lines examined (Figure 4.1A,C). The specific binding of [3H]αβmeATP 
to HEK293-hP2X1 (Figure 4.1B) and HEK293-hP2X3 (Figure 4.1D) membranes 
increased of 8 and 6 fold, respectively with the raise of the Ca2+ concentration 
from 1 µM to 1 mM. On the contrary, further increasing in the calcium 
concentration from 1 to 10 mM led to a decline of specific [3H]αβmeATP 
binding. The addition of Mg2+ (from 1 to 10 mM) in the same experimental 
conditions resulted in a strong reduction (80%, n=3) of the binding suggesting that 
the [3H]αβmeATP binding was regulated in an opposite way by physiological 
concentrations of  Ca2+ and  Mg2+, respectively. 
 
Kinetic binding assays to human P2X1 and P2X3 purinergic receptors 
Kinetic behaviour of  [3H]αβmeATP binding was studied at 5°C in HEK293-
hP2X1 (Figure 4.2) and HEK293-hP2X3 (Figure 4.3) membranes. Figures 4.2A 
and 4.3A show that [3H]αβmeATP binding reached equilibrium after 
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approximately 20 and 5 min, respectively and was stable for at least 90 min. 
[3H]αβmeATP binding was rapidly reversed by the addition of 10 µM αβmeATP 
as shown in figures 4.2B and 4.3B. Association and dissociation curves in 
HEK293-hP2X1 and HEK293-hP2X3 membranes were fitted to a one component 
model significantly better than to a two component model (p<0.05). The rate 
constants were: kobs = 0.106 ± 0.012 1/min and  = 0.712 ±  0.010  1/min, 
respectively. The k+1 values were = 0.017 ± 0.002  1/min nM and  = 0.133 ± 0.014  
1/min nM , respectively. The apparent equilibrium dissociation constant (KD) was 
estimated to be 3.29 nM and 2.35 nM, respectively.  
 
Saturation binding assays to human P2X1 and P2X3 purinergic receptors 
Saturation binding experiments in HEK 293 cells were performed to better 
characterize human P2X1 and P2X3 purinergic receptors and evaluate affinity 
(KD) and receptor density (Bmax) values (Table 4.1). These binding parameters 
were determined at various temperatures by using [3H]αβmeATP as radioligand at 
different concentrations. In both purinergic receptors examined the KD values 
change with temperature and Bmax values appear to be largerly independent of it. 
Figures 4.4 and 4.5 illustrate saturation binding curves and Scatchard plot relative 
to human P2X1 and P2X3 purinergic receptors, respectively. Scatchard plots were 
linear at all temperatures investigated and computer analysis of the data failed to 
show a significantly better fit to a two site than to a one site binding model, 
indicating that only one class of high affinity binding site was present under our 
experimental conditions. Saturation binding experiments performed employing 
HEK 293 wild type and HEK 293 transfected with the vector alone failed to show  
significant values of specific binding (n=4 experiments, % of specific binding = 2 
± 1% and 3 ± 1%, respectively) suggesting that the P2X1 and P2X3 transfection is 
essential to the presence of specific binding. 
 
Competition binding assays to human P2X1 and P2X3 purinergic receptors 
Figures 4.6 and 4.7 show the dose response curves of [3H]αβmeATP binding in 
HEK293-hP2X1 and HEK293-hP2X3 membranes by using typical agonists and 
antagonists. The order of potency in [3H]αβmeATP displacement assays for 
purinergic agonists in HEK293-hP2X1 was as follows: αβmeATP > BzATP> 
2meSATP > ATP > ADP. A similar order of potency was also obtained in 
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HEK293-hP2X3  even if the affinity values were much higher than in HEK293-
hP2X1 membranes. The order of potency of antagonists in HEK293-hP2X1 was 
similar to those obtained in HEK293-hP2X3  as follows: TNP-ATP > A 317491  > 
NF 279  > NF 023 > Suramin > PPADS and  TNP-ATP > A 317491 > NF 023 > 
Suramin > NF 279 > PPADS, respectively. 
 
Thermodynamic analysis  to human P2X1 and P2X3 purinergic receptors 
The van’t Hoff plots show that the effect of temperature on the equilibrium 
binding association constants, KA appears to be essentially linear in the range 4-
30°C for purinergic ligands examined to human P2X1 and P2X3 purinergic 
receptors (Figures 4.8 and 4.9). Slopes of van’t Hoff plots are positive for agonists 
and antagonists of P2X1 purinergic receptors showing that the affinities decrease 
with the increase of the temperature (Table 4.2A).The slopes of van’t Hoff plots 
regarding P2X3 purinergic receptors are positive for agonists whose affinities 
decrease with the increase of the temperature and negative for antagonists whose 
affinities are improved by an increase in temperature (Table 4.2B). Final 
thermodynamic parameters calculated for the binding equilibria of the different 
compounds investigated are reported in Table 4.3. In P2X1 purinergic receptors 
∆G° values range from  -46.0  to – 37.4  kJ/mol for agonists and from  -30.1 to -
25.5 kJ/mol for antagonists. In P2X3 purinergic receptors ∆G° values range from -
46.2 to -41.0 kJ/mol for agonists and from –39.8 to -29.3 kJ/mol for antagonists. 
Equilibrium standard enthalpy  ∆H°  and entropy ∆S° values show similar values 
for agonists and antagonists examined suggesting that P2X1 purinergic receptors 
are not thermodynamically discriminated. The analysis of thermodynamic 
parameters of P2X3 purinergic receptors shows that the binding  for agonists is 
always enthalpy- and entropy-driven (∆H° values ranging from -26 to -18 kJ/mol 
and  ∆S° values from 59 to 68  J/K/mol) while for antagonists it is totally entropy-
driven (∆H° values ranging from 14 to 36 kJ/mol and  ∆S° values from 149 to 249 
J/K/mol). Therefore, agonists and antagonists at P2X3 purinergic receptors are 
thermodynamically discriminated. Interestingly, the compound TNP-ATP, 
reported to be from a functional point of view as a purinergic antagonist (Burgard 
et al., 2000), shows a typical agonist behaviour with an affinity value and 
thermodynamic parameters strictly similar to those obtained for the other 
purinergic agonists. Figure 4.10 summarizes the results in the form -T∆S° versus 
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∆H° scatter plot (T = 298.15 K) showing that for human P2X1 receptors the points 
are present in the region that characterises the enthalpy and entropy-driven 
binding without a thermodynamically discrimination. In human P2X3 purinergic 
receptors antagonists are clustered in the endothermic region (14 ≤ ∆H° ≤ 36 
kJ/mol) with large positive entropy values (-74.20 ≤ -T∆S° ≤ -44.40 kJ/mol) 
revealing that their binding is totally entropy-driven. Agonist binding is enthalpy 
and entropy-driven (-26 ≤ ∆H° ≤ -18 kJ/mol  and   –21.75 ≤ -T∆S° ≤ -17.58 
kJ/mol).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 166 
Table 4.1: Binding parameters of  HEK293-hP2X1 and HEK293-hP2X3 
membranes (A) and thermodynamic parameters for the binding equilibrium 
of [3H]αβmeATP in the same substrates (B). 
 
 
 
 
(B) 
Cell lines ∆G° (kJ/mol) ∆H° (kJ/mol) ∆S° (J/mol/K) 
 
HEK293-hP2X1   
 
-46.0±0.2 
 
-32±3 
 
46±3 
 
 
HEK293-hP2X3 
 
-46.7±0.2 
 
-28±2 
 
64±6 
 
 
   
 
 
 
 
(A) 
[3H]αβme 
ATP binding 5°C (278 K) 10°C (283 K) 15°C (288 K) 20°C (293 K) 25°C (298 K) 30°C (303 K) 
      
 
HEK293-hP2X1 
KD (nM) 3.2±0.3 4.1±0.4 4.8±0.4 6.4±0.6 8.1±0.7 11.1±1.1 
Bmax 
(fmol/mg protein) 3120±290 3200±310 3300±320 3400±330 3050±315 3500±325 
 
     
 
HEK293-hP2X3 
KD (nM) 2.6±0.3 3.5±0.4 4.0±0.4 4.9±0.5 6.2±0.6 7.5±0.7 
Bmax 
(fmol/mg protein) 18800±1600 18900±1650 19000±1700 19200±1750 18500±1520 19500±1800 
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Table 4.2A: Affinities, expressed as Ki values (nM) of selected purinergic compounds  to human P2X1 receptors expressed in 
HEK293 cells 
 
 
Ligand 
 
 
5 °C 
278 K 
 
 
10 °C 
283 K 
 
15 °C 
288 K 
 
20 °C 
293 K 
 
25 °C 
298 K 
 
30 °C 
303 K 
 
Purinergic 
Agonists Ki (nM) Ki (nM) Ki (nM) Ki (nM) Ki (nM) Ki (nM) 
 ATP 120±10 150±14 180±15 215±20 250±24 306±28 
ADP 125±11 155±13 200±16 227±18 245±22 316±30 
 αβmeATP 3.5±0.3 4.2±0.4 4.8±0.5 6.4±0.6 8.1±0.7 11.4±1.1 
2meSATP 100±10 120±11 150±12 180±15 200±18 250±22 
BzATP 60±6 90±9 113±10 137±12 168±18 200±16 
 
      
Purinergic 
Antagonists       
Suramin 7500±650 8300±730 9600±850 11200±950 13700±1100 16700±1200 
NF023 6140±500 7500±600 10000±970 11200±1050 12800±1080 14000±1270 
TNP-ATP 50±4 60±5 75±7 92±8 113±10 137±15 
PPADS 16700±1500 18500±1700 20400±2000 27500±2400 30400±2800 33600±3120 
A317491 2500±220 3000±210 3500±250 4300±300 5000±420 5600±510 
NF279 4000±300 4500±350 5000±380 5600±460 6800±610 8500±720 
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Table 4.2B: Affinities, expressed as Ki values (nM) of selected purinergic compounds  to human P2X3  receptors expressed 
in HEK293 cells 
 
Ligand 
 
 
5 °C 
278 K 
 
 
10 °C 
283 K 
 
15 °C 
288 K 
 
20 °C 
293 K 
 
25 °C 
298 K 
 
30 °C 
303 K 
 
Purinergic 
Agonists Ki (nM) Ki (nM) Ki (nM) Ki (nM) Ki (nM) Ki (nM) 
 ATP 15±2 18±2 20±2 25±2 30±3 37±4 
ADP 30±3 37±3 45±4 50±5 60±5 75±6 
 αβmeATP 2.9±0.3 4.1±0.4 4.6±0.5 5.3±0.5 7.6±0.6 9.2±0.8 
2meSATP 5.1±0.4 6.8±0.5 8.2±0.7 9.7±0.8 11.2±1.0 13.8±1.2 
BzATP 5.4±0.4 7.2±0.5 9.4±0.7 10.7±0.9 12.5±1.1 14.9±1.3 
 
      
Purinergic 
Antagonists       
Suramin 4000±380 3730±350 3100±280 2800±245 2500±240 2100±180 
NF023 3500±320 3200±300 3000±260 2700±252 2300±210 2000±195 
TNP-ATP 28±3 34±3 40±4 46±4 50±5 60±5 
PPADS 20000±1850 15000±1200 12000±1100 9170±840 7500±720 6000±510 
A317491 250±22 226±20 185±15 137±12 100±9 70±6 
NF279 10000±920 9170±810 8290±780 7500±740 6790±630 5560±450 
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Table 4.3: Thermodynamic parameters for the binding equilibrium of 
[3H]αβmeATP to human P2X1 (A) and P2X3 (B) purinergic receptors 
expressed in HEK293 cells. 
 
 
 
(A) ∆G° ∆H° ∆S° 
 Ligand (kJ/mol) (kJ/mol) (J/K/mol) 
Purinergic Agonists    
 ATP -37.4±0.1 -25±3 43±3 
ADP -37.6±0.1 -24±2 47±3 
 αβmeATP -46.0±0.2 -31±3 51±4 
2meSATP -37.8±0.1 -24±1 46±3 
BzATP -38.4±0.1 -23±2 50±4 
 
   
Purinergic Antagonists    
Suramin -27.8±0.1 -21±2 21±3 
NF023 -27.6±0.1 -22±2 20±2 
TNP-ATP -39.3±0.2 -27±3 41±4 
PPADS -25.5±0.1 -20±2 17±1 
A317491 -30.1±0.2 -22±3 27±2 
NF279 -29.3±0.1 -19±1 34±2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(B) ∆G° ∆H° ∆S° 
 Ligand (kJ/mol) (kJ/mol) (J/K/mol) 
Purinergic Agonists    
 ATP -42.7±0.1 -24±1 62±5 
ADP -41.0±0.1 -24±2 59±4 
 αβmeATP -46.2±0.2 -26±3 68±5 
2meSATP -45.1±0.2 -26±2 65±5 
BzATP -44.9±0.1 -18±2 64±4 
 
   
Purinergic Antagonists    
Suramin -31.9±0.1 18±2 168±8 
NF023 -32.0±0.1 14±1 153±8 
TNP-ATP -41.4±0.2 -20±2 73±6 
PPADS -29.3±0.1 36±3 218±9 
A317491 -39.8±0.2 35±3 249±9 
NF279 -29.5±0.1 15±2 149±7 
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Figure 4.1: Effect of pH on [3H]αβmeATP binding in HEK293-hP2X1 and 
HEK293-hP2X3 membranes (A,C). Effect of Ca2+ on [3H]αβmeATP binding 
in HEK293-hP2X1 and HEK293-hP2X3 membranes (B,D).  
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Figure 4.2: Kinetics of [3H]αβmeATP binding to HEK-293-hP2X1 
membranes with associaton (A) and dissociation (B) curves. 
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Figure 4.3: Kinetics of [3H]αβmeATP binding to HEK-293-hP2X3 
membranes with associaton (A) and dissociation (B) curves. 
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Figure 4.4: Saturation curves of [3H]αβmeATP to HEK-293-hP2X1 
membranes at 5 and 25 °C (A) and relative Scatchard plot (B). 
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Figure 4.5: Saturation curves of [3H]αβmeATP to HEK-293-hP2X3 
membranes at 5 and 25 °C (A) and relative Scatchard plot (B). 
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Figure 4.6: Competition curves of specific [3H]αβmeATP binding to HEK-
293-hP2X1 by purinergic agonists (A) and antagonists (B). 
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Figure 4.7: Competition curves of specific [3H]αβmeATP binding to HEK-
293-hP2X3 by purinergic agonists (A) and antagonists (B). 
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Figure 4.8: van’t Hoff plots showing the effect of temperature on the 
equilibrium binding association constant, KA, for P2X1 purinergic agonists 
(A) and antagonists (B).  
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Figure 4.9: van’t Hoff plots showing the effect of temperature on the 
equilibrium binding association constant, KA, for P2X3 purinergic agonists 
(A) and antagonists (B).  
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Figure 4.10: Scatter plot showing –T∆S° versus ∆H° values for purinergic 
ligands studied in HEK-293-P2X1 (A) and HEK-293-P2X3 (B) 
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DISCUSSION 
 
Thermodynamic parameters have been collected for a remarkable number of 
ligands at P2X1 and P2X3 receptors, including full, partial and inverse agonists or 
antagonists (Borea et al., 2000). The information provided by these data could be 
useful from a pharmacological point of view to discover new thermodynamic 
relationships related to drug-receptor interactions and their molecular mechanisms 
(Gilli et al., 1994; Grunwald and Steel, 1995; Raffa, 2001). In the last few years, it 
has been reported that equilibrium standard enthalpy (∆H°) and entropy (∆S°) 
values of drug interaction with a defined receptor can often give a simple “in 
vitro” way to discriminate the capability of the drug to interfere with the signal 
transduction pathways (Borea et al., 1996, 1998, 2000; Merighi et al., 2002; Gilli 
et al., 2005; Lorenzen et al., 2000). This phenomenon, called “thermodynamic 
discrimination” has been evaluated for various membrane and 
cytoplasmatic/nuclear receptors. Six G-protein coupled receptors such as β-
adrenergic, D2 dopamine, 5HT1A serotonin and A1, A2A and A3 ARs subtypes were 
studied and four out of six of these were thermodynamically discriminated (Borea 
et al., 1998, 2000; Merighi et al., 2002). In addition four ligand-gated ion channel 
receptors such as glycine, GABAA, 5HT3 serotonin and nicotinic membrane 
receptors were analyzed and all resulted discriminated from a thermodynamic 
point of view (Maksai, 2001; Gessi et al., 1999, Borea et al., 2004). Finally, the 
cytoplasmatic receptor for glucocorticoid hormones and three cytoplasmatic 
steroid/nuclear estrogen, progesterone and androgen receptors were investigated 
and three of these were discriminated (Gilli et al., 2005). All these data suggest an 
intercorrelation between specific binding and the variation of water molecules 
present to receptor surfaces. In addition, based on the thermodynamic 
compensation a general model of drug-receptor interaction has been proposed. In 
this model the solvent molecules do not modify the intrinsic values of the affinity 
constant (KA) of the drug-receptor interaction because the standard free energy for 
solvent reorganization can be near to zero and the values of binding parameters 
are due to specific features of the ligand and receptor in the binding process and 
not by the solvent (Grunwald and Steel, 1995). On the other hand, ∆H° and -T∆S° 
values are related to the rearrangements occurring during the binding, in the 
solvent-drug and solvent-receptor interfaces (Grunwald and Steel, 1995). It seems 
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reasonable to assume that solvent effects might be responsible for the in vitro 
thermodynamic discrimination between agonists and antagonists. From this 
background, one of the most significant results of this paper is the presence of the 
linearity of van’t Hoff plots for P2X purinergic receptors similarly to what 
verified for other membrane receptors showing that ∆H° and ∆S° values are 
independent of temperature and obtained by linear van’t Hoff plots. Van’t Hoff 
plots turn out to be linear for all compounds considered implying that the value of 
∆H° is not significantly affected by temperature variation in the range 
investigated. The second result concerns the interdependence of ∆H° and -T∆S° 
values for the P2X3 purinergic receptors where all the experimental points appear 
to be arranged along a same diagonal line according to the equation: -T∆S° 
(kJ/mol  at 278 K) = - 37.8 (± 2) –0.80 (± 0.05) ∆H° (kJ/mol )  (n=11, r= 0.985, 
p<0.0001). This equation is of the form ∆H° = β∆S° which is expected for a case 
of enthalpy-entropy compensation with a compensation temperature of 278 K 
(Borea et al., 1996, 1998, 2000; Merighi et al., 2002; Gilli et al., 2005). The 
enthalpy-entropy compensation phenomenon has been attributed for drug-receptor 
interactions to the solvent reorganization (Grunwald and Steel, 1995). While ∆G° 
values are most probably determined by the features of the ligand-receptor 
binding process, ∆H° and -T∆S° values appear strongly affected by the 
rearrangements occurring in the solvent (Tomlinson and Steel, 1983). As it can be 
seen from the data plotted in Figure 4.10, all experimental points are arranged on 
the same diagonal band encompassed between the two dashed lines which 
represent the loci of points defined by the limiting KD values of 100 µM and 10 
pM. This band is the expression of the enthalpy-entropy compensation 
phenomenon probably due to drug-receptor interactions, to the solvent 
reorganization that accompanies the receptor binding process (Borea et al., 1996, 
1998, 2000; Merighi et al., 2002; Gilli et al., 2005). The most remarkable 
differences between P2X1 and P2X3 receptors are elucidated by the comparison of 
thermodynamic data. Interestingly, P2X1 and P2X3 purinergic receptors have a 
different thermodynamic behaviour as demonstrated by the fact that agonists and 
antagonists for P2X1 receptors show similar enthalpy and entropy values. On the 
contrary, P2X3 receptors can be considered thermodynamically discriminated 
because agonist binding is enthalpy and entropy-driven and antagonist binding is 
totally entropy-driven. Another observation on purinergic ligands studied is 
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represented by a higher affinity versus P2X3 than versus P2X1 receptors. High 
affinity values, in the nanomolar range, were found for αβmeATP in both 
purinergic receptors studied. The order of potency for P2X3 receptors of the 
agonists was: αβmeATP > 2meSATP >BzATP > ATP > ADP. Similar potencies 
were also observed to P2X1 receptors even if all ligands, with the exception of 
αβmeATP, showed a lower affinity in comparison with that obtained to P2X3 
receptors. It should be noted that other examples of binding experiments have 
been reported by using different agonist or antagonist radioligands (Jarvis et al., 
2004; Michel et al., 1995, 1996; Schafer and Reiser, 1997). It was found that in 
synaptosomal membranes from rat brain cortex, ATP, 2MeSATP and suramin 
revealed lower Ki values by using [35S]-ATPαS as a radioligand to label P2X 
receptors, than those found in our conditions (Schafer and Reiser, 1997). The 
same authors reported a clear difference between the binding characteristics of 
different agonists and antagonists using [35S]-ATPαS or  [3H]αβmeATP (Schafer 
and Reiser, 1997). Furthermore, different affinity values were found using [3H]-
A317491 to label P2X3 receptors expressed in 132N1 human astrocytoma cells 
(Jarvis et al., 2004). In particular, the main difference in affinity values compared 
to our data concern the Ki values of the antagonists. In fact, A317491, TNP-ATP 
and PPADS revealed a higher affinity using [3H]-A317491 instead of  
[3H]αβmeATP. On the contrary, the affinity values of the agonists were strictly 
similar using [3H]-A317491 or [3H]αβmeATP as radioligands. Some reports 
revealed weak correlation between radioligand binding profiles and the functional 
activity of various P2 ligands (Yu et al., 1999). Binding and functional studies 
reported that P2X receptor agonists with high affinity values in the nanomolar 
range also showed a very low potency (Lambrecht, 2000). In addition, differences 
in P2X binding parameters could be attributed to various additional factors. In 
particular it was found that several divalent and trivalent cation salts markedly 
increase binding of αβmeATP (Michel and Humphrey, 1994). Some 
discrepancies between our and previous data might be related either to a different 
radioligand used to reveal P2X purinergic receptors or to a various cells or tissues 
expressing purinergic receptors. Some differences are also present by using 
human or rat purinergic tissues suggesting a species diversity despite their high 
homology (Michel et al., 1996). In our experimental conditions suramin analogs 
such as NF 023 and NF 279 revealed affinity values in the micromolar range for 
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both purinergic subtypes even if they have been reported be selective for P2X1 
receptors (Burnstock, 2007). This is probably due to the various experimental 
conditions used and may also be complicated by the fact that functional P2X 
ligand-gated ion channels exist as oligomeric combinations with specific subunit 
arrangements (North, 2002; North and Surprenant, 2000; Jacobson et al., 2002; 
Burnstock, 2007). Interestingly, TNP-ATP a typical nucleotide with a ribose-
substituted trinitrophenyl group, defined to be an antagonist in functional assays, 
behaves in our experimental thermodynamic conditions as an agonist. It is 
possible to hypothesize that TNP-ATP could interact with the site occupied by the 
agonists. Another possible explanation could be that the binding of TNP-ATP is 
present to an allosteric site on a large extracellular region of the receptor 
representing a common domain that interacts with the strongly electronegative 
trinitrophenyl mojety (Burgard et al., 2000; Virginio et al., 1998). More generally, 
the present study demonstrates that thermodynamic parameters reflect a common 
mechanism of ligand-receptor interaction and emphasizes the possibility to obtain 
information about the agonist-antagonist discrimination by simple in vitro binding 
experiments. Thus, analysis of thermodynamic data of drug-receptor interactions 
appears to be an effective tool for investigating, at a molecular level, the role 
played during the binding of the ligands. These novel research could be of interest 
in the identification of novel and potent P2X1 and P2X3 purinergic ligands. 
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INTRODUCTION 
 
Chondrocytes within articular cartilage are responsible for the synthesis and 
degradation of the extracellular matrix, which in healthy tissue provide 
mechanical functionality. In degenerative diseases such as OA and RA there is a 
net loss of cartilage because the rate of catabolism exceeds the rate of synthesis 
and deposition of the macromolecular components of the extracellular matrix 
(Leong et al., 1994). Several chondrocyte activities are associated to cartilage 
damage, and include the up-regulation of nitric oxide (NO) and lipid 
inflammatory mediators such as prostaglandins (PGE), as well as the increased 
production of matrix-degrading enzymes (De Mattei et al., 2002). Growing 
evidence suggests that extracellular nucleotides, might play important roles in the 
regulation of cartilage metabolism (Hoebertz et al., 2003; Picher et al., 2003). 
Extracellular nucleotides have been shown to enhance growth factor-induced 
proliferation of chondrocytes (Kaplan et al., 1996). Further it has been reported 
that ATP and ADP can stimulate the production of cartilage inflammatory 
mediators such as PGE by cultured human chondrocytes, which is enhanced by 
the pro-inflammatory cytokines IL-1β, IL-1α and TNF- α (Caswell et al., 1991, 
1992; Koolpe et al., 1999). ATP can promote cartilage resorption through the 
breakdown of proteoglycans and the release of glycosaminoglycans (Leong et al., 
1994; Brown et al., 1997). On the other hand, it has been also reported that the 
release of ATP and the activation of purinergic pathways induced by 
physiological mechanical stimulation can be involved in beneficial effects on 
cartilage, including the up-regulation of proteoglycan synthesis and the 
downregulation of inflammatory mediators such as NO (Graff et al., 2000; Kono 
et al., 2006; Millward et al., 2000, 2004; Chowdhury and Knight, 2006). These 
previous studies indicate the involvement of purinergic pathways in the 
modulation of cartilage metabolism, however, to date, the pharmacological 
characterization of purinergic receptors and the effects of nucleotides in 
chondrocytes have not been investigated in detail. Several pharmacological 
studies on transduction mechanisms and molecular biology indicate the basis for 
subdivision of P2 receptors into P2X and P2Y families (North, 2002; Burnstock, 
2004). In particular, seven subtypes of P2X receptors and eight subtypes of P2Y 
receptors are currently recognized (Abbracchio et al., 2006). P2X purinergic 
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receptors are membrane ligand-gated ion channels that open in response to the 
binding of extracellular ATP which represents an important local regulatory factor 
of the inflammatory response. P2X receptors are abundantly distributed and 
functional responses have been described in neurons, glia, epithelia, endotelia, 
bone, muscle and hemopoietic tissues (North, 2002). Over the last few years 
attempts to characterize endogenous and recombinant P2X purinergic receptors 
using radioligand binding techniques have had limited success, primarily due to a 
lack of selective radioligands (North, 2002; Jacobson et al., 2002). The 
availability of [3H]-α,βmeATP as a selective radioligand to study P2X 
purinoceptors presents a very good tool for determining the distribution of these 
receptors and their binding parameters (Michel et al., 1995). In addition, to better 
characterize the ligand-receptor interaction a thermodynamic analysis of human 
P2X1 and P2X3 purinergic receptors expressed in HEK293 cells has been 
performed (Varani et al., 2008a). Numerous thermodynamic studies have reported 
that the discrimination of the agonists and antagonists occur in different classes of 
membrane or intracellular receptors confirming the important role of the 
thermodynamic parameters to clarify the mechanisms of ligandereceptor binding 
(Borea et al., 1996, 1998, 2000, 2004; Merighi et al., 2002a). From the current 
background, the aim of this study was to investigate the presence of P2X receptors 
in bovine chondrocyte membranes by using western blotting, 
immunohistochemistry and saturation binding assays. Competition binding 
experiments and thermodynamic analysis with typical purinergic ligands were 
also performed to characterize, from a pharmacological point of view, P2X 
purinergic receptors expressed in bovine chondrocytes. The capabilities of the 
same purinergic ligands to modulate chondrocyte catabolic activities were 
evaluated by analyzing the effects on NO release and PGE2 production, both in 
the absence and in the presence of IL-1.  
 
MATERIALS AND METHODS 
 
Human P2X1 and P2X3 purinergic receptors expressed in HEH-293 cell 
culture and membrane preparation 
HEK293-hP2X1 and HEK293-hP2X3 cells were kindly provided by Prof A. 
Surprenant (Institute of Molecular Physiology, University of Sheffield, Sheffield, 
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England, UK). In particular, HEK293-hP2X1 and HEK293-hP2X3 cells were 
generated by transformation of human embryonic kidney cell cultures and stably 
expressed purinergic receptors (Virginio et al., 1998). These cells were grown 
adherently and maintained in DMEM/F12, containing 10% FBS, penicillin (100 
U/ml), streptomycin (100 mg/ml) and Geneticin (G418, 0.2 mg/ml) at 37°C in 5% 
CO2 /95% air. For membrane preparation, the culture medium was removed, the 
cells were washed with PBS and scraped in ice-cold hypotonic buffer. The cell 
suspension was homogenized and centrifuged for 30 min at 100,000 g. The 
membrane pellet was resuspended in Tris HCl 50 mM, CaCl2 4-mM, pH 7.4 and 
frozen at -80°C. 
 
Chondrocytes culture and membrane preparation 
Bovine articular cartilage derived from the metacarpophalangeal joints of 14-18 
month-old animals (Limousin breed). Chondrocytes were isolated from cartilage 
fragments obtained from the weight-bearing region of the articular surface 
(Pezzetti et al., 1999; De Mattei et al., 2004). Briefly, the cartilage was dissected 
out and cut into small pieces that were subjected to a sequential digestion in 
DMEM/F12 (1:1) medium (Gibco-Invitrogen, Paisley, UK) with pronase from 
Streptomyces griseus (Calbiochem, Darmstadt, Germany) for 90 min and 
collagenase P from Clostridium histolyticum (Roche, Indianapolis, USA) for 12 h. 
The resulting suspension was filtered to remove undigested cartilage and 
chondrocytes were recovered by centrifugation, counted and plated at high density 
(150,000/cm2) in 75-cm2 flasks and in multiwells (1.6 cm the diameter of each 
well). Chondrocytes were cultured in DMEM/F12 supplemented with 10% FBS 
and antibiotics (penicillin 100 U/ml, streptomycin 0.1 mg/ml) (GibcoeInvitrogen, 
Paisley, UK). Only chondrocytes without subculturing and maintained in culture 
for 1 week were used in the binding and functional experiments. In chondrocyte 
cultures the presence of aggrecan and type II collagen and the absence of type I 
collagen were shown by immunohistochemistry indicating the maintenance of the 
chondrocyte phenotype (Varani et al., 2008b). For membrane preparation, the 
culture medium was removed and the cells were washed with PBS and scraped off 
T75 flasks in ice-cold hypotonic. The cell suspension was homogenized, 
centrifuged for 30 min at 100,000 g and used in saturation and competition 
binding experiments. 
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Western blotting analysis for P2X1 and P2X3 receptors 
Bovine chondrocytes in comparison with HEK293-hP2X1 and HEK293-hP2X3 
cells were harvested and washed with ice-cold PBS containing sodium 
orthovanadate 1 mM, 4-(2-aminoethyl)-benzenesulfonyl fluoride 104 mM, mM 
aprotinin 0.08, leupeptin 2 mM, bestatin 4 mM, pepstatin A 1.5 mM, E-64 1.4 
mM. Then cells were lysed in Triton lysis buffer and the protein concentration 
was determined using bicinchoninic acid (BCA) protein assay kit (Pierce). 
Aliquots of total protein sample (50 mg) were analyzed using polyclonal 
antibodies for human P2X1 and P2X3 purinergic receptors (Neuromics Antibodies, 
1 mg/ml dilution) and for GAPDH (Novus Biologicals) (Merighi et al., 2002b). 
Filters were washed and incubated for 1 h at room temperature with peroxidase-
conjugated secondary antibodies (1:2000 dilution). Specific reactions were 
revealed with Enhanced Chemiluminescence Western blotting detection reagent 
(Amersham Biosciences). 
 
Immunohistochemistry for P2X1 and P2X3 receptors 
The expression of P2X1 and P2X3 receptors was also evaluated by 
immunohistochemistry in cartilage fragments immediately after dissection from 
the articular surface (Brady et al., 2004). Briefly, cartilage fragments were fixed in 
freshly prepared 4% paraformaldehyde (PFA) w/v in PBS, pH 7.2 for 3 h and then 
transferred to 10% sucrose in PBS and refrigerated overnight. The samples were 
embedded in optimum cutting temperatures medium and 4-5-mm thickness 
sections were cut using a cryostat and collected onto clean glass superfrost slides. 
After washing in PBS, endogenous peroxidase was blocked by incubation with 
0.3% w/v hydrogen peroxide in methanol. After a further wash in PBS, the tissue 
sections were incubated with polyclonal rabbit antibodies to P2X1 and P2X3 
receptors (Neuromics Antibodies, 1:500) overnight. Stain was obtained by 
developing with ultraystain polyvalent horseradish peroxidase (HRP) 
immunostaining kit (Ylem, Rome, Italy), using the procedure recommended by 
the manufacturer. Negative controls were prepared without primary antibody and 
nuclei were counterstained by hematoxylin. 
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Saturation and competition binding assays 
Saturation binding experiments of [3H]-α,β-meATP (from 0.1 to 50 nM) to the 
membranes previously obtained (100 mg of protein/assay) were performed by 
incubating from 40 min at 5°C to 90 min at 30°C according to the results of 
previous time-course experiments. Competition experiments of 3 nM [3H]-α,β-
meATP were performed in duplicate in test tubes containing Tris HCl 50 mM, 
CaCl2 4 mM buffer, 100 ml of membranes and at least 8-10 different 
concentrations of P2X1 and P2X3 agonists or antagonists studied. ATP, ADP, α,β-
meATP, BzATP, TNP-ATP, suramin, NF023, PPADS, A317491 were obtained 
from Sigma-Aldrich Advanced Sciences (Milan, Italy). NF279 and 2-meSATP 
were obtained from Tocris Cookson Ltd (Bristol, UK). Non specific binding was 
determined in the presence of 10 mM α,β-meATP (Froldi et al., 1997). Bound and 
free radioactivity were separated by rapid filtration through Whatman GF/B glass-
fiber filters using a Brandel instrument. The filter bound radioactivity was counted 
on a Scintillation Counter Tri Carb Packard 2500 TR (efficiency 57%). The 
protein concentration was determined according to a Bio-Rad method with bovine 
albumin as reference standard (Bradford, 1976). 
 
Thermodynamic data determination 
For a generic binding equilibrium L+R = LR (L = ligand, R = receptor) the 
affinity association constant KA = 1/KD is directly related to the standard free 
energy ∆G° (∆G° = -RTlnKA) which can be separated in its enthalpic and entropic 
contributions according to the Gibbs equation: ∆G° = ∆H° -T∆S°. The standard 
free energy was calculated as ∆G° = -RTlnKA at 298.15 K, the standard enthalpy, 
∆H°, from the van’t Hoff plot lnKA versus (1/T) (the slope of which is -∆H°/R) 
and the standard entropy as ∆S° = (∆H°- ∆G°)/T with T = 298.15 K and R = 8.314 
J/K/mol (Jacobson et al., 2002; Merighi et al., 2002; De Mattei et al., 2004). KA 
values were obtained from [3H]-α,β-methyleneATP saturation experiments in 
bovine chondrocyte membranes carried out at 0, 10, 15, 20, 25 and 30°C in a 
thermostatic bath assuring a temperature of ± 0.1°C. 
 
Pharmacological treatments of bovine chondrocytes 
In functional assays including the analysis of PGE2 and NO release, chondrocytes 
isolated from cartilage, plated at high density (150,000/cm2) in multiwells and 
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maintained in culture for 1 week were used. At the beginning of the experiments 
(time 0), medium was changed in all cultures. To test the effects of purinergic 
agonists cells were incubated in complete medium containing increasing doses of 
ATP (10, 100, 500 µM) and α,β-meATP (1, 10, 100 µM). In a second series of 
experiments ATP (10, 100, 500 µM) and α,β-meATP (1, 10, 100 µM) were added 
to medium containing 50 ng/ml Recombinant Human IL-1β (Preprotech INC, 
Rocky Hill, NJ, USA), used to activate inflammatory activities in chondrocytes. 
To evaluate the capability of A317491 to antagonize the effects of the purinergic 
agonists, 1 mM of this antagonist was added to the treated cultures. All treatments 
were made up in triplicate wells for 24 h. At the end of treatment, the culture 
medium was removed from the wells and stored at -80°C for subsequent 
determination of PGE2 and NO release. The monolayers were solubilized in 
sodium hydroxide and protein concentration was evaluated (Bradford, 1976). 
 
NO assay 
The release of nitrite, a stable breakdown product of NO was measured as an 
indicator of NO synthesis. At the end of the 24 h of treatment period, nitrite 
concentration was determined in the conditioned media according to Greiss 
method (Green et al., 1982.) Briefly, culture medium was mixed with an equal 
volume of the Greiss reagent and absorbance was measured at 550 nm. Nitrite 
concentration was calculated from a standard curve of sodium nitrite.  
 
PGE2 assay  
The concentration of PGE2 was measured using a commercially available 
competitive enzyme immunoassay (PGE2 ASSAY, R&D Systems, Inc., MN, 
USA). Briefly, medium was diluted threefold in Calibrator Diluent (RD5-39) 
included in the kit and 100 µl of diluted sample or standard were added to each 
well of a microplate coated with goat antimouse antibody. Subsequently, 
horseradish peroxidase (HRP)-labeled PGE2 and a mouse monoclonal antibody to 
PGE2 were added to each well and the plate was incubated for 2 h and washed. 
The substrate solution was added to each well and following 30-min incubation a 
stop solution containing phosphoric acid was added to each well and the 
absorbance was measured at 450 nm with a reference of 570 nm. All samples and 
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standards were assayed in duplicate. PGE2 production was normalized to the total 
protein content and expressed as picogram (pg) PGE2/mg protein. 
 
Statistical analysis 
A weighted non linear least-squares curve fitting program Ligand (Munson and 
Rodbard, 1980) was used for computer analysis of saturation and competition 
binding experiments. Functional experiments were calculated by non linear 
regression analysis using the equation for a sigmoid concentration response curve 
(GraphPAD Prism, San Diego, CA, USA). Analysis of data was done with 
Student’s t test (unpaired analysis). Differences were considered significant at a 
value of p<0.01. All data are reported as mean ± SEM of independent experiments 
(n = 3-4). 
RESULTS 
 
Western blotting 
Figure 5.1 shows the immunoblot signals of P2X1 and P2X3 purinergic receptors 
in bovine chondrocytes in comparison with HEK293-hP2X1 and HEK293-hP2X3 
cells. P2X1 and P2X3 purinergic receptors are present in bovine chondrocytes 
showing a minor expression than in HEK293-hP2X1 and HEK293-hP2X3 cells. In 
addition, in bovine chondrocytes P2X1 receptor expression resulted lower than 
P2X3 receptor. Figure 5.1 also reports the immunoblot signals of GAPDH used as 
loading control. 
 
Immunohistochemistry 
The immunohistochemistry of purinergic receptors in cartilage slices showed that 
chondrocytes in all zones of the articular cartilage stained positive for P2X3 
receptors con-firming the expression of the receptor in intact cartilage (Figure 
5.2A). No signal for P2X1 receptors was observed in cartilage slices (Figure 
5.2B). Negative controls, obtained without primary antibodies, did not show any 
staining. 
 
Saturation and competition binding experiments 
Saturation binding experiments in bovine chondrocytes were performed to 
evaluate affinity (KD) and receptor density (Bmax) values of P2X purinergic 
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receptors (Table 5.1, figure 5.3). The binding parameters were determined at 
various temperatures (0, 10, 15, 20, 25 and 30°C) by using [3H]-α,β-meATP as 
radioligand at different concentrations. These results demonstrate that KD values 
change with temperature and Bmax values appear to be largely independent of it. 
Computer analysis of the data failed to show a significantly better fit to a two site 
than to a one site binding model, indicating that only one class of high affinity 
binding site is present under our experimental conditions. Figure 5.4 shows the 
dose response curves of [3H]-α,β-meATP binding in bovine chondrocyte 
membranes by using typical agonists and antagonists (Table 5.2). The order of 
potency in [3H]-α,β-meATP displacement assays for purinergic agonists was as 
follow: α,β-meATP > BzATP > 2-meSATP > ATP > ADP. Similarly, the order of 
potency of antagonists in bovine chondrocyte membranes was as follow: TNP-
ATP > A317491 > Suramin > NF023 > NF279 > PPADS. 
 
Thermodynamic analysis 
The van’t Hoff plots show that the effect of temperature on the equilibrium 
binding association constants, KA appears to be essentially linear in the range 4-
30°C for the purinergic ligands examined (Figure 5.5). Final thermodynamic 
parameters calculated for the binding equilibria of the different compounds 
investigated are reported in table 5.3 Thermodynamic parameters of bovine 
chondrocytes for agonists show an enthalpy- and entropy-driven binding and the 
antagonist binding was totally entropy-driven. Interestingly, the compound TNP-
ATP that functional experiments reported to be a purinergic antagonist (Burgard 
et al., 2000) shows a typical agonist behavior with an affinity value and 
thermodynamic parameters strictly similar to those obtained from other purinergic 
agonists. Figure 5.6A reports the van’t Hoff plot and thermodynamic parameters 
of the [3H]-α,β-meATP radioligand showing that this binding was enthalpy- and 
entropy-driven. Figure 5.6B summarizes the results obtained in bovine 
chondrocytes in the form of –T∆S° vs ∆H° scatter plot (T = 298.15 K) and shows 
that purinergic antagonists are clustered in the endothermic region (15 ≤ ∆H° ≤ 30 
kJ/mol) with large positive entropy values (-58.11 ≤ T∆S° ≤ -44.40 k/J/mol) 
revealing that their binding is totally entropy-driven. Agonistic binding was 
enthalpy- and entropy-driven (-26 ≤ ∆H° ≤ -24 kJ/mol and -20.26 ≤ T∆S° ≤ -
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11.62 k/J/mol) suggesting that agonists and antagonists in bovine chondrocytes 
are discriminated from a thermodynamic point of view. 
 
Effects of purinergic ligands on NO production in chondrocyte monolayers 
Figure 5.7 illustrates the effects of ATP and α,β-meATP on NO production in 
bovine chondrocytes in basal condition (Figure 5.7A) and after IL-1β treatment 
(Figure 5.7B). In the absence of IL-1β, treatment of cells with 500 µM ATP and 
100 µM α,β-meATP induced a low but significant increase on basal NO 
production (Figure 5.7A). In the same experimental conditions described above, 
ATP until 100 µM concentration and α,β-meATP until 10 µM concentration were 
not able to modulate NO release. In the presence of IL-1β (Figure 5.7B), both 
ATP and α,β-meATP induced a dose-dependent increase on NO production, 
ranging from 11 to 84% with respect to IL-1β -treated cells. The purinergic 
antagonist A317491 efficiently counteracted the activity of both ATP and α,β-
meATP inhibiting NO production to the levels of cells treated with IL-1β alone. 
 
Effects of purinergic ligands on PGE2 production in chondrocyte monolayers 
Figure 5.8 shows the effects of ATP and α,β-meATP on PGE2 production in 
bovine chondrocytes in basal condition (Figure 5.8A) and after IL-1β treatment 
(Figure 5.8B). In the absence of IL-1β, treatment of cells with ATP in the range of 
concentrations from 10 to 500 µM and α,β-meATP (10 and 100 µM) induced a 
significant increase on basal PGE2 production (Figure 5.8A). In the same 
experimental conditions described above, 1 µM of α,β-meATP was not able to 
modulate PGE2 release. In the presence of IL-1β, both ATP (500 µM) and α,β-
meATP (100 µM) induced a maximum increase on PGE2 production, of 137-79%, 
respectively. ATP at the 100 µM concentration was able to induce slightly but 
significant PGE2 release (p<0.05; figure 5.8B). The purinergic antagonist 
A317491 counteracted in a different way the activity of both ATP and α,β-meATP 
(Figure 5.8B). In particular, A317491 partially reduced ATP-mediated PGE2 
release whilst it completely inhibited α,β-meATP-mediated PGE2 release. 
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Table 5.1:Binding parameters, expressed as KD and Bmax, of [3H]-α,β-meATP in bovine chondrocyte membranes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[3H]αβmeATP  
binding 
5°C  
(278 K) 
10°C  
(283 K) 
15°C  
(288 K) 
20°C  
(293 K) 
25°C  
(298 K) 
30°C  
(303 K) 
       
KD (nM) 3.3±0.3 4.3±0.4 5.5±0.5 6.6±0.6 7.5±0.7 8.4±0.7 
 
      
Bmax (fmol/mg 
protein) 4900±420 4950±440 5050±480 5000±470 4800±450 4750±490 
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Table 5.2: Affinity, expressed as Ki values, of selected purinergic agonists and antagonists in bovine chondrocyte 
membranes at different temperatures. 
 
 
Ligand 
 
 
5 °C 
(278 K) 
 
 
10 °C 
(283 K) 
 
15 °C 
(288 K) 
 
20 °C 
(293 K) 
 
25 °C 
(298 K) 
 
30 °C 
(303 K) 
 
Purinergic 
Agonists Ki (nM) Ki (nM) Ki (nM) Ki (nM) Ki (nM) Ki (nM) 
ATP 90±8 120±11 137±15 168±17 200±19 250±22 
ADP 120±11 150±12 186±17 205±18 250±20 306±28 
αβmeATP 3.0±0.3 4.1±0.3 5.0±0.4 6.1±0.5 6.9±0.6 8.1±0.7 
2meSATP 85±8 110±10 130±12 150±15 185±20 220±22 
BzATP 80±7 100±9 124±13 145±14 170±16 205±21 
 
      
Purinergic 
Antagonists       
Suramin 9000±850 8000±750 7000±650 6500±550 5500±450 5000±400 
NF023 11000±850 10000±850 9000±850 8500±850 7500±850 6000±850 
TNP-ATP 100±10 135±15 150±16 180±18 230±25 280±20 
PPADS 25000±2200 21000±2000 18000±1700 12000±1000 10000±900 9000±800 
A317491 950±85 800±70 750±60 600±60 550±50 450±40 
NF279 15000±1400 13000±1300 12500±1200 11000±1100 9500±900 8000±700 
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Table 5.3: Thermodynamic parameters for the binding equilibrium of [3H]-
α,β-meATP to bovine chondrocyte membranes of selected purinergic agonists 
and antagonists. 
 
 
Ligand ∆G° ∆H° ∆S° 
  (kJ/mol) (kJ/mol) (J/mol/K) 
Purinergic Agonists    
 ATP -38.0±3.8 -26±2 39±2 
ADP -37.5±3.7 -24±1 44±3 
 αβmeATP -46.4±4.1 -26±2 68±3 
2meSATP -38.2±3.4 -25±1 45±4 
BzATP -38.4±3.6 -25±2 46±2 
 
   
Purinergic Antagonists    
Suramin -30.0±3.0 16±1 155±5 
NF023 -29.2±2.9 15±1 149±5 
TNP-ATP -37.7±3.5 -27±2 38±3 
PPADS -21±2.0 30±2 195±8 
A317491 -35.6±3.4 19±1 184±7 
NF279 -28.6±2.8 16±0 150±5 
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Figure 5.1: Western blotting analysis of bovine chondrocytes for purinergic 
receptors in comparision with HEK293-hP2X1 and HEK293-hP2X3 cells. 
 
 
 
 
 
 
 
 
 
 
Figure 5.2: Immunohistochemistry of P2X3 receptors (A) and P2X1 receptors 
(B) in cartilage section. In (B) nuclei are counterstained by hematoxylin. 
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Figure 5.3: Saturation curves of [3H]-α,β-meATP binding to P2X purinergic 
receptors in bovine chondrocytes at 5°C and 25°C (A) and relative Scatchard 
plot (B). 
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Figure 5.4: Competition curves of typical purinergic agonists (A) and 
antagonists (B) in bovine chondrocytes. 
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Figure 5.5: Van’t Hoff plot in bovine chondrocytes showing the effect of 
temperature on the equilibrium binding association constant, KA, for P2X 
purinergic agonists (A) and antagonists (B). 
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Figure 5.6: Van’t Hoff plot in bovine chondrocytes showing the effect of 
temperature on the equilibrium binding association constant, KA, of [3H]-α,β-
meATP to P2X purinergic receptors (A). Scatter plot showing –T∆S° vs ∆H° 
values for the purinergic ligands studied (B). 
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Figure 5.7: Effect of purinergic ligands in the absence (A) and in the presence 
(B) of IL-1β on NO release in bovine chondrocytes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ** p<0.01 vs Control; # p< 0.01 vs IL-1β 50 ng/ml 
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Figure 5.8: Effect of purinergic ligands in the absence (A) and in the presence 
(B) of IL-1β on PGE2 release in bovine chondrocytes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ** p<0.01 vs Control; * p< 0.05 vs Control; # p< 0.01 vs IL-1β 50 ng/ml; § p< 
0.05 vs IL-1β 50 ng/ml 
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DISCUSSION 
 
The purpose of the current investigation was to document the expression, the 
binding parameters and the functionality of P2X purinergic receptor subtypes in 
bovine chondrocytes. The presence of purinergic receptors was investigated 
through western blotting analysis, immunohistochemistry and saturation binding 
experiments. Western blotting assays reveal the presence of P2X1 and P2X3 
purinergic receptors as reported in figure 5.1 where bovine chondrocytes were 
analyzed in comparison with HEK293-hP2X1 and HEK293-hP2X3 cells. In both 
cell types, P2X3 purinergic receptors were present at higher level than P2X1 
purinergic receptors. Immunohistochemistry in cartilage slices confirmed the 
presence of P2X3 purinergic receptors while P2X1 purinergic receptors were not 
detectable probably due to the low presence of these receptors in this substrate. 
Another possible hypothesis could be that P2X1 purinergic expression was 
induced by the in vitro culture conditions. Purinergic receptors were also 
characterized in saturation binding experiments showing the presence of an high 
affinity binding site with a KD of 3.3 ± 0.3 nM and a receptor density (Bmax) of 
4900 ± 420 fmol/mg protein. In addition, thermodynamic parameters obtained 
from the van’t Hoff plot indicate that [3H]-α,β-meATP binding to purinergic 
receptors is enthalpy- and entropy-driven, with a major contribution of the 
enthalpic component. The information provided by these data could be useful 
from a pharmacological point of view to discover new thermodynamic 
relationships linked to ligand-receptor interactions useful to the development of 
new potential classes of drugs (Gilli et al., 1994, 2005; Raffa, 2001; Lorenzen et 
al., 2000; Gessi et al., 1999; Maksai, 2001). From the competition binding 
experiments, performed with the aim to calculate the affinity of the agonists for 
purinergic receptors, the order of potency was α,β-meATP > BzATP > 2-meSATP 
> ATP > ADP. The same order of potency was reported at all the temperatures 
investigated even if the affinity values of the purinergic compounds decreased 
with the increase of the temperature. The order of potency of the studied 
purinergic antagonists was TNP-ATP > A31749 > Suramin > NF023 > NF279 > 
PPADS. Similarly, the order of potency was the same from 5°C to 30°C even if 
the affinities of the antagonists increased (Ki decreased) with the increase of the 
temperature. Moreover, in our experimental conditions, purinergic agonists 
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revealed a higher affinity, in the nanomolar range, when compared to purinergic 
antagonists that showed an affinity in the low nanomolar-micromolar range. In 
addition α,β-meATP was the most affine and potent agonist showing an high 
affinity in the nanomolar range. On the contrary ATP, a typical purinergic 
endogenous ligand, revealed a lower affinity than α,β-meATP vs P2X purinergic 
receptors. Collectively, these binding data of affinity are important to identify the 
specific concentrations of agonists and antagonists to use in functional and 
molecular in vitro and in vivo experiments. Another purpose of the present study 
was to investigate from a functional point of view the purinergic P2X receptors in 
bovine chondrocytes. To this aim, the effects of ATP and α,β-metATP on NO 
production and PGE2 release were analyzed. Both NO and PGE2 are synthesized 
by chondrocytes (Stadler et al., 1991), and have been implicated as critical 
inflammatory mediators of cartilage matrix degradation (Stefanovic-Racic et al., 
1997; Bankers-Fulbright et al., 1996; Stabellini et al., 2003; Knott et al., 1994). 
ATP and α,β-meATP were able to increase NO production at micromolar 
concentration similarly to that reported in literature (Leong et al., 1994; Caswell et 
al., 1991) and the P2X antagonist A317491 was able to decrease the stimulatory 
effect mediated by the purinergic agonists investigated. It is well known that IL-
1β, a proinflammatory agent which is present in elevated amount in osteoarthritic 
cartilage and plays a decisive role in osteoarthritis, also increases the production 
of NO (Stefanovic-Racic et al., 1997). In agreement the treatment of bovine 
chondrocytes with 50 ng/ml of IL-1β significantly increased NO synthesis. 
Interestingly, ATP and α,β-meATP were able to further stimulate the production 
of NO in a dose-dependent manner and A317491 completely inhibited the 
stimulatory effect mediated by the purinergic agonists. The similar behavior of 
ATP and α,β-meATP and the complete inhibition of their effects by A317491 
indicate the involvement of P2X receptors in the stimulation of NO release. In 
addition, ATP and α,β-meATP stimulated the production of PGE2 in a dose-
dependent manner, both in the absence and in the presence of IL-1β, indicating a 
role for P2X in PGE2 release. Interestingly, ATP had an higher effect than α,β-
meATP and A317491 was able only to partially inhibit the effect of ATP and to 
completely decrease the effect of α,β-meATP. These differences are probably due 
to the presence of P2Y receptors, involved in PGE2 release (Burnstock, 2004), 
which can be activated by ATP but not by α,β-meATP. The results of this paper 
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confirm ATP as an important extracellular signal involved in cartilage metabolism 
and indicate that the stimulation of purinergic pathways, mediated by P2X 
receptors, can increase the inflammation process associated to cartilage 
pathological conditions. On the other hand, studies concerning physiological 
mechanical stimulation on cartilage suggest that ATP, acting via purinergic 
pathways, may have beneficial effects on cartilage by stimulating proteoglycan 
synthesis and inhibiting NO production (Graff et al., 2000; Kono et al., 2006; 
Milward-Sadler et al., 2000, 2004; Chowdhury and Knight, 2006). In addition, it 
is reported that a chronic treatment of human chondrocytes with 100-500 µM ATP 
induced the loss of glycosaminoglycans but a single dose of 500 µM ATP increase 
proteoglycan and collagen synthesis (Picher et al., 2003). The reasons for this 
apparent discrepancy concerning the role of ATP and purinergic pathways are 
difficult to establish due to the limited knowledge concerning the expression, 
affinities and functional roles of purinergic receptors in cartilage. It is possible to 
hypothesize that various ATP levels associated to the cartilage physiological 
and/or pathological conditions can lead to the activation of different purinergic 
receptors subtypes. In conclusion, for the first time, the present study states in a 
quantitative way the presence and the binding parameters of P2X1 and P2X3 
purinergic receptors in bovine chondrocytes. Binding and functional data on NO 
production and PGE2 release confirm a pivotal role of these purinergic receptor 
subtypes in the inflammatory pathologies linked to the articular cartilage. Novel 
purinergic ligands could be potential targets for drug development in the future in 
several cartilage pathological conditions. 
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CHAPTER 6: 
 
P2X1 and P2X3 purinergic receptors differentially  
modulate the inflammatory response in human 
osteoarthritic fibroblasts-like synoviocytes. 
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INTRODUCTION 
 
Fibroblast-like synoviocytes play a central role in the pathogenesis of joint 
destruction primarily by the secretion of a wide range of pro-inflammatory 
mediators including cytokines, growth factors and lipid mediators of 
inflammation. Pro-inflammatory agents produced by fibroblast-like synoviocytes 
are detrimental to articular cartilage in different joint diseases such as OA and RA 
(Abramson et al., 2006; Varani et al., 2008a). Purine receptors have historically 
been classified in two categories named as P1 and P2 purinergic receptors which 
were subdivided into G protein coupled P2Y receptors and P2X ligand-gated ion 
channels (Burnstock, 2006; Sawynok, 2007). Different functional responses due 
to these purinergic receptors have been described in a wide range of tissues and 
biological systems suggesting that ATP may contribute to various physiological 
processes (Koles et al., 2007; Burnstock, 2008). The effect of extracellular 
nucleotides, through P2 receptors, was previously reported in the regulation of 
bone metabolism, in the breakdown of proteoglycans and in the production of 
cartilage inflammatory mediators (Hoebertz et al., 2003; Picher et al., 2003). The 
pharmacological characterization of P2 receptors and the effects of nucleotides on 
fibroblast-like synoviocytes have not been investigated in detail although it has 
been shown that these cells respond to extracellular ATP (Hoebertz et al., 2003). 
Synergistic interaction between IL-6, PGE2 and the presence of purinergic 
receptors in fibroblast-like synoviocytes may be important in the modulation of 
the joint tissue destruction including the damage related to inflammatory 
pathologies (Loredo and Benton, 1998; Caporali et al., 2008). It is well reported 
that ATP was able to mediate an increase of IL-6 and TNF-α in different cell lines 
(Inoue et al., 2007; Bulanova et al., 2009). The study of the pharmacologic 
modulation of the NF-kB pathways linked to p50 and p65 polypeptides suggest its 
involvement in the pathogenesis of several inflammatory diseases (Roman-Blas 
and Jimenez, 2006). The characterization of endogenous and recombinant P2X 
purinergic receptors by using radioligand binding techniques have had limited 
success. Purinergic receptor pharmacological studies have been also hampered by 
the lack of highly potent and selective agonists and/or antagonists (Burnstock, 
2006). The availability of [3H]αβmeATP as radioligand to study P2X 
purinoceptors represent a useful tool in determining the distribution of these 
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receptors (Michel et al., 1995). Recently, [3H]-αβmeATP binding and 
thermodynamic characterization of human P2X1 and P2X3 purinergic receptors in 
HEK 293 cells and in bovine chondrocytes revealed the possibility to obtain 
informations by agonist-antagonist discrimination (Varani et al., 2008b,c). The 
aim of this study was to investigate the presence of P2X receptors in primary 
cultures of fibroblast-like synoviocytes from patients with OA and in SW 982 
cells derived from human synovial sarcoma by using mRNA and western blotting 
assays. Affinity values expressed as Ki or KH and KL of selected purinergic 
agonists and antagonists were determined by using competition binding 
experiments. A thermodynamic analysis was performed to investigate new 
insights into the forces driving drug-purinergic receptor coupling. In order to 
complete the pharmacological characterization, P2X receptors were studied from 
a functional point of view. The effect of selected P2X1 and P2X3 agonists was 
investigated on NF-kB and NF-IL-6 activation and on TNF-α, IL-6 and PGE2 
release. The capability of well-known purinergic antagonists to block the effect of 
the purinergic agonists was also carried out to better verify the involvement of the 
P2X1 and P2X3 purinergic receptors.  
 
MATERIALS AND METHODS 
Materials 
[3H]αβmeATP, was obtained from NEN-Perkin Elmer Life and Analytical 
Sciences (USA). ATP, ADP, αβmeATP, BzATP, TNP-ATP, PPADS, A317491, 
suramin, vimentin, CD14 and von-Willebrand antibodies were purchased from 
Sigma-Aldrich Advanced Sciences (St. Louis, MO, USA). NF023, NF279,  
2meSATP and KN-62 (4-[(2S)-2-[(5-isoquinolinylsulfonyl) methylamino]-3-oxo- 
3-(4-phenyl-1-piperazinyl) propyl] phenyl iso-quinolinesulfonic acid ester) were 
obtained from Tocris Cookson Ltd (Bristol, UK). NF-kB kit was purchased from 
Active Motif, Carlsbad, USA. TNF-α, IL-6  and PGE2 ELISA kits were purchased 
from R&D Systems, Inc. Minneapolis, USA. HEK-293 cells transfected with the 
human recombinant P2X1 and P2X3 receptors were kindly provided by Prof. 
Annmarie Surprenant (Institute of Molecular Physiology, University of Sheffield, 
Sheffield, England, UK). All other reagents were of analytical grade and obtained 
from commercial sources. 
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Cell culture and membrane preparation  
HEK293-hP2X1 and HEK293-hP2X3 cells were generated by stable transfection 
of human embryonic kidney cell cultures with P2X1 and P2X3 purinergic 
receptors (North, 2002). Fibroblast-like synoviocytes were obtained by enzymatic 
digestion of synovial tissues derived from 27 patients with end-stage OA 
undergoing total joint replacement surgery (Miyashita et al., 2004; Bilgen et al., 
2007). The diagnosis was based on clinical and radiological criteria. Human 
samples were collected with approved informed consent in accordance with the 
principles of the Declaration of Helsinki. The study protocol was approved by the 
local Ethics Committee of the University of Ferrara and the subjects provided 
written consent after receiving detailed verbal and written explanations of the 
study. SW 982 cells derived from a human synovial sarcoma are fibroblast-like 
synoviocytes obtained from American Type Culture Collection (Bethesda, MD) 
(Christensen et al., 2005). To avoid the degradation of nucleotides, cells were 
incubated in serum-free medium during the pharmacological treatment with 
purinergic agonists and/or antagonists investigated.  
 
Fibroblast-like synoviocytes characterization 
Immunofluorescence with the primary monoclonal antibody specific for the human 
vimentin was used to evaluate the expression of vimentin, a fibroblast marker, in SW 
982 and in primary cultures of human fibroblast-like synoviocytes, as previously 
described (Varani et al., 2008b; Miyashita et al., 2004). Human fibroblast-like 
synoviocytes and SW 982 were maintained in culture in DMEM, 10% FBS, penicillin 
(100 U/ml), streptomycin (100 µg/ml), L-glutamine (2 mM). Human fibroblast-like 
synoviocytes when reaching confluence were passaged and used at the 3rd-4th passages 
for binding and functional experiments. Nuclei were stained with the selective DNA 
dye, DAPI (0.1 mg/ml in PBS-EGTA) for 10 minutes. Fluorescence was visualized 
using the Nikon Eclipse TE 2000-E microscope equipped with a digital camera (DXM 
1200F, Nikon Instruments Spa, Sesto Fiorentino, Firenze, Italy). Monoclonal antibodies 
to CD14 and von-Willebrand factor were also used to exclude the presence of 
contaminating macrophages or endothelial cells.  
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RT-PCR experiments  
Total cytoplasmic RNA was extracted by the acid guanidinium thiocyanate phenol 
method (Gessi et al., 2004). Quantitative real-time RT-PCR assay of P2X1, P2X2, 
P2X3, P2X4, P2X5, P2X6, P2X7 mRNAs was carried out using gene-specific 
fluorescently labelled TaqMan MGB probe (minor groove binder) in a ABI Prism 
7700 Sequence Detection System (Applied Biosystems). Human GAPDH was 
used as a reference gene.  
 
Western blotting analysis  
Primary cultures of human fibroblast-like synoviocytes and SW 982 cells in 
comparison with HEK293-hP2X1 and HEK293-hP2X3 cells were harvested and 
washed with ice-cold PBS containing sodium orthovanadate 1 mM, 4-(2-
aminoethyl)-benzenesulfonyl fluoride 104 mM, aprotinin 0.08 mM, leupeptin 2 
mM, bestatin 4 mM, pepstatin A 1.5 mM, E-64 1.4 mM [23]. Aliquots of total 
protein sample (50 µg) were analyzed using antibodies specific for human P2X1 
and P2X3  purinergic receptors (1 µg/ml dilution). Filters were washed and 
incubated for 1 hour at room temperature with peroxidase-conjugated secondary 
antibodies (1:2000 dilution). Specific reactions were revealed with Enhanced 
Chemiluminescence Western blotting detection reagent (Amersham Biosciences). 
β-actin was used as a loading control. Additional western blotting analysis was 
also performed for the NF-IL-6 protein expression as previously described 
(Kiehntopf et al., 1995). 
 
Saturation and competition binding assays  
Saturation and competition binding assays were carried out in primary cultures of 
fibroblast-like synoviocytes and in SW 982 membranes at 5, 10, 15, 20, 25 and 
30°C. Saturation binding experiments of [3H]αβmeATP (from 0.1 to 50 nM) were 
performed by using the membranes previously obtained (100 µg protein/assay). 
Previous time course experiments showed that  [3H]αβmeATP binding reached 
equilibrium after approximately 15 min and was stable for at least 3 hours. The 
incubation times used in binding experiments were: 40 min at 5°C, 50 min at 
10°C, 60 min at 15°C, 70 min at 20°C, 80 min at 25°C and 90 min at 30°C. 
Competition experiments of 3 nM [3H]αβmeATP were conducted incubating 
membranes (100 µg protein/assay) and 13 different concentrations of purinergic
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agonists or antagonists examined for thermodynamic studies. Non specific 
binding was determined in the presence of 1 µM αβmeATP (Varani et al., 
2008b,c). Bound and free radioactivity were separated by rapid filtration through 
Whatman GF/B glass-fiber filters using a Brandel instrument and the radioactivity 
was counted on a Scintillation Counter Tri Carb Packard 2500 TR.  
 
Thermodynamic data determination  
For a generic binding equilibrium L+R = LR (L = ligand, R = receptor) the 
affinity association constant KA = 1/KD is directly related to the standard free 
energy ∆G° (∆G° = -RTlnKA) which can be separated in its enthalpic and entropic 
contributions according to the Gibbs equation: ∆G° = ∆H°-T∆S° (Borea et al., 
2000).  
 
NF-kB activation in human fibroblast-like synoviocytes  
The NF-kB activation in nuclear extracts from human fibroblast-like synoviocytes 
and SW 982 cells was evaluated by detecting phosphorylated p65 and p50 
proteins in nuclear extracts using the TransAM NF-kB kit (Active Motif, 
Carlsbad, USA) (Gomez et al., 2006). Phosphorylated NF-kB subunits 
specifically bind to the immobilized oligonucleotides containing the NF-kB 
consensus site (5’-GGGACTTTCC-3’). The primary antibody used to detect NF-
kB recognized an epitope on each subunit that is accessible only when activated 
and bound to its DNA target. A horseradish peroxidase (HRP)-conjugated 
secondary antibody provided a sensitive colorimetric readout that was quantified 
by spectrophotometry at 450 nm. 
 
Enzyme-linked immunosorbent assay (ELISA)  
The concentration of TNF-α, IL-6 and PGE2 was measured using commercially 
available competitive enzyme immunoassays (R&D Systems, Minneapolis, USA) 
in duplicate samples or standards (Forrest et al., 2005; De Mattei et al., 2007).  
 
Data and statistical analysis 
The protein concentration was determined according to a Bio-Rad method with 
bovine albumin as reference standard (Bradford, 1976). A weighted non linear 
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least-squares curve fitting program Ligand was used for computer analysis of 
saturation and competition binding experiments (Munson and Rodbard, 1980). 
Functional experiments were calculated by non linear regression analysis using 
the equation for a sigmoid concentration-response curve (GraphPAD Prism, San 
Diego, CA, USA). Analysis of data, expressed as mean ± SEM, was performed by 
one-way analysis of variance. Differences were analyzed with Dunnett’s test and 
were considered significant at a value of p<0.01.  
 
RESULTS 
 
Phenotype characterization of fibroblast-like synoviocytes  
Fibroblast-like synoviocytes isolated from synovial of OA patients showed to be a 
homogenous population as demonstrated by their fibroblast-like morphology. 
Primary cultures of fibroblast-like synoviocytes (Figure 6.1A) and SW 982 cells 
(Figure 6.1B) also showed the expression of vimentin, a specific cellular marker 
for mesenchymal cells and fibroblast-like synoviocytes. No stain was observed 
with MoAbs, to CD14 and von-Willebrand factor indicating the absence of 
contaminating cells (data not shown). 
 
Evaluation of P2X purinergic receptor mRNA expression and protein level  
The expression of P2X1-7 mRNA was shown and high levels of P2X1, P2X3 and 
P2X7 mRNA were found in human fibroblast-like synoviocytes and SW 982 cells 
(Figure 6.2A). The presence of P2X1 and P2X3 was confirmed by western blotting 
in comparison with HEK293-hP2X1 and HEK293-hP2X3 cells (Figure 6.2B). 
Densitometric analysis of the bands obtained was also performed as shown in 
figure 6.2C,D. 
 
Saturation and competition binding experiments  
Saturation binding experiments in primary cultures of human fibroblast-like 
synoviocytes (Figure 6.3A,B) and in SW 982 (Figure 6.3C,D) membranes were 
carried out to evaluate affinity (KD) and receptor density (Bmax) values of P2X 
receptors. Binding parameters were determined at various temperatures (5, 10, 15, 
20, 25 and 30°C) by using [3H]αβmeATP as radioligand and showed that KD 
values changed with temperature (from 3 to 9 nM, respectively) and Bmax values 
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in the picomolar range appeared to be largerly independent of it. Saturation 
binding experiments, performed at 5°C, in human fibroblast-like synoviocytes 
demonstrated the presence of an high affinity binding site (KD= 3.1 ± 0.3 nM) and 
a receptor density (Bmax= 1500 ± 140 fmol/mg protein). Similarly, SW 982 cells 
showed KD value of 4.1 ± 0.4 nM and Bmax values of 2400 ± 230 fmol/mg 
protein. With the increase of the temperature, affinity values decreased (KD= 6.5 ± 
0.6 nM, KD= 8.4 ± 0.7 nM, at 25°C, respectively) (Figure 6.3B,D). Affinity values 
obtained in [3H]αβmeATP competition binding experiments by using selected 
purinergic agonists and antagonists in human fibroblast-like synoviocytes 
membranes are shown in table 6.1A. In human fibroblast-like synoviocytes 
membranes affinity values of the purinergic ligands used in functional 
experiments were obtained incubating 13 different concentration of purinergic 
agonists (Figure 6.4A) or antagonists (Figure 6.4B). Interestingly, βγmeATP, 
BzATP, A317491 and NF 023 showed a better fit for a two binding site model, 
suggesting a different affinity for P2X1 and P2X3 purinergic receptors. On the 
contrary, αβmeATP showed a better fit for a one site binding model, confirming a 
similar affinity for P2X1 and P2X3 purinergic receptors. KN62 was not able to 
displace [3H]αβmeATP (Ki > 20 µM). Similar affinity values were also obtained 
in SW 982 cells for purinergic agonists (Figure 6.4C) and antagonists (Figure 
6.4D). In human fibroblast-like synoviocytes and in SW982 cells, the affinities of 
αβmeATP, βγmeATP and BzATP were decreased with the increase of the 
temperature (from 5 to 30°C) as reported in table 6.1B. Interestingly, the increase 
of the temperature differentially modulated the affinity of the antagonists and 
mediated: i) the reduction in KH of A317491 and in KL of NF023; ii)  the increase 
in KL of A317491 and in KH of NF023 (Table 6.1B). 
 
Thermodynamic analysis  
The van’t Hoff plots for purinergic ligands examined were essentially linear in the 
range 5-30°C in human fibroblast-like synoviocytes (Figure 6.5A,B) and in SW 
982 cells (Figure 6.5C,D). Thermodynamic parameters (∆G°, ∆H°, ∆S°) were 
reported in Table 6.2. The standard free energy was calculated as ∆G° = -RTlnKA 
at 298.15 K, the standard enthalpy, ∆H°, from the van’t Hoff plot lnKA versus 
(1/T) (the slope of which is -∆H°/R) and the standard entropy as ∆S° = (∆H°- 
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∆G°)/T with T = 298.15 K and R = 8.314 J/K/mol). KA values were obtained from 
saturation experiments of [3H]αβmeATP binding to fibroblast-like synoviocytes 
membranes carried out at 0, 10, 15, 20, 25 and 30°C in a thermostatic bath 
assuring a temperature of ± 0.1°C. The slopes of van’t Hoff plots were positive for 
the purinergic agonists examined whose affinities decreased with increase of the 
temperature. Different behavior was reported for the purinergic antagonists. In 
fact, the slopes of van’t Hoff plots for the KH of A317491  and the KL of NF023 
were negative whose affinities are improved by an increase of the temperature. In 
contrast, the slopes of van’t Hoff plots for KL of A317491  and KH of NF023 were 
positive. Final thermodynamic parameters of the selected purinergic compounds 
revealed that the binding of agonists was enthalpy and entropy driven (Table 6.2). 
In addition, high affinity of A317491 and low affinity of NF023 were associated 
with an entropy driven binding whilst low affinity of A317491 and high affinity 
of NF023 showed an enthalpy and entropy driven binding (Table 6.2).  
 
Transcription factors in human fibroblast-like synoviocytes  
NF-kB levels were evaluated studying P50 and P65 subunits activation. In human 
fibroblast-like synoviocytes, αβmeATP (P2X1 and P2X3 agonist) and BzATP 
(P2X7 agonist) were able to increase of 85% and 152% the basal level of P65 
subunit, respectively. βγmeATP (P2X1 agonist) reduced of 58% the basal level of 
P65 subunit (Figure 6.6A). The capability of typical purinergic antagonists were 
investigated using A317491 and NF 023 which are able to block the effect of 
βγmeATP or αβmeATP respectively . In addition, a P2X7 antagonist, KN 62 
partially reduced the effect of BzATP and was not able to counteract the effect of  
βγmeATP or αβmeATP. Similar results were also obtained in SW 982 cells 
confirming that P2X1 and P2X3 purinergic receptors present in human fibroblast-
like synoviocytes were closely similar to those observed in this cell line. No 
modulation by purinergic agonists and antagonists was found on P50 subunit 
activation and NF-IL6 transcription factor with the exception of BzATP that was 
able to increase the basal level of P50 subunit and NF-IL-6 transcription factor. 
This effect was blocked only by KN-62 and not by A317491 or NF 023, 
suggesting the involvement of P2X7 receptors (Figure 6.7).  
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TNF-α, IL-6 and PGE2 production  
In both OA fibroblast-like synoviocytes and SW cells the effect of selected 
purinergic agonists and antagonists was evaluated in the presence of LPS (10 
µg/ml) specific stimulation in TNF-α release (Figure 6.6B), in IL-6 (Figure 6.8A) 
and PGE2 production (Figure 6.8B). The stimulation of P2X1 and P2X3 receptors 
mediated a decrease and an increase of TNF-α release, respectively. No effect was 
present on the modulation of IL-6 and PGE2 production by the stimulation of these 
purinergic receptors (Figure 6.8A,B). In human fibroblast-like synoviocytes, 
αβmeATP was able to significantly increase TNF-α production by 47%.  P2X1 
stimulation by using βγmeATP revealed a significant decrease by  51%. In the 
same experimental conditions, the effect of BzATP was to increase of 88% the 
TNF-α release. A317491 (100 µM) counteracted the effect of αβmeATP but not 
of βγmeATP. NF023 (100 µM) blocked the effect of βγmeATP but not of 
αβmeATP. In addition, evaluating the effect of the three purinergic antagonists, 
only KN 62 was able to decrease partially the BzATP-mediated increase of TNF-
α production.  
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Table 6.1A: Affinities, expressed as Ki or KH and KL values (nM) of selected purinergic agonists and antagonists in human fibroblast-like 
synoviocytes at different temperatures. 
 
     
Ligand 
 
 
5 °C 
278 K 
 
 
10 °C 
283 K 
 
15 °C 
288 K 
 
20 °C 
293 K 
 
25 °C 
298 K 
 
30 °C 
303 K 
 
Agonists       
 αβmeATP 
Ki (nM) 2.7±0.3 3.5±0.3 4.6±0.5 5.8±0.6 6.5±0.6 7.4±0.7 
βγmeATP 
KH (nM) 14±1 17±2 19±2 24±2 31±3 38±3 
KL (nM) 339±34 395±37 452±41 526±48 597±53 671±64 
BzATP 
KH (nM) 11±1 13±1 16±1 20±2 24±2 28±3 
KL (nM) 132±11 163±15 195±20 239±22 286±27 358±32 
 
      
Antagonists       
A317491 
KH (nM) 114±10 102±9 89±8 74±7 56±6 43±5 
KL (nM) 2021±190 2817±265 3381±323 3852±374 4268±413 4815±468 
NF023 
KH (nM) 642±63 823±77 992±91 1076±105 1184±113 1328±129 
KL (nM) 10623±1054 9223±892 8412±826 7636±697 6844±672 5729±536 
KN62 
Ki (nM) >20000 >20000 >20000 >20000 >20000 >20000 
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Table 6.1B: Affinities, expressed as Ki or KH and KL values (nM) of selected purinergic agonists and antagonists in SW 982 cells at different 
temperatures. 
 
Ligand 
 
 
5 °C 
278 K 
 
 
10 °C 
283 K 
 
15 °C 
288 K 
 
20 °C 
293 K 
 
25 °C 
298 K 
 
30 °C 
303 K 
 
Agonists       
 αβmeATP 
Ki (nM) 3.2±0.3 3.8±0.4 5.2±0.5 6.3±0.5 7.0±0.6 7.9±0.6 
βγmeATP 
KH (nM) 17±1 19±2 20±2 25±2 32±3 40±3 
KL (nM) 353±31 403±39 464±42 538±51 611±57 693±63 
BzATP 
KH (nM) 13±1 15±1 18±2 21±2 26±2 30±3 
KL (nM) 136±12 171±16 198±18 245±21 293±28 365±35 
 
      
Antagonists       
A317491 
KH (nM) 121±11 105±10 93±9 78±8 59±6 48±5 
KL (nM) 1865±172 2724±213 3243±311 3726±353 4115±391 4737±424 
NF023 
KH (nM) 622±59 815±73 983±88 1052±97 1148±102 1296±116 
KL (nM) 10456±1023 9185±871 9356±794 7518±702 6738±623 5612±513 
KN62 
Ki (nM) >20000 >20000 >20000 >20000 >20000 >20000 
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Table 6.2: Thermodynamic parameters for the binding equilibrium of 
[3H]αβmeATP in human fibroblast-like synoviocytes (A) and SW982 cells (B) 
of selected purinergic agonists and antagonists. 
 
(A) 
Ligand  ∆G° ∆H° ∆S° 
 (kJ/mol) (kJ/mol) (J/mol/K) 
Agonists    
 αβmeATP 
Ki -46.7±0.2 -28.8±2.3 60.0±5.8 
βγmeATP 
KH -42.9±0.2 -27.9±2.2 50.4±5.3 
KL -35.5±0.1 -19.4±1.9 54.1±4.9 
BzATP 
KH -43.5±0.2 -26.9±2.1 55.6±5.7 
KL -37.3±0.1 -27.6±2.4 32.6±3.6 
 
   
Antagonists    
A317491 
KH -41.4±0.2 27.2±2.5 230.1±22.4 
KL -30.6±0.1 -23.2±2.1 24.7±2.2 
NF023 
KH -33.8±0.1 -19.5±1.9 48.1±4.7 
KL -29.5±0.1 16.4±1.7 153.9±13.5 
KN62 
Ki > -26.8 NC NC 
 
(B) 
Ligand  ∆G° ∆H° ∆S° 
  (kJ/mol) (kJ/mol) (J/mol/K) 
Agonists    
 αβmeATP 
Ki -46.5±0.2 -26.3±2.4 67.8±6.1 
βγmeATP 
KH -42.8±0.2 -24.2±2.1 62.4±5.9 
KL -35.4±0.1 -19.1±2.0 54.9±5.2 
BzATP 
KH -43.3±0.2 -24.0±2.2 64.7±6.3 
KL -37.2±0.1 -27.2±2.3 33.8±3.4 
 
   
Antagonists    
A317491 
KH -41.3±0.2 26.0±2.4 225.6±23.5 
KL -30.7±0.1 -24.4±1.9 21.1±2.1 
NF023 
KH -33.9±0.1 -19.2±1.8 49.3±4.6 
KL -29.6±0.1 16.6±1.7 154.5±14.2 
KN62 
Ki > -26.8 NC NC 
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Figure 6.1: Culture of human fibroblast-like synoviocytes (A) and SW 982 
cells (B). Left panels: phase contrast. Right panels: vimentin expression by 
immunofluorescence. Nuclei were counterstained in blue with DAPI. 
 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
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Figure 6.2: mRNA expression of P2X purinergic receptors (A) and western 
blotting analysis (B) in human fibroblast-like synoviocytes (SFs) and SW 982 
cells in comparison with HEK293-hP2X1 and HEK293-hP2X3 cells. 
Densitometric analysis for hP2X1 and hP2X3 purinergic receptors are shown 
(C,D). 
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Figure 6.3. Saturation curves and Scatchard plot of [3H]αβmeATP binding to 
P2X 
 
purinergic receptors in human fibroblast-like synoviocytes (A,B) and  
SW 982  (C,D) membranes at 5°C and 25°C.  
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Figure 6.4: Competition curves of  typical purinergic agonists and 
antagonists in human fibroblast-like synoviocytes (A,B) and in SW 982 (C,D) 
membranes. 
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Figure 6.5. Van’t Hoff plots  in human fibroblast-like synoviocytes (A,B) and 
in SW 982 (C,D) membranes showing the effect of temperature on the 
equilibrium binding association constant, KA, for P2X  purinergic agonists 
(A,C) and antagonists (B,D). 
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Figure 6.6: Effect of αβmeATP, βγmeATP and BzATP (100 µM) in human 
fibroblast-like synoviocytes (SFs) and in SW 982 cells on NF-kB activation by 
detecting phosphorylated p65 (A) in nuclear extracts and on TNF-α (B) levels 
in control conditions and stimulated by LPS (10 µg/ml). 
 
 
(A): *, p<0.01 vs control; #, p<0.01 vs αβmeATP; §, p<0.01 vs βγmeATP; ‡, 
p<0.02 vs BzATP; (B): †, p<0.01 vs control; *, p<0.01 vs LPS; #, p<0.01 vs 
αβmeATP; §, p<0.01 vs βγmeATP; ‡, p<0.02 vs BzATP. 
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Figure 6.7: Effect of αβmeATP, βγmeATP and BzATP (100 µM) in human 
fibroblast-like synoviocyes and in SW 982 cells on NFkB activation which 
was evaluated by detecting phosphorylated p50 (A) in nuclear extracts. No 
effect was present in western blotting analysis by αβmeATP and βγmeATP 
(100 µM) in human fibroblast-like synoviocytes on NF-IL-6 activation. 
BzATP (100 µM) was able to statistically increase NF-IL-6 activation (B). 
Densitometric analysis for NF-IL-6 was shown (C)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A): *, p<0.01 vs control; ‡, p<0.01 vs BzATP; (C): *, p<0.01 vs control 
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Figure 6.8: Effect of αβmeATP, βγmeATP and BzATP (100 µM) in human 
fibroblast-like synoviocytes (SFs) and in  SW 982 cells on IL-6 (A) and PGE2 
(B) production. The effect of typical purinergic antagonists were also 
evaluated  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
†, p<0.01 vs control; *, p<0.01 vs LPS; ‡, p<0.01 vs BzATP 
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DISCUSSION 
 
Nowadays no specific therapy, based on intracellular pathways of chondrocytes 
and/or fibroblast-like synoviocytes, exists for the medical management of OA. 
Although different cytokines provide a potential therapy for OA it will be 
necessary to elucidate novel targets to be employed in this disease (Blom et al., 
2007). The purpose of the present paper was to document the presence, the 
binding parameters and the functionality of P2X1 and P2X3 receptors in 
fibroblast-like synoviocytes derived from OA patients and in SW 982 cells used 
as a representative model of human synovial cell line. These data could be very 
important considering that synovial tissue is known to have a key role as target 
tissue in the joint during inflammation and in the pathophysiology of OA 
(Korkusuz et al., 2005; Goldring and Goldring, 2007). In this paper we report for 
the first time a binding and functional characterization of P2X purinergic 
receptors in human fibroblast-like synoviocytes. No works are present in the 
literature showing the presence and the role of P2X1 and P2X3 purinergic 
receptors in human fibroblast-like synoviocytes. In human fibroblast-like 
synoviocytes the presence of purinergic receptors was investigated through 
mRNA and western blotting analysis. To quantify exactly the affinity and density 
of the P2X receptors investigated, saturation binding studies were performed 
revealing  that the affinity (KD, nM) was in the nanomolar range and the receptor 
density (Bmax, fmol/mg protein) was very high. The binding was rapid, 
reversible, saturable and indicated similar parameters in both human fibroblast-
like synoviocytes and in SW 982 cells. In addition, as demonstrated by a previous 
work from our group, αβmeATP was able to label with a similar affinity both 
P2X1 and P2X3 purinergic receptors expressed in HEK 293 cells (Varani et al., 
2008b). These results were also confirmed by competition binding experiments 
where αβmeATP showed a closely similar affinity for human P2X1 and P2X3 
purinergic receptors expressed in HEK 293 cells. On the basis of these previous 
results, we can hypothesis that in saturation binding experiments performed in 
human fibroblast-like synoviocytes, [3H]-αβmeATP labeled both P2X1 and P2X3 
purinergic receptors with similar affinity. Competition binding experiments 
revealed that αβmeATP have higher affinity, in the nanomolar range, than other 
agonists and antagonists. To evaluate if the ligands used in functional experiments 
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had different affinity values for P2X1 and P2X3 receptors, competition binding 
experiments with 13 various concentrations of these compounds were performed. 
As expected, αβmeATP revealed a monophasic curve showing the best fit for a 
receptor population constituted from P2X1 and P2X3 with similar affinity. 
Interestingly, βγmeATP, BzATP, A317491 and NF 023 showed a best fit for a 
two site binding model, suggesting that these compounds have a different affinity 
for P2X1 and P2X3 purinergic receptors. From these results we can hypothesis that 
KH for βγmeATP and NF 023 represent their affinity versus P2X1 purinergic 
receptors whilst BzATP and A317491 were able to bind with high affinity P2X3 
purinergic subtypes. We have also performed competition experiments at six 
different temperatures that could represent an useful in vitro experimental 
approach to discriminate agonists from antagonists by means of binding 
experiments. Thermodynamic parameters obtained from the van’t Hoff plots in 
the cells examined indicated that αβmeATP binding to purinergic receptors is 
enthalpy- and entropy-driven, with a major contribution of the enthalpic 
component. The presence of the linearity of van’t Hoff plots for P2X receptors 
similarly to those verified for other membrane receptors showed that ∆H° and ∆S° 
values are independent of temperature (Varani et al., 2008b, c). These results 
provide further informations to the several data present in literature showing the 
thermodynamic parameters for a remarkable number of ligands and receptors that 
allow a precise investigation at molecular level on the role played during the 
binding by ligand substituents and by receptor aminoacids (Borea et al., 2000, 
2004; Gilli et al., 2005). We previously reported that P2X3 purinergic receptors 
are thermodynamically discriminated whilst P2X1 receptor subtypes are not 
discriminated (Varani et al., 2008b). For human P2X1 receptors expressed in 
HEK293 cells, purinergic agonists and antagonists showed an enthalpy-entropy 
driven binding. In HEK293-hP2X3 cells only the agonists had an enthalpy-entropy 
driven binding whilst the antagonists showed an entropy driven binding. The 
novel results obtained in human fibroblast-like synoviocytes and SW 982 cells, 
suggest that the purinergic agonists examined have an enthalpy-entropy driven 
binding. In addition, the purinergic antagonists such as A137491 and  NF023 
showed a different thermodynamic behavior. In fact, high affinity binding site for 
A137491 was closely associated to the typical P2X3 thermodynamic behavior as 
previously reported in HEK293 cells. The high affinity binding site of NF023 was 
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similar to the thermodynamic behavior of P2X1 receptors (Varani et al., 2008b). 
These experimental data in human fibroblast-like synoviocytes and in SW 982 
cells confirm that P2X3 receptors are thermodynamically discriminated and P2X1 
receptors are not discriminated. Another purpose of the present study was to 
investigate the purinergic receptor functional activities in human fibroblast-like 
synoviocytes. To this aim, the effect on NF-kB activation and on the release of 
pro-inflammatory factors such as TNF-α suggested the possible involvement in 
inflammatory process of P2X1 and P2X3 agonists and/or antagonists. These 
experiments demonstrated an anti-inflammatory effect of P2X1 receptors and a 
pro-inflammatory effect of P2X3 receptors as confirmed by the contrasting effect 
of αβmeATP and βγmeATP in NF-kB activation and TNF-α release. These data 
are in agreement with those reported in literature regarding NF-kB that is one of 
the most important signalling pathways able to regulate pro-inflammatory 
cytokines such as TNF-α (Hong et al., 2008). Interestingly, IL-6 and PGE2 are not 
modulable by the presence of P2X1, P2X3 but only by the presence of P2X7 
receptors confirming previous data obtained in rheumatoid synoviocytes where is 
evident the involvement of P2X7 purinergic receptors (Caporali et al., 2008). 
These results on IL-6 and PGE2 production demonstrated a direct link in human 
fibroblast-like synoviocytes of different nuclear transcription factors involved in 
the modulation of pro-inflammatory molecules. In fact, NF-kB-p50 and NF-IL-6 
proteins, that binds responsive elements in the IL-6 and PGE2 gene promoters, 
were not modified by P2X1 and P2X3 agonists (LeClair et al., 199; Uematsu et al., 
2002). Finally, binding, thermodynamic and functional data demonstrated that 
P2X1 and P2X3 receptors present in human fibroblast-like synoviocytes and in 
SW 982 cells are closely similar and suggested the potential use of this cell line as 
an in vitro model to study purinergic receptors from a pharmacological point of 
view. In conclusion, the novel findings carried out in human fibroblast-like 
synoviocytes from OA patients and in SW 982 cells are represented by the 
presence of high density of the P2X1 and P2X3 purinergic receptors. The 
functional results revealed the direct and contrasting involvement of P2X1 and 
P2X3 purinergic receptors which could represent potential mediators in the 
complex pathways regulating inflammatory processes in fibroblast-like 
synoviocytes suggesting their potential beneficial target for the treatment of 
inflammatory joint diseases. 
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GENERAL CONCLUSION 
 
Chronic inflammation is a significant factor in the pathophysiology of many 
forms of joint disease such as OA and RA. Chondrocytes and fibroblast-like 
synoviocytes are the two kind of cells particular involved in these diseases. In OA 
and RA there is a net loss of cartilage because the rate of catabolism exceeds the 
rate of synthesis and deposition of the macromolecular components of the 
extracellular matrix. Several chondrocyte activities are associated to cartilage 
damage, and include the up-regulation of NO and lipid inflammatory mediators 
such as PGE2, as well as the increased production of matrix-degradating enzymes. 
As well as chondrocytes, fibroblast-like synoviocytes play a central role in the 
pathogenesis of joint destruction primarly by the secretion of a wide range of 
proinflammatory mediators including cytokines, growth factors and lipid 
mediators of inflammation. Growing evidence suggest that extracellular 
nucleotides, such as ATP and adenosine, might play important roles in the 
regulation of inflammatory processes, including the inflammatory process in joint 
diseases. In the first part of this study we analized the presence and the binding 
parameters of A1, A2A, A2B and A3 ARs in bovine chondrocytes and fibroblast-like 
synoviocytes. We found that all the adenosine receptors are present in these 
substrates and similarly distributed in both cell types showing high-affinity values 
in the nanomolar range and a receptor density from 30 to 83 fmol/mg of protein. 
We have also evaluated the capability of typical A2A or A3 adenosine agonists and 
antagonists to modulate cAMP levels. These compounds showed potency values 
in the nanomolar range, in agreement with their affinity in binding experiments, 
the antagonists were able to prevent the effect of cAMP induced by the agonists 
through a selective modulation of the adenylyl cyclase via A2A or A3 ARs. In 
addition, the levels of cAMP increased in response to NECA, a non selective 
agonist, suggesting that in physiological condition (presence of endogenous 
adenosine) the activation of A2A may prevail over the A3 mediated inhibitory 
action. We have also analized the role of adenosine analogs on PGE2 release and 
COX-2 expression in bovine fibroblast-like synoviocytes. We have used as 
adenosine agonists CHA, CGS21680, NECA and Cl-IB-MECA. In fibroblast-like 
synoviocytes treated with two different type of inflammatory stimuli (TNF-α and 
LPS) we observed the increase of PGE2 release. All the adenosine agonists, except 
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Cl-IB-MECA significally inhibited PGE2 production. These data indicated for the 
involvement of A1 and A2A ARs in negative modulation of PGE2 synthesis. We 
have also found that the changes in PGE2 levels were associated to modification of 
COX-2 expression the primary enzyme controlling PGE2 synthesis in response to 
inflammatory stimuli. Finally, we have performed a pharmacological and 
biochemical characterization of A1, A2A, A2B and A3 ARs in human fibroblast-like 
synoviocytes. We found that the ARs were present, well known adenosine 
agonists and antagonists showed affinity values in the nanomolar range and were 
coupled to stimulation or inhibition of adenylyl cyclase. A2A and A3 ARs 
activation inhibited p38 MAPK and NF-κB pathway, an effect abolished by 
selected adenosine antagonists. A2A and A3 agonists were able to diminish TNF-α 
and IL-8 production. A1 and A2B ARs were not implicated in the inflammation 
downstream whereas the stimulation of A2A and A3 ARs were closely associated 
with a down-regulation of the inflammatory status. These results indicate that A2A 
and A3 ARs could represent a potential target in therapeutic anti-inflammatory 
joint interventions. In the second part of the study the role of ATP in bovine 
chondrocytes and fibroblast-like synoviocytes have been evaluated. First of all 
thermodynamic parameters of the binding equilibrium of well-known purinergic 
agonists and antagonists were determinate in human P2X1 and P2X3 receptors 
expressed in HEK-293 cells. Our analysis showed that P2X1 receptors are not 
thermodynamically discriminated and that the binding of agonists and antagonists 
was both enthalpy and entropy-driven. P2X3 receptors were thermodynamically 
discriminated and purinergic agonist binding was enthalpy and entropy-driven, 
while antagonist binding was totally entropy-driven. As a consequence a 
biochemical and functional study on P2X1 and P2X3 receptors in bovine 
chondrocytes have been performed. We found that bovine chondrocytes expressed 
P2X1 and P2X3 purinergic receptors and thermodynamic parameters indicated that 
purinergic binding is enthalpy- and entropy-driven for agonists and totally 
entropy-driven for antagonists. Purinergic agonists such as ATP and αβ-meATP 
were able to increase NO and PGE2 release. A purinergic antagonist, A317491, 
was able to block the stimulatory effect on functional experiments mediated by 
the agonists, suggesting the potential role of novel purinergic antagonists in the 
treatment of pathophysiological disease involved in inflammatory of the joints. In 
addition, the pharmacological characterization of P2X1 and P2X3 purinergic 
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receptors in fibroblast-like synoviocytes obtained from OA patients and in SW982 
cells derived from human synovial sarcoma have been performed. Moreover their 
possible involvement in modulating the inflammatory response by assessing the 
activation of NF-kB and the production of TNF -α, IL-6 and PGE2 have been 
investigated. Interestingly P2X1 and P2X3 receptors were present in human 
fibroblast-like synoviocytes and SW982 cells. In these cells purinergic agonists 
and antagonists have a different thermodynamic behavior. This study report, for 
the first time the presence of P2X1 and P2X3 purinergic receptors in human 
fibroblast-like synoviocytes. Moreover from the functional point of view P2X1 
receptors exhibit anti-inflammatory effects, by reducing the activation of NF-kB 
and the release of TNF-α, whereas P2X3 receptors mediate an opposite response 
suggesting pro-inflammatory effects. 
In conclusion, overall these data demonstrate the presence of A1, A2A, A2B, A3 
ARs and P2X1, P2X3 purinergic receptors in bovine chondrocytes and fibroblast-
like synoviocytes. The functionality of these purine receptors suggest the use of 
selective adenosine and/or purinergic ligands in the treatment of inflammatory 
diseases. In addition, the expression and the signal transduction system of 
adenosine and purine receptors in human fibroblast-like synoviocytes highlight 
the potential pharmacological use of novel purine ligands in disorders associated 
with inflammation. 
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